
















The Dissertation Committee for Tracy Peksim Ooi Certifies that this is the 
approved version of the following dissertation: 
 
 
The Generation of Antigen-Specific CD8+ T Cells from Stem Cells for 








Haley Tucker, Supervisor 





The Generation of Antigen-Specific CD8+ T Cells from Stem Cells for 









Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 










The success of this work would not have been possible without my family, 
friends, and mentors. First, I would like to thank my advisor, Dr. Krishnendu Roy, for 
giving me the opportunity to work in his lab, and for providing the support, guidance, and 
motivation needed to complete this work. I also express gratitude to my co-advisor, Dr. 
Haley Tucker, who has been an encouraging mentor and with whom I have had many 
insightful discussions. I would like to thank my other committee members, Dr. Lauren 
Ehrlich, Dr. George Georgiou, and Dr. Jennifer Maynard, for providing their specialized 
expertise, helpful suggestions, and encouragement. I am also grateful for Dr. Jörg 
Kirberg, who gave me the opportunity to intern in his lab in Germany, an experience 
which enhanced my understanding of T cell biology.  
Next, I would like to acknowledge the hard-working scientific staff at The 
University of Texas at Austin’s Institute for Cellular and Molecular Biology Core 
Facilities and The Georgia Institute of Technology’s Institute for Bioengineering and 
Biosciences Core Facilities. Many thanks go out to Dr. Richard Salinas (UT Austin) and 
Dr. Nadia Boguslavsky (Georgia Tech), who assisted numerous cell sorts and provided 
training on several flow cytometers. I also want to acknowledge Matt Barnett (UT 
Austin) and Andrew Shaw (Georgia Tech) for providing training on the respective real-
time PCR machines.  
I would like to give sincere thanks to my friends and colleagues from The 
University of Texas at Austin and The Georgia Institute of Technology. I am grateful for 
the mentorship and patience of Dr. Myunghee Michelle Kim when I first joined the Roy 
Lab. I sincerely thank my collaborator, Dr. Irina Fernandez, for her scientific expertise 
 vi 
and guidance throughout many long experiments. I would like to recognize Dr. Jian Lin, 
who began the early work that fueled the fire for my research projects. I want to express 
my appreciation for the “official” Klub Krish members, Dr. Rachit Agarwal, Dr. Eileen 
Dawson, Dr. Krista Ewing, Asha Fleury, Jardin Leleux, Dr. Mary Caldorera-Moore, Dr. 
Lonnissa Nguyen, Dr. Pallab Pradhan, and Dr. Prinda Wanakule, who have provided a 
plethora of scientific advice, and with whom I have shared many fond memories. I also 
want to thank our previous Administrative Assistant, Michelle Harper, for her hard work 
and help. 
Many thanks go out to Dr. Arnold Estrada, Dr. Mark Gebhard, Dr. Vincent 
Holmberg, Dr. Tarik Khan, Dr. Tom Linsky, and Dr. Justina Tam, who have provided 
support throughout graduate school. I would like to acknowledge the “new” Roy Lab 
members at The Georgia Institute of Technology, Jiaying “Ingrid” Liu, Dr. Ranjna 
Madan-Lala, Joscelyn Mejias, Michael Nelson, Kirsten Parratt, Dr. Kyung-Ho Roh, and 
Dr. Randall Toy, for their insightful discussions and encouragement. Many thanks go out 
to my previous undergraduate students, Anisha Ganguly, Isac Lee, and Xinhie “Scarlet” 
Liu for their assistance in many experiments.  
Last, but certainly not least, I would like to express the deepest gratitude to my 
family for their unconditional love and support. My parents have been an unwavering 
source of encouragement and stability throughout my life, for which I am eternally 
grateful. I am very thankful for my sisters, who are my best friends and biggest 





The Generation of Antigen-Specific CD8+ T Cells from Stem Cells for 
Adoptive Transfer Immunotherapy 
 
Tracy Peksim Ooi, Ph.D. 
The University of Texas at Austin, 2014 
 
Supervisor:  Haley Tucker 
Co-Supervisor: Krishnendu Roy 
 
Adoptive T cell transfer is a form of immunotherapy that has shown promise in 
treating several cancers and post-transplant lymphoproliferative diseases. This therapy 
relies on the unique ability of cytotoxic T lymphocytes to specifically recognize and 
eliminate pathogen-infected or malignant cells. Adoptive transfer involves the isolation 
of patient-derived T cells, followed by ex vivo expansion, and in some cases genetic 
manipulation, before infusion into the recipient. The procedure is often limited by the 
availability of donor cells, problems with primary cell expansion, the time required to 
generate adequate numbers of T cells, and the complications associated with using 
genetically modified cells in vivo. As a result, there is need for a high-throughput system 
from which large quantities of antigen-specific cytotoxic T cells can be generated.  
The multipotency of stem cells makes them attractive, scalable cell sources for 
adoptive transfer T lymphocytes. In this work, functional, antigen-specific CD8
+
 T cells 
were differentiated from human CD34
+
 cord blood-derived hematopoietic stem cells, in 
vitro, using exogenous Notch ligands and peptide-loaded human leukocyte antigen 
tetramers. Tetramer-differentiated, progenitor-derived, antigen-specific CD8
+
 T cells 
were then enriched and expanded using media supplemented with co-stimulatory 
 viii 
molecules and proliferative cytokines. The enriched T cells remained functional, but did 
not undergo robust expansion, suggesting that they entered a state of dysfunction. Lastly, 
the effects of peptide major histocompatibility complex (pMHC) density and surface 
presentation on thymocyte TCR signaling and antigen-specific differentiation were 
studied. Microplates and microbeads, fabricated with varying densities of pMHC 
molecules, were used to stimulate and differentiate thymocytes. Plate- and bead-
immobilized pMHCs were more efficient at stimulating thymocytes compared to soluble 
pMHC tetramers, and were capable of inducing antigen-specific T cell differentiation in a 
density-dependent manner. In conclusion, the findings of this research indicate that 
antigen-specific CD8
+
 T cells can be generated from progenitor cells in vitro, with the 
potential of high-throughput and large-scale production. 
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Chapter 1: Overview, Specific Aims, and Outline 
1.1 OVERVIEW 
T lymphocytes are a unique set of white blood cells that play a critical role in the 
body’s adaptive immune response. Over the past twenty years, scientists and clinicians 
have exploited the ability of CD8
+
 cytotoxic T cells to specifically recognize and kill 
pathogen-infected or cancerous cells. This form of immunotherapy, known as adoptive T 
cell transfer, has shown promise in treating several cancers including metastatic 
melanoma, renal cancer, prostate cancer, B lymphoid malignancies, and nasopharyngeal 
cancer, as well as post-transplant lymphoproliferative diseases (PTLDs).
1-22
 Adoptive 
transfer has conventionally involved the isolation of peripheral blood or tumor-infiltrating 
lymphocytes (TILs), followed by the enrichment and expansion of antigen-specific T 
cells in vitro.
23,24
 Novel technologies to engineer cells with genes encoding exogenous T 
cell receptors (TCRs) or chimeric antigen receptors (CARs) have facilitated the 
generation of T cells with defined specificity, affinity, and avidity.
2,3,22,25
  
Despite its immense promise, several limitations must be overcome in order for 
adoptive cell transfer to be translated into a widely used immunotherapy. The process of 
cell isolation from autologous or allogeneic donors is often difficult and inefficient. 
Populations of antigen-specific cytotoxic T lymphocytes (CTLs) or TILs may be very 
rare, making it difficult to obtain sufficient numbers during enrichment. In addition, it is 
not uncommon for TILs to be non- or sub-functional due to the immunosuppressive 
nature of the tumor microenvironment.
23,24
 Expanding the desired T cell population to 
clinically relevant numbers (> 10
10
 per infusion) can take several months - a time frame 
that is inappropriate for advanced diseases requiring immediate intervention.
23,24
 While 
the use of T cells expressing exogenous receptors eliminates the need to screen and 
 2 
enrich for a population of interest, it still relies on peripheral blood isolation and poses 
the potential of implanting genetically modified cells that could be oncogenic.  
Therefore, a high-throughput in vitro system for generating antigen-specific T 
cells that can be used “on demand” is needed. The multipotency of stem cells, or their 
ability to differentiate into multiple types of cells, makes them attractive sources from 
which adoptive transfer T cells can be generated, and ideal candidates with which to 
study T lymphopoiesis. With the advent of umbilical cord blood (UCB) banks, 
hematopoietic stem cells (HSCs), which are capable of differentiating into the various 
blood lineages, have become readily accessible and routinely used for transplants in 
cancer patients. The retrieval of cord blood is relatively easy, as it is delivered during 
childbirth, and much work has already been done to optimize the isolation and expansion 
of cord blood-derived HSCs.
26
 
T cells are unique from other subsets of white blood cells in that they develop 
within the thymus, not the bone marrow. In the adult, the start of T cell development 
begins when common lymphoid progenitors (CLPs) migrate into the thymus from the 
bone marrow. Two signals, presented by thymic epithelia are essential for proper T 
lymphopoiesis: (1) Notch receptor-Delta like ligand (DLL) signaling and (2) TCR-major 
histocompatibility complex (MHC) or human leukocyte antigen (HLA) signaling.
27,28
 
Work pioneered by Dr. Zúñiga-Pflücker’s laboratory has shown that stromal cells 
expressing Delta like ligands can induce the development of mature T cells from mouse 
and human HSCs.
29-35
 This system has been seminal for studying the biology of in vitro T 
cell differentiation; however it is not scalable or clinically relevant. Others have 
demonstrated that immobilized Notch ligands, with a defined combination of cytokines, 
can commit HSCs to the T lineage and induce early T cell development, although the 
 3 




Antigen-specific T cells for adoptive transfer are typically obtained by expanding 
ex vivo-isolated T cells with epitope-loaded antigen-presenting cells (APCs).
23,24
 
Alternatively, numerous studies have shown that artificial antigen-presenting cell (aAPC) 
microbeads, functionalized with co-stimulatory molecules and/or peptide MHC (pMHC) 
or peptide HLA (pHLA) oligomers, can be used to expand specific T cell populations.
41-
43
 Based on work published by Dr. Krishnendu Roy’s laboratory, showing that antigen-
specific CD8
+
 T cells can be generated from murine progenitors using pMHC Class I 
tetramers,
44
 it was hypothesized that treating human stem cell-derived T cell progenitors 
with artificial pHLA tetramers could induce the differentiation of antigen-specific CTLs.  
With this objective in mind, a scalable system with quantitatively controlled 
ligand presentation, free of stromal cell contact, was designed. This system, which 
employed immobilized Notch ligands, exogenous pHLA tetramers, and supporting 





hematopoietic progenitors into functional, antigen-specific CD8
+
 T cells. In order for 
antigen-specific T cells to be used in the clinic, they must have the capacity to expand. In 
this dissertation, progenitor-derived antigen-specific CD8
+
 T cells were enriched and 
cultured in the presence of T cell expansion factors. Results indicate that the enriched, 
progenitor-derived T cells remained functional throughout the expansion culture, but did 
not undergo robust proliferation. These studies, as well as possible solutions to enhance 
expansion, are described in detail in Chapter 4. 
Within the thymus, the signaling strength resulting from TCR-pMHC engagement 
plays a critical role in positive and negative selection, as well as the CD4 versus CD8 
lineage commitment, of developing T cells.
45-50
 Many studies have focused on the role of 
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pMHC density and solid phase presentation on mature T cell activation and function;
51-55
 
however, much less is known about how these parameters influence the development of 
thymocytes ex vivo or how they affect antigen-specific differentiation. To investigate the 
effects of pMHC density and surface presentation on TCR signaling and T cell 
differentiation, T cell progenitors were cultured with microplates and beads 
functionalized with varying densities of pMHC molecules. It was found that pMHC-
immobilized plates and beads could trigger TCR signaling more efficiently than soluble 




1.2 SPECIFIC AIMS 
The specific aims of this exploratory and developmental research are as follows: 
1.2.1 Aim 1: To generate functional, antigen-specific CD8+ T cells from human 
CD34
+
 umbilical cord blood hematopoietic progenitors using immobilized Notch 
ligands, soluble pHLA tetramers, and stromal cell-conditioned media:  
In this aim, a system to generate antigen-specific CD8
+
 T cells from CD34
+
 UCB 
HSCs was rationally designed. Based on previous evidence, it was hypothesized that 
immobilized Notch ligands, in particular DLL1, could induce T lineage commitment and 
early T cell development. Secreted factors from the bone marrow-derived stromal cell 
line expressing DLL1, OP9-DL1, were included to support differentiation. To confirm 
successful T lineage commitment and early T cell development, the phenotype of the 
cells was evaluated after 16 and 25 days of culture with immobilized DLL1. At day 25, 
early T cells were cultured with pHLA Class I tetramers presenting cytomegalovirus 
(CMV) or influenza (GIL) epitopes. After 7 days, T cell maturation and antigen-
specificity was confirmed using flow cytometry. The cytotoxic activity of the 
differentiated T cells against epitope-loaded target cells was determined by CD107a 
mobilization, interferon gamma (IFNγ) production, and granzyme B activity.  
1.2.2 Aim 2: To enrich and expand progenitor-derived antigen-specific CD8+ T 
cells to clinically relevant numbers: 
Next, the capability of progenitor-derived antigen-specific CD8
+
 T cells to expand 
to clinically relevant numbers was evaluated. Due to their easy accessibility and high cell 
yields, murine C57BL/6 double positive (DP) thymocytes were used as starting 
populations for these experiments. Sorted DP thymocytes were differentiated with pMHC 
tetramers presenting ovalbumin or lymphocytic choriomeningitis virus epitopes 
(OVA257p-MHC and LCMV.GP34p-MHC, respectively), in media supplemented with 




 single positive (SP) T cells were sorted and then expanded with 
the respective tetramers for an additional 7 days, in media containing anti-CD3, anti-
CD28, and IL-2. After 7 days of expansion, cells were harvested and analyzed by flow 
cytometry to confirm antigen-specific enrichment. The functionality of the enriched, 
antigen-specific T cells was tested using granzyme B activity assays.  
1.2.3 Aim 3: To quantitatively evaluate the effects of plate- and bead-immobilized 
pMHC oligomers on TCR signaling and the antigen-specific differentiation of 
immature thymocytes: 
To complete this aim, microplates and microbeads were fabricated with 
OVA257p-MHC Class I molecules at varying densities. Ligand density was quantified, 
and DP thymocytes from OT-1 transgenic mice were cultured with OVA257p-MHC-
functionalized microplates, microbeads, or soluble tetramers at equivalent numbers of 
pMHC molecules per cell. Ligand density was also varied to determine its effect on 
thymocyte stimulation. TCR signaling was evaluated by the expression of activation 
marker, CD69. To determine the efficiency of microplates and beads to induce antigen-
specific differentiation, DP thymocytes from C57BL/6 mice were cultured with 
LCMV.GP34p-MHC-functionalized plates, beads, or soluble tetramers at equivalent 
numbers of pMHC molecules per cell. As with the signaling assays, ligand density was 
varied to determine its effect on thymocyte differentiation. T cell maturation and antigen-




The body of this research dissertation focuses on generating functional, antigen-
specific T cells from HSCs and progenitors, with the end goal of adoptive transfer 
immunotherapy. In the following chapter, Chapter 2, adoptive T cell transfer is outlined 
to provide the long-term motivation for this project. Information regarding in vivo and in 
vitro T cell development, from which the rational design of this project is based, is also 
discussed. In Chapter 3, the generation of human antigen-specific CD8
+
 T cells from 
hematopoietic progenitors using a novel, scalable differentiation system, employing 
Notch and TCR ligands, is presented. The enrichment and expansion of progenitor-
derived antigen-specific CD8
+
 T cells is described in Chapter 4. Chapter 5 details the 
fabrication of microplates and microbeads with varying densities of pMHC ligand. The 
ability of these surfaces to stimulate thymocytes and induce antigen-specific 
differentiation is investigated in Chapter 5 as well. Lastly, Chapter 6 discusses the 




PTLD – post-transplant lymphoproliferative disease 
TIL – tumor-infiltrating lymphocyte 
TCR – T cell receptor 
CAR – chimeric antigen receptor 
CTL – cytotoxic T lymphocyte 
HSC – hematopoietic stem cell 
UCB – umbilical cord blood 
CLP – common lymphoid progenitor 
DLL – Delta like ligand 
MHC – major histocompatibility complex 
HLA – human leukocyte antigen 
APC – antigen-presenting cell 
aAPC – artificial antigen-presenting cell 
pMHC – peptide major histocompatibility complex 
pHLA – peptide human leukocyte antigen 
OP9-DL1 – stromal cells expressing Delta like ligand 1 
CMV – cytomegalovirus 
GIL – influenza 
IFNγ – interferon gamma 
DP – double positive 
OVA257p-MHC – ovalbumin epitope (SIINFEKL) pMHC 
LCMV.GP34p-MHC – lymphocytic choriomeningitis virus glycoprotein epitope 
(AVYNFATC) pMHC 
IL – interleukin 
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SP – single positive 
OT-1 – transgenic mouse line with T cells expressing receptors specific for OVA257p-
MHC 
SIINFEKL – (serine – isoleucine – isoleucine – asparagine – phenylalanine – glutamic 
acid – lysine – leucine) 
AVYNFATC – (alanine – valine – tyrosine – asparagine – phenylalanine – alanine – 
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Chapter 2: Background and Significance 
2.1 T CELL ADOPTIVE TRANSFER IMMUNOTHERAPY 
Over the past two decades, the use of adoptive T cell transfer as a treatment for 
cancer and post-transplant lymphoproliferative diseases (PTLDs) has become a clinical 
reality due to advances in the fields of immunology and tumor biology.
1-23
 Adoptive T 
cell therapy encompasses the use of circulating cytotoxic T lymphocytes (CTLs), tumor 
infiltrating lymphocytes (TILs), or genetically modified cells that express high-
affinity/avidity T cell receptors (TCRs) or chimeric antigen receptors (CARs) as 




Figure 2.1: Schematic of adoptive transfer T cell therapy. Endogenous T cells (TILs or 
CTLs) are isolated, and expanded with antigen-presenting cells, or 
genetically modified with exogenous TCRs or CARs prior to reinfusion.
*
 
                                               
* Reproduced with permission from The Authors © 2014 via the Creative Commons Attribution License 
(CC BY), Published by Elsevier Ltd.: Trends in Biotechnology.5  
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 The efficacy of adoptive T cell transfer relies on the ability of T lymphocytes to 
specifically recognize and eliminate target cells with long-lasting immune protection. 
Numerous strategies have been developed to isolate and expand antigen-specific T cells, 
engineer lymphocytes with desired specificities and effector functions, and to improve 
the in vivo efficacy and safety of adoptively transferred T cells.  
This chapter focuses on the clinical promise of endogenous CTLs and TILs, as 
well as genetically modified TCR- and CAR-expressing T cells, for the treatment of 
cancers and viral infections. The limitations and safety concerns of each cell type will be 
debated, and an alternative process for producing antigen-specific CTLs, by 
differentiating stem cell into T cells, will be discussed. It was hypothesized that by using 
stem cells to generate functional T cells, the limitations associated with CTL and TIL 
isolation, and the dangers of using TCR- or CAR-modified T cells, could be minimized. 
The rational design of the proposed system will be presented in the biological context of 
T cell development and the various methods that are currently used to differentiate T cells 
in vitro. 
2.1.1 General Approaches for the Isolation, Enrichment, and Expansion of 
Endogenous Adoptive Transfer T Cells 
Significant progress has been made to optimize the isolation and expansion of 
antigen-specific CTLs or TILs, as well as to extend the in vivo persistence of ex vivo-
manipulated T cells. In order to generate sufficient numbers of cells for infusion, T 
lymphocytes must first be isolated from a patient’s resected tumor tissue or peripheral 
blood. In the case of resected tumors, TILs are disaggregated from the tissue and 
expanded in vitro for 4-8 weeks.
13,17
 Patients are pre-conditioned with lymphodepleting 
agents such as cyclophosphamide or fludarabine, and after T cell transfer, high doses of 





Figure 2.2: TIL therapy. TILs are dissociated from tumor tissue, followed by A) 
enrichment and expansion with IL-2 for 4-8 weeks. Young TIL cultures 
undergo shorter expansion periods, which are thought to yield cells with 
greater proliferative potential. B) Patients undergo lymphodepleting 
regimens prior to infusion. TILs are infused, and high doses of IL-2 are 
given post-infusion to enhance the tumor response.† 
From the peripheral blood, antigen-specific T cells of interest are enriched and 
expanded using multiple rounds of stimulation with autologous epitope-presenting 
antigen-presenting cells (APCs).
13,17
 Following enrichment, the cells are sorted by 
fluorescence activated cell sorting (FACS) or cloned by limiting dilution and further 
expanded using irradiated feeder cells in the presence of co-stimulatory factors, anti-
CD3, anti-CD28, and interleukin (IL)-2 (Figure 2.3).
13,17
 It takes approximately 6-14 
weeks to generate sufficient numbers of cells required for each infusion (≥ 5 to 10 
                                               
† Reproduced and adapted with permission from © 2013 John Wiley & Sons Inc: Immunological Reviews, 




 Alternatively, the starting polyclonal T cell population can be non-
specifically expanded using several rounds of stimulation with anti-CD3 and anti-CD28 
antibodies.
13,17
 The expanded population can be genetically modified with TCRs or CARs 
of interest, screened for effector function, and/or depleted of regulatory T (TREG) cells to 





Figure 2.3: Circulating antigen-specific T cell therapy. A) CTLs are stimulated and 
enriched from isolated PBMCs using APCs and then B) selected for antigen-
specificity by cloning or sorting. Cells are expanded by several rounds of 
stimulation before reinfusion.‡ 
The best results to date for the rapid expansion of CTLs utilizes irradiated 
allogeneic peripheral blood mononuclear cells (PBMCs).
24
 While this method of 
expansion has been successful, it has been difficult to translate clinically. Due to patient 
                                               
‡ Reproduced and modified with permission from © 2013John Wiley & Son Inc: Immunological Reviews, 
2013. John Wiley & Sons A/S retains rights to all figures reproduced here.17 
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variability and the inherent inefficiency of primary cell isolation, the scale-up of PBMCs 
for T cell expansion is expensive, tedious, and unable to conform to FDA-mandated 
requirements for validation. As a result, much effort has been given to the development 
of non-patient derived artificial APCs (aAPCs) capable of supporting large-scale adoptive 
transfer clinical trials.  
Murine fibroblasts, engineered to express exogenous peptide human leukocyte 
antigen (pHLA) molecules and/or co-stimulatory molecules, have been used to expand 
melanoma antigen recognized by T cells (MART)-1-specific and glycoprotein (gp)100-
specific CTLs.
25,26
 Fc-expressing cell lines coated with co-stimulatory antibodies have 
also shown promise in stimulating polyclonal populations of T cells.
27
 Acellular 
expansion methods, which can more easily conform to Good Manufacturing Practice, 
have also been fabricated and evaluated. The non-specific expansion of T cells has been 
shown using beads coated with anti-CD3 and/or anti-CD28 antibodies.
28
 Additionally, 
microplates and microbeads, loaded with oligomeric forms of pHLA molecules, have 
shown promise in expanding various types of cancer and virus-specific CTLs, such as 





expanded cells have been shown to retain functionality and are capable of killing antigen-
loaded target cells after ex vivo manipulation.  
2.1.2 Antigen-Specific CTLs and TILs for Adoptive Transfer 
Over the last two decades, the use of endogenous T cells, isolated from peripheral 
blood or tumor resections, as therapeutic agents in adoptive transfer immunotherapy has 
become increasingly promising. Numerous strategies to optimize isolation and expansion, 
direct functionality, and increase the in vivo efficacy and persistence of endogenous, 
antigen specific CTLs or TILs has made patient-specific adoptive transfer a clinical 
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reality. Adoptive T cell transfer has shown success in the treatment of renal cancer, 
leukemia, multiple myeloma, and prostate cancer, as well as PTLDs, such as CMV and 
Epstein-Bar Virus (EBV); however, some of the most well-studied and promising  results 
have been seen in the treatment of melanoma. 
2.1.2.1 Circulating Antigen-Specific T Cells and TILs for Treatment of Melanoma 
The basis for adoptive T cell therapy as a treatment modality for cancer relies on 
the idea that a circulating population of tumor antigen-specific T cells exists in vivo. The 
earliest evidence for this was shown in metastatic melanoma patients who, when given 
high doses of immunomodulatory cytokines, such as interferon gamma (IFNγ) or IL-2, 
were more likely to exhibit clinical responses if they developed signs of autoimmune 
vitiligo.
32
 The advent of peptide major histocompatibility complex (pMHC  in mice, 
pHLA in humans) multimer technology facilitated the detection of antigen-specific T cell 
populations, and confirmed that populations of potentially reactive tumor antigen-specific 
T cells exist in melanoma patients.
33
  
The first phase II clinical adoptive transfer trial for patients with melanoma was 
performed using a preparative dose of cyclophosphamide followed by high numbers of 
TILs (up to 2 x 10
11
) and high-dose IL-2 infusions every 8 hours.
34
 Eleven of the 20 
patients in this study experienced tumor regression at multiple metastatic sites. Studies 
performed by Yee and colleagues using melanoma-specific CTL clones, isolated from 
PBMCs, have also shown promise in treating metastatic melanoma.
35
 In their work, 
Chapius et al. expanded autologous MART-1 and gp100-specific T cell clones up to 20-






 Four infusions of CTLs with subsequent low-
doses of IL-2 were administered to 10 patients, without serious toxicity.
35
 8 out of 10 
patients maintained minor, mixed, or stable responses for up to 21 months, indicating that 
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adoptively transferred CTLs could mediate the elimination of antigen-expressing tumor 




2.1.2.2 Circulating Antigen-Specific T Cells for Treatment of Human CMV and EBV 
Human CMV is a herpesvirus that infects 50-70% of the population. It is normally 
maintained in a latent state in immunocompetent hosts; however, in settings of T cell 
immunodeficiency, where immune responses to antigen exposure are impaired, primary 
infection or reactivation of the virus can progress to life-threatening conditions.
6,36
 
Patients with acquired immunodeficiency syndrome (AIDS), or those undergoing 
immunosuppressive regimens during allogeneic bone marrow or organ transplantation, 
are at increased risk.
6,36
  
The use of CMV-specific T cells as safe, therapeutic agents in adoptive T cell 
transfer was demonstrated in a Phase I clinical trial performed by Riddell and colleagues. 
In this study, allogeneic bone marrow transplant recipients were given escalating doses of 
CD8
+
 CMV-specific CTL clones isolated from three bone marrow donors.
37
 These clones 
were screened for CMV-specificity, expanded in vitro, and infused into 14 patients 
weekly, for 4 weeks.
37
 After 4 weeks of administration, 11 of the 14 patients exhibited 
CTL responses equivalent to that of donor peripheral blood lymphocytes (PBLs).
37
 
Analysis of TCR gene rearrangements confirmed that the donor-derived CTL clones were 
responsible for reconstitution and persisted in vivo for up to 12 weeks after infusion.
37
 
Interestingly, the CTL response declined in patients who did not reconstitute CMV-
specific CD4
+
 cells, suggesting that T helper (TH) responses may be necessary for the 
long-term persistence of adoptively transferred CTLs. CMV disease was not detected in 




Significant therapeutic potential of adoptive T cell transfer has been demonstrated 
in EBV patients. Similar to CMV, EBV is a herpesvirus that is present in approximately 
90% of adults. CTLs are responsible for controlling EBV, and induced 
immunosuppression can result in PTLD.
38
 In a Phase 2 multicenter clinical trial, 33 
patients bearing EBV epitope-expressing tumors were administered EBV-specific CTL 
clones weekly for 4 weeks.
38
 Consistent with the hypothesis that CD4
+
 TH cells may 
sustain CTL activity, better responses were seen in patients receiving CTLs containing 
higher percentages of CD4
+
 cells. Seventeen of the 33 recipients showed a tumor 
response rate 6 months after administration.
38
  
2.1.2.3 Limitations of Patient-Isolated Antigen-Specific T Cells or TILs 
Despite the success of adoptively transferred TILs and antigen-specific T cells to 
mitigate viral disease and induce tumor regression, limitations associated with the use of 
these cells have prevented adoptive transfer from becoming a more widely used clinical 
therapy. It is often difficult to isolate enough tumor-specific T cells to mediate a 
therapeutic response. In addition, T cells isolated from patients bearing tumors or chronic 
viral infections are often sub-functional due to immunosuppression by the tumor 
microenvironment or from chronic antigen stimulation. Increasing evidence has 
demonstrated that T cells can become exhausted or senescent as a result of 
immunosuppressive signals presented by tumor cells, or by constant antigenic 
stimulation. Thus, the efficiency of isolating functional TILs or antigen-specific T cells 
varies from patient-to-patient and is only successful for some people. Even if sufficient 
numbers of T cells can be isolated, it is often difficult and time-intensive to expand CTL 
clones to sufficient numbers for adoptive transfer. For patients with advanced stages of 
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disease, this is not optimal and has contributed to the high attrition rates of adoptive T 
cell transfer clinical trials. 
2.1.3 TCR Gene-Modified T Cells, CARS, and TRUCKs 
Due to the inherent complications of using endogenous CTLs or TILs, many 
researchers have shifted their efforts to developing T cells with pre-defined antigen-




Figure 2.4: Gene-modified T cell therapy targeted against tumor antigens. A) High-
affinity αβTCRs can be isolated from tumor-specific T cells or from HLA-
transgenic mice. B) CARs consist of an antibody-derived scFv, an 
extracellular linker, a transmembrane domain, and an intracellular T cell-
derived signaling domain.§  
2.1.3.1 TCR Gene-Modified T Cells  
The process of TCR gene transfer has advantages over traditional T cell adoptive 
transfer. First, it eliminates the expensive and time-consuming process of screening for 
patient-derived antigen-specific T lymphocytes.
11,18,39,40
 Additionally, TCR affinity, 
avidity, and stability can be finely optimized to engineer cells with unique functional 
capabilities.
11,18,39,40
 Finally, TCR gene-modified T cells facilitate the production of 
clinically feasible numbers of antigen-specific T cells in a short amount of time.
11,18,39,40
  
                                               
§ Adapted by permission from © 2013 Macmillan Publishers Ltd: Nature Reviews Cancer, 2013. 
Macmillan Publishers Ltd. retains all rights to figures reproduced here.39 
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The majority of TCR-engineered cells that have been clinically evaluated are 
directed against melanoma antigens (MART-1, gp100, carcinoembryonic antigen (CEA), 
and melanoma-associated antigen (MAGE)-A3).
41
 Results from these trials indicate that 
TCR-engineered cells can successfully induce tumor response in patients with metastatic 
melanoma, and can even successfully treat melanoma brain metastasis. However, these 
clinical trials also highlight potential toxicity of engineered TCRs, especially if they 
target antigens present on tumors and normal tissue.
41
 In studies testing MAGE-A3 
engineered TCRs, two patients fell into comas and died, most likely due to the 




Such findings indicate the need for further preclinical optimization and 
characterization of TCRs to reduce cross-reactivity and increase specificity of targeting. 
Vectors have been constructed with various promoters, internal ribosome entry site 
(IRES) elements, and peptide linkers to maximize expression and optimize proper TCRα- 
and TCRβ- pairing in transduced T lymphocytes.43 High-avidity T cells have been 
generated by enhancing TCR transgene expression levels using TCRα- and TCRβ- chain 
genes which have had mRNA instability motifs and cryptic splice sites removed.
44
 
Additionally, high-avidity TCRs can be isolated from allo-specific human T cells or from 
HLA-transgenic mice (Figure 2.4A).
44
  
2.1.3.2 CARs and TRUCKs 
CAR-modified T cells are attractive alternatives to endogenous T cells or TCR-
engineered cells in adoptive transfer therapies.
18,39
 Unlike TCRs, CARs consist of a 
polypeptide chain with a tumor-associated antigen (TAA)-binding domain, derived from 
antibody single-chain variable fragments (scFvs), an extracellular hinge region, a 
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transmembrane domain, and an intracellular signaling chain, normally the TCR-derived 
CD3ζ chain (Figure 2.4B).18,39 As a result, CARs can recognize antigens in a 





Figure 2.5: First, second, and third generation CARs. First generation CARs contain a 
single intracellular signaling domain of T cell-derived CD3ζ subunits. 
Second generation CARs contain the intracellular portion of co-stimulatory 
molecule, CD28, and third generation CARs contain an additional signaling 
unit.** See Section 2.7 for list of abbreviations. 
Upon antigen engagement by the CAR, activation of CD3ζ-associated kinases 
results in T cell stimulation, cytokine production, and increased cytotoxicity (Figure 
2.5).
39
 Second generation CARs have been modified to express co-stimulatory domains 
of CD28 in addition to CD3ζ in order to prolong T cell activation (Figure 2.5).39 Third 
generation CAR T cells have been engineered to contain additional co-stimulatory B7 
                                               
** Adapted by permission from © 2013 Macmillan Publishers Ltd: Nature Reviews Cancer, 2013. 
Macmillan Publishers Ltd. retains all rights to figures reproduced here.39 
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(i.e. inducible T cell co-stimulator (ICOS)) or tumor necrosis factor receptor (TNFR) 
family members (i.e CD137, CD134), and have shown enhanced anti-tumor activity 




Figure 2.6: Differences between CARs and TRUCKs. TRUCKs are CARs that have been 
redirected to secrete cytokines upon antigen-activation. Inducible IL-12 
(iIL-12)-secreting TRUCKs produce IL-12 locally, which attracts cells of 
the innate immune system to enhance the anti-tumor response.†† 
To combat the effects of antigen loss on tumor cells, as well as the 
immunosuppressive effects of TREG cells or myeloid derived suppressor cells (MDSCs), 
CAR-derived T cells known as TRUCKs (T cells redirected for universal cytokine-
mediated killing) have been generated (Figure 2.6).
18
 TRUCKs are CAR T cells that have 
been engineered to release transgenic pro-inflammatory cytokine products at the site of 
                                               
†† Reproduced with permission from © 2013 John Wiley & Sons Ltd: Immunological Reviews, 2013. John 
Wiley & Sons Ltd. retains all rights to figures reproduced here.18 
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targeted tissue. This local accumulation of cytokines attracts a second wave of immune 
cells that can attack cells which are not targeted by the CAR T cells.
18
 The feasibility of 
this technology has been demonstrated using IL-12-expressing TRUCKs. Studies by 
Chmielewski and colleagues have shown that IL-12-secreting TRUCKs can recruit 
natural killer (NK) cells and macrophages to tumor tissue, resulting in enhanced local 
killing.
18
 Additional studies have shown that IL-12-secreting TRUCKs have the capacity 




2.1.3.3 Limitations and Safety Concerns of TCR-Gene Modified T Cells, CARs, and 
TRUCKs 
Re-directing T cell specificity using high-affinity or high-avidity TCRs is a 
promising strategy for adoptive transfer immunotherapy because it eliminates the need to 
screen for patient antigen-specific T cells and allows one to fine tune T cell responses. 
However, re-directed T cells pose several risks. Recent studies indicate that hybrid TCRs 
between exogenous and endogenous TCR chains can form. This could alter the desired 
specificity, resulting in off-target effects and potentially auto-reactive T cells.
18,39,43
 
Transduction of hematopoietic stem cells (HSCs) with TCR genes controlled by 
endogenously active promoters facilitates early, exclusive expression of the exogenous 
TCR and helps to circumvent the risk of autoimmunity.
45
 However, genetic modification 
of HSCs or T cells with retroviral vectors still poses the threat of insertional mutagenesis, 
potentially resulting in lymphoma.
18,39,43
  
Similar concerns apply to CAR-modified T cells. Unexpected targeting may occur 
in vivo, and insertional mutagenesis during genetic modification poses safety concerns. In 
addition, systemic inflammatory reactions known as cytokine release syndrome (CRS), 
have been reported.
13,18,39-41
 CRS is caused by an acute systemic immune response 
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mediated by T cells, B cells, NK cells, and macrophages which release large amounts of 
cytokines.
13,18,39,41
 This response is seen in GVHD, monoclonal antibody treatment, and 
during severe bacterial and viral infections, and can lead to organ damage, heart failure, 
and in some cases death. CRS has been observed in clinical trials utilizing CD19- or 
CD20-specific CAR T cells to treat hematologic malignancies.
11,19-21
 Out of six clinical 
trials reporting CRS, two-thirds of patients who were administered CAR T cells 
experienced CRS within 6-20 days post-infusion.
46,47
 Two cases have reported fatalities. 
Corticosteroids and immunosuppressive cytokines are currently used to alleviate 
symptoms of CRS.
18,19,46,47
 Efforts to minimize CRS occurrence during CAR T cell 
therapy have been proposed, including the in-depth quantification of cytokine levels and 
identification of cytokine polymorphisms that may make patients more susceptible to 
CRS.
18,19,46,47
 Additionally, a conservative dose-escalation strategy has been implemented 
for many Phase I clinical trials, and the design of short-lived or less-differentiated CAR T 
cells is being pursued.
18,19,46,47
 
2.1.4 Optimal Extrinsic and Intrinsic Conditions for Ex Vivo Expanded T Cells  
 Extrinsic conditions, such as preemptive lymphodepletion or nonmyeloablative 
conditioning, have been shown to enhance the efficiency of adoptively transferred T 
cells, either by eliminating suppressor TREG cells and/or MDSCs, or by reducing 
competition for homeostatic cytokines, IL-7 and IL-15.
48,49
 In studies done by Gattinoni 
et al., the genetic deletion of TREG cells significantly enhanced anti-tumor efficacy of 
adoptively transferred CTLs.
48
 By systematically deleting γc cytokine-responsive cells, 
Gattinoni and colleagues showed enhanced anti-tumor responses due to increased CTL 
functionality, but not number.
48
 However, genetic deletion of IL-7 and IL-15 abrogated 
CTL effectiveness.
48
 Their data indicates that lymphodepletion enhances the functionality 
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of adoptively transferred CTLs by removing endogenous cells that compete for cytokines. 
These findings have been corroborated by Wrzesinksi et al., who have demonstrated that 
the intensity of lymphodepletion and the anti-tumor efficacy of adoptively transferred 
CTLs are positively correlated.
49
  
  The subsets of CD8
+
 T cells that are available for adoptive transfer express 
distinct surface markers and differ greatly in terms of function and homing ability. One 
crucial limitation of adoptive T cell transfer has been the inability of T lymphocytes to 
persist and maintain functionality in vivo. Recent studies to identify T cell subsets, 
including naïve (TN) T cells, antigen-experienced central memory (TCM) and effector 
memory (TEM) T cells, which are capable of in vivo persistence, indicates that the 
selection of T cells prior to adoptive transfer is critical.
50
 Riddell and colleagues have 
demonstrated that effector cells derived from CD62L
hi
 TCM cells have the capability of 
re-expressing the molecules required for homing and persisting in the lymphoid organs. 
CD62L
hi
 TCM cells are also capable of establishing reservoirs of TCM and TEM cells, which 
are necessary for long-lasting immune reconstitution.
50
 These findings demonstrate that 
the intrinsic properties of T cells are important factors to consider when screening T 
lymphocytes for adoptive transfer.    
2.2 DIRECTION OF THIS TREATISE 
Numerous clinical studies have shown the potential of adoptively transferred T 
cells to treat malignancies and viral diseases, and much research has gone towards 
developing new targeting strategies, as well as to understanding the biology behind T cell 
transfer. These findings have undoubtedly enhanced the field of immunotherapy; 
however, they also highlight the limitations and safety concerns associated with using 
endogenous or genetically modified T cells. As a result, a high-throughput method for 
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generating antigen-specific CTLs, without the unforeseen risks of genetic modification, is 
needed. It was hypothesized that stem cells could serve as renewable sources for adoptive 
transfer T cells. To support this hypothesis, the biology behind T cell development and 
the successes of many groups to generate T cells from stem or progenitor cells in vitro are 
discussed in Sections 2.3 and 2.4.  
2.3 T CELL DEVELOPMENT IN THE THYMUS 
2.3.1 Stages of T Cell Development  
T cells are unique lymphocytes that develop primarily in the thymus. The unique 
microenvironment within the thymus provides signals that drive the generation of a 
diverse repertoire of self-restricted and self-tolerant T cells. Thymic seeding progenitors 
(TSPs) enter the thymus from the adult bone marrow at the cortical-medullary junction. 
There, the progenitors undergo T lineage commitment followed by a series of well-
characterized phenotypic changes (Figure 2.7).
51,52
 Initially, the cells are double negative 




), and are subdivided based on the presence of CD25 




) have the potential to become αβ T cells, γδ T cells, 





Figure 2.7: T cell development within the thymus. Hematopoietic progenitors migrate 
from the bone marrow to the thymus. Notch signaling induces T lineage 
commitment and differentiation through the DN1-DP stage. pMHCs on the 
surface of APCs induce positive and negative selection, resulting in a 




 T cells.‡‡   










) indicates full commitment to the T cell lineage.
51,52
 DN3 cells 
                                               
‡‡ Adapted by permission from © 2004 Macmillan Publishers Ltd: Nature Reviews Immunology, 2004. 
Macmillan Publishers Ltd. retains all rights for figures adapted here.52 
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express pre-TCRs consisting of a successfully rearranged TCRβ chain, associated with 
invariant TCRα and invariant CD3 signaling molecules. The expression of a productive 
pre-TCR rescues these precursors from apoptosis and initiates proliferation.
51,52
 The 




) stage, followed by an up-regulation 











Approximately 98% DP thymocytes will undergo apoptosis during a series of 
developmental checkpoints known as positive and negative selection. During positive 
selection, DP thymocytes, which primarily inhabit the thymic cortex, undergo “death by 
neglect” if their αβTCRs fail to engage self pMHCs, presented by cortical thymic 
epithelial cells (cTECs), with appreciable affinity.
51,52
 Cells that bind with intermediate 





 cells, respectively. SP T cells migrate to the medulla, where they come 
into contact with Aire
+
 medullary TECs (mTECs) expressing tissue-restricted antigens 
(TRAs).
51,52
 Thymocytes that bind with high affinity to these self-antigens undergo 
negative selection and are eliminated from the repertoire. Thymocytes that pass both 








2.3.2 Notch-DLL and TCR-pMHC Signaling in T Lymphocyte Development 
The development of T cells within the thymus is a highly controlled and well-
orchestrated process dependent on two sequential signals: 1.) Notch receptor-Delta like 
ligand (DLL) signaling and 2.) TCR-pMHC signaling.
51,52
 The quality and quantity of 
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these two cues are critical for T lymphoid commitment, progression through the various 
developmental stages, and the production of self-recognizing, non-autoimmune T cells.  
2.3.2.1 Notch Signaling in T Lymphopoiesis 
Notch receptors are highly conserved heterodimeric transmembrane proteins that 
are essential for transducing signals that control cell fate decisions, including T cell 
development. Mammalian Notch receptors (Notch 1-4) recognize the DSL ligands (Delta, 
Serrate/Jagged, Lag), and upon ligand binding, the extracellular portion of the Notch 
receptor undergoes proteolytic cleavage by a disintegrin and metalloproteinase 
(ADAM).
51,54-59
 The second proteolytic cleavage of Notch, mediated by γ-secretase, 
cleaves the intracellular portion, which translocates to the nucleus and interacts with C-
promoter binding factor 1 (CBF1) to promote the transcription of hairy and enhancer of 
split (HES) gene products (Figure 2.8).
59
  
Notch signaling is essential for proper T lymphopoiesis. Studies have shown that 
deletion of Notch-1 in bone marrow stem cells results in a population of immature 
thymocytes that express markers similar to B cell precursors of the bone marrow; 
however, the absence of Notch-1 does not affect the development of B cells in the bone 
marrow or spleen.
56,60-63
 Conversely, gain-of-function experiments show that bone 
marrow stem cells with constitutively expressed Notch-1 give rise to T lineage-
committed cells expressing CD4, CD8, Thy1, CD3 and TCRβ in the bone marrow.56,60-63 
Constitutively expressed Notch-1 also prevents bone marrow stem cells from 
differentiating into B cells, suggesting that Notch signaling inhibits B lineage 
commitment, which may be sufficient to induce T cell lineage commitment.
56,60-63
 
In the context of the thymus, Notch-1 receptors on the surface of lymphoid 
progenitors interact with DLLs presented by TECs. While both DLL1 and DLL4 are 
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expressed by TECs, conditional deletion experiments have shown that only DLL4 is 
essential for T cell development.
64-66
 When ectopically expressed on OP9 stromal cells, 
lower levels of DLL4 than DLL1 are needed to induce T cell development.
67
 However, it 
has been shown that both DLL1- or DLL4-expressing stromal cells are capable of 




Figure 2.8: Notch-Delta (like) ligand binding induces cleavage of extracellular Notch via 
ADAM, followed by cleavage of intracellular Notch by γ-secretase. 
Intracellular Notch translocates to the nucleus and binds to the CSL (Cbf1, 
Su(H), and LAG-1) protein, facilitating transcription of HES genes.§§ 
2.3.2.2 TCR-pMHC Signaling in T Lymphopoiesis 
TCR-pMHC signaling strength is known to drastically influence the fate and 
survival of developing thymocytes, both in the context of positive and negative selection, 
and the CD4 versus CD8 lineage decision.
68,69
 TCR-pMHC interactions span a wide 
range of affinities due to the diversity of TCRs and self-peptides displayed on each MHC. 
                                               
§§ Adapted by permission from © 2006 Macmillan Publishers Ltd: Nature Reviews Cellular and Molecular 
Biology, 2006. Macmillan Publishers Ltd. retains all rights for figures adapted here.59 
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It is well-established that the strength of TCR signaling determines qualitatively different 
cell fates during development. Experiments using TCR transgenic mice have shown that 
a narrow affinity window for positive versus negative selection exists and slight 
alterations in affinity can change fate of immature thymocytes.
70-74
 Recent work done by 
Moran and colleagues has shown that T cells undergoing negative selection receive 





TREG cells perceive stronger TCR signals than conventional CD4
+





Figure 2.9: The kinetic signaling model used to explain CD4/CD8 lineage commitment. 
According to this theory, DP thymocytes that receive positive 





 cells. The absence of Class I signaling results in IL-7-induced 
coreceptor reversal and directs cells to the CD8
+
 lineage. Sustained 




Several models have been presented to explain how strength of signal influences 
the CD4/CD8 lineage commitment.
69
 An early model, termed the stochastic selection 
                                               
*** Reproduced by permission from ©2008 Macmillan Publisher Ltd: Nature Reviews Immunology, 2008. 
Macmillan Publisher Ltd. retains all rights to figures reproduced here.69 
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model, suggested that the termination of co-receptor gene expression was a random 
event, and only thymocytes with matching TCRs and co-receptors survived.
75,76
 
According to the instructive strength- or duration-of-signal models, differences in signal 
strength or duration, transduced via the TCR and co-receptor, instruct lineage 
commitment, with stronger/longer signals directing CD4
+
 lineage commitment and 





There has been much debate over the accuracy of these models. The most recent 
findings suggest that IL-7R signaling acts as a sensor for TCR signaling (Figure 2.9).
69,83
 




 DP cells that receive positively 







 Loss of signal from Class I molecules at the ISP stage permits 










 stage blocks IL-7 signaling and results in CD4
+
 SP commitment. This 




2.4 CURRENT T CELL DIFFERENTIATION SYSTEMS 
2.4.1 Ex Vivo Methods to Study T Cell Development 
2.4.1.1 Fetal Thymus Organ Culture and Reaggregate Thymus Organ Culture 
Many systems to study T cell development and generate T cells ex vivo have been 
explored, the earliest of these being fetal thymus organ culture (FTOC). FTOC has been a 
seminal tool for studying T cell development and the role of thymic stromal cells in T 
lymphopoiesis.
84
 This system involves the isolation and in vitro maintenance of 
embryonic thymic lobes.
84
 Modifications of FTOC, such as hanging drop cultures or 
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reaggregate thymus organ culture (RTOC), in which defined cohorts of thymocytes 
and/or stromal cells are cultured together, has provided much insight into specific stages 
of T cell development.
84
 However, from a clinical standpoint, using FTOC and RTOC to 
generate transplantable T cells is not feasible. 
2.4.2 In Vitro Methods to Study T Cell Development 
2.4.2.1 OP9 Cells for In Vitro Hematopoiesis and B Cell Development 
Nakano and colleagues were the first group to show that the bone marrow stromal 
cell line, OP9, could direct undifferentiated embryonic stem cells (ESCs) into the 
erythroid, myeloid and B cell lineages.
85
 Later efforts by Cho et al. showed that the 
addition of FMS-like tyrosine kinase 3 ligand (Flt3L) to the OP9/ESC co-culture 
enhanced B lymphopoiesis and the proliferation of B cell progenitors.
86
 The temporal 
progress and phenotypic characteristics of ESC-derived B cell precursors in the OP9/ESC 
system were analogous to that of progenitor and mature B cells in vivo.
86
 Although OP9 
co-cultures were successful in producing multiple types of hematopoietic cells in vitro, T 
cells could not be generated because OP9 cells do not express the Notch ligands 
necessary for T cell commitment and differentiation. 
2.4.2.2 Notch Ligand-Expressing OP9 Cells for Murine T Cell Development 
Efforts to generate T cells in vitro using Notch ligand-transfected OP9 cells were 
pioneered by Dr. Zúñiga-Pflücker and colleagues. Schmitt et al. developed OP9 cells 
expressing high levels of DLL1 via retroviral transfection (OP9-DL1) (Figure 2.10).
57
 












 immature DP T cells and a small population of CD8
+
 SP T cells after 12 
days, similar to the time frame following transfer of HPCs into FTOC.
57
 In HPC-derived 
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 SP T cells isolated from co-cultures could respond to plate-
bound anti-CD3 and anti-CD28, and were capable of activation-induced proliferation and 
IFNγ production.57  
Schmitt et al. have also demonstrated that murine ESCs are able to differentiate 
into functionally mature CD8
+
 T cells using OP9-DL1 co-culture (OP9-DL1/ESC). 
Importantly, ESC-derived T cell progenitors can reconstitute immunodeficient mice and 
mount a functional immune response.
87









DN cells were sorted from OP9-DL1/ESC co-cultures and transferred into fetal thymic 














 T cells. Rag2
-/-
 mice reconstituted with ESC-derived T cell progenitors 
were also able to mount an immune response similar to that of normal C57BL/6 mice 




Figure 2.10: Schematic of OP9-DL1/stem cell co-culture.††† 
                                               
††† Adapted by permission from © 2004 Macmillan Publishers Ltd: Nature Reviews Immunology, 2004. 
Macmillan Publishers Ltd. retains all rights for figures adapted here.52 
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2.4.2.3 Notch Ligand-Expressing OP9 Cells for Human T Cell Development 
La Motte-Mohs et al. have used the OP9-DL1 co-culture system to differentiate 




 HSCs cultured on OP9-DL1 
monolayers rapidly express CD38 and follow the normal steps of human T cell 













 SP T cells.
55
 Further studies indicate that human CD8
+
 SP T cells 
generated from OP9-DL1 co-cultures are functionally equivalent to ex vivo thymus-
derived T cells and bear a diverse TCRVβ repertoire.55 Pro-T progenitors from OP9-DL1 
co-cultures showed successful engraftment when transferred into immunocompromised 
NOD/SCID/γcnull or BALB/c Rag2-/-γc-/- mice, as CD3-expressing CD4+CD8+ DP cells, 
CD4
+
 SP, and CD8
+
 SP cells were found 4-6 weeks after transplantation.
88
  
2.4.2.4 Antigen-Specific and Self-Tolerant T Cells from OP9-DL1 Co-Cultures 
Results show that an antigen-specific response can be initiated by in vitro-derived 
murine CD8
+
 T cells from OP9-DL1 co-cultures. Bulk CD8
+
 cells from OP9-DL1 co-
cultures were stimulated with DCs presenting model antigens, gp33 or human tyrosinase-
related protein (hTrp)2.
89
 For both epitopes, the frequency of antigen-specific T cells 
were similar to those observed in ex vivo CD8
+
 T cells at the time of peak response, 14 
days after DC stimulation, demonstrating the ability of in vitro-derived cells to mount a 
normal antigen response.
89
 Additionally, mixed lymphocyte reaction (MLR) assays 
indicate that in vitro-derived T cells are self-tolerant. When CD8
+
 T cells from OP9-DL1 
cultures were stimulated with irradiated, syngeneic PBMCs, no proliferation was 
detected.
89
 As expected, CD8
+
 T cells cultured with allogeneic splenocytes displayed 
increased proliferation. Upon transfer of in vitro-derived, carboxyfluorescein 
succinimidyl ester (CFSE)-labeled CD8
+
 T cells into syngeneic mice, no proliferation 
was observed, confirming a loss of self-reactivity.
89




 T cells were transferred into allogeneic mice, suggesting that in 




2.4.2.5 Limitations of OP9-DL1 Co-Cultures 
While promising, the therapeutic use of the OP9-DL1 co-culture systems is 
complicated by several factors. The inherent nature of co-culture systems poses 
difficulties for large scale T cell production, especially in 3D biomimetic scaffolds or 
bioreactor cultures. Using genetically-modified feeder cells complicates clinical 
applications because they must be separated to yield a pure T cell population, free of 
contaminating stromal cells. Recent studies have also demonstrated the dependence of 
Notch ligand dose on T cell differentiation. By using a cell-based system, such as OP9-
DL1 co-culture, it is difficult to control and validate the amount of Notch ligand 
presented to progenitors in mixed cultures.  
2.4.3 Immobilized Notch Ligands for T Cell Differentiation 
2.4.3.1 Plate-Immobilized Notch Ligands Induce Early Murine T Cell Development in 
a Dose-Dependent Manner 
Several reports indicate that plastic plates, immobilized with DLL1, along with a 
defined combination of cytokines, can induce Notch signaling and early T cell 




 HPCs in a dose-dependent 
manner. Dallas et al. showed that culture of mouse LSK cells with high densities (≥ 1.25 
µg/mL) of immobilized DLL1 resulted in a 4-log increase of Thy1+CD25+ T cell 
precursors compared to control cultures.
90
 After 28 days of culture with Notch ligand-
coated plates, CD3 and TCRα expression was significantly higher compared to control 
cultures, and increased in a dose-dependent manner.
90
 High densities of immobilized 
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 B cell 
precursors increased when lower densities of DLL1 was used (≤ 1.25 µg/mL).90  
2.4.3.2 Lymphoid Commitment of Human Cord Blood CD34+ Cells Using Plate-Bound 
Notch Ligands 










with low densities of immobilized DLL1 (< 5 µg/mL) resulted in a 5-fold increase in 
CD7
+ 
lymphoid-committed cells compared to the control cultures after 21 days.
91
 A 
progressive increase in CD7
+
 lymphoid cells was observed with increasing concentrations 
of DLL1, suggesting that lymphoid maturation is density-dependent.
91
 After 10 days of 







 This population was shown to increase significantly as a 
function of Notch ligand density. After 14 days of culture with high concentrations of 




2.4.3.3 Bead-Immobilized Notch Ligands can Induce T Cell Development without 
Stromal Cell Contact 
Recently, Taqvi et al. showed that insert co-cultures employing Notch ligand-
functionalized microbeads can induce the differentiation of mouse bone marrow LSK 




 Cells differentiated with control microbeads 
differentiated into B lineage-committed CD19
+
 cells (Figure 2.11).
92
 This supports the 
idea that artificially-presented Notch ligands are sufficient to support T cell development 
and that stromal cell contact is not necessary, as long as the appropriate soluble factors 
are provided during differentiation.
92
 Based on these data, it was hypothesized that early 




progenitor cells with 
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 early T cells using immobilized Notch ligands and 
stromal cell-secreted soluble factors is demonstrated. 
 
 
Figure 2.11: Notch ligand-coated microbeads induce T lineage commitment in the 
presence of secreted stromal factors. A,B) DLL4-coated beads induced 
significantly higher percentages of Thy1.2
+
 cells from bone marrow LSK 
cells compared to control beads, in cultures free of stromal cell contact.‡‡‡ 
2.4.3.4 Generation of Antigen-Specific CD8+ SP T Cells from Murine Progenitors 
Using pMHC Class I Tetramers  
Lin et al. previously demonstrated that pMHC Class I tetramers can induce the 
development of antigen-specific T cells from murine DP thymocytes and ESC-derived 




DP thymocytes and early T cells, generated from OP9-
DL1/ESC co-cultures, were cultured with LCMV.GP34p-MHC Class I tetramers in the 
presence of co-stimulatory molecules tetramers for 7 days.
93
 Both groups of progenitor 
cells differentiated into CD8
+
 LCMV.GP34-specific T cells after the 7-day time period 
(Figure 2.12).
93
 Importantly, these cells exhibited specific killing ability against epitope-
presenting target cells in vitro. In this dissertation, the differentiation of human HSC-
                                               
‡‡‡ Reproduced with permission from © 2006 Wiley Periodicals, Inc.: Journal of Biomedical Materials 
Research, 2006. John Wiley and Sons retains full rights to figures reproduced here.92 
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derived early T cells into functional, antigen-specific CD8
+
 T cells using pHLA Class I 
tetramers is demonstrated. 
 
Figure 2.12: Antigen-specificity and functionality of in vitro-differentiated DP cells A) 
Antigen specific CD8
+ 
LCMV.GP34-specific T cells were generated in 
cultures that employed LCMV.GP34p-MHC Class I tetramers. B) 
LCMV.GP34-specific T cells exhibited specific cytotoxic activity against 
peptide-loaded target cells.§§§ 
                                               
§§§ Adapted with permission from © 2010 Mary Ann Liebert Inc.: TISSUE ENGINEERING: Part A.  
Mary Ann Liebert Inc. retains all rights to figures reproduced here.93 
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2.5 INFLUENCE OF MHC LIGAND DENSITY AND PRESENTATION ON TCR 
SIGNALING AND T CELL ACTIVATION 
T cells are activated by engagement of their TCRs with pMHCs displayed on the 
surface of APCs. These interactions are essential for the recognition of foreign antigens 
in the periphery and are critical for the adaptive immune response. TCR-pMHC 
engagement results in the phosphorylation of the TCR-CD3 cytoplasmic domain by Src-
family tyrosine kinases, followed by docking of adaptor proteins on these phosphorylated 
domains.
94
 The result is a complex signaling unit consisting of TCR-CD3 cytoplasmic 
domains, adaptor proteins, and kinases.
94
  
2.5.1 MHC/HLA Oligomer Technology 
MHC tetramers consist of 4 peptide-loaded MHC molecules that are non-
covalently bound by a streptavidin molecule. Tetramers that are tagged with fluorescent 
molecules allow enumeration or enrichment of antigen-specific T cell populations by 
flow cytometry.
33
 This technology has been seminal in evaluating antigen-specific T cell 
responses such as proliferation, cytotoxic T cell assays, and cytokine production. In 
addition to detection, pMHC oligomers have been used for in vitro T cell expansion. It 
was recently demonstrated that aAPC microbeads presenting HLA-Ig dimers or HLA-







 In addition, stimulation of PBMCs with plate-bound tetrameric CMVp-MHCs 
resulted in significant expansion of CMV-specific CD8
+
 T cells at levels comparable to 
that achieved with CMV peptide-loaded DCs.
31
  
2.5.2 Density and Surface Presentation 
The use of soluble crosslinking reagents, such as anti-TCR antibodies, has 
indicated that TCR oligomerization is a key step of activation. Several studies show that 
APCs pre-cluster their pMHCs prior to interaction with TCRs.
95
 Activated B cells are 
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known to cluster peptide pMHCs in lipid rafts, and the disruption of lipid raft formation 
is deleterious to antigen presentation.
96
 In addition, DCs have been shown to transport 
pMHC-rich endocytic vesicles that fuse to the plasma membrane, resulting in pMHC 
dense patches.
97
 Indeed, it has been shown that monomeric pMHC molecules are not 
sufficient to stimulate or activate T cells.
98
 Higher-valency oligomers such as MHC 




Increasing evidence highlights the importance of pMHC surface presentation on 
inducing TCR signaling and directing T cell fate and effector function. Plate-immobilized 
peptide pMHC monomers, dimers, and tetramers can stimulate low-affinity TCRs 
significantly more effectively than their soluble counterparts.
102
 Detailed studies have 
been done to control and characterize the role of ligand density on TCR signaling in 
mature T cells, as well as the effects of mobility, spatial distribution, and solid-phase 
presentation on T cell activation.
103
 These studies are described in detail in Chapter 5. 
Much less is known about the influences of pMHC density and solid-phase presentation 
on immature thymocyte TCR signaling, maturation, and antigen-specific differentiation. 
In this treatise, the abilities of pMHC ligand density and surface presentation to 
differentially influence TCR stimulation and antigen-specific differentiation are explored. 
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2.6 SUMMARY AND CONCLUSION  
The clinical promise of adoptive T cell transfer immunotherapy has been 
demonstrated with a wide variety of malignant and viral diseases. Despite its success, 
adoptive transfer is limited by inherent difficulties with isolating, expanding, and 
maintaining functional CTLs. Gene modification techniques, to express exogenous TCRs 
or CARs in endogenous hematopoietic cells, have been used to combat these problems, 
but pose their own set of complications including unforeseen specificities, insertional 
mutagenesis, and fatal systemic inflammatory responses. The results from numerous 
clinical studies suggest that a high-throughput method for generating functional, antigen-
specific T cells from a renewable cell source, such as HSCs, is needed. By differentiating 
HSCs into antigen-specific T cells, the limitations and dangers of using patient-derived T 
cells and gene-modified T lymphocytes may be eliminated.  
Based on the success of other groups at generating T cells from stem and 
progenitor cells in vitro, it was hypothesized that stem cells could be used as sources for 
adoptive transfer T cells. In this dissertation, a novel differentiation system, employing 
exogenous Notch and TCR ligands, was used to induce the generation of antigen-specific 
CD8
+
 T cells from human cord blood CD34
+
 HSCs. Following this, methods to enrich 
and expand progenitor-derived antigen-specific T cells were explored. Lastly, based on 
results that highlight the importance of TCR signaling strength on determining T cell fate, 
the effects of pMHC ligand density and solid-phase presentation on in vitro T cell 





PTLD – post-transplant lymphoproliferative disease 
CTL – cytotoxic T lymphocyte 
TIL – tumor infiltrating lymphocyte 
TCR – T cell receptor 
CAR – chimeric antigen receptor 
APC – antigen-presenting cell 
FACS – fluorescence activated cell sorting 
IL – interleukin 
TREG – regulatory T cell 
PBMC – peripheral blood mononuclear cell 
aAPC – artificial antigen-presenting cell 
pHLA – peptide human leukocyte antigen 
MART-1 – melanoma antigen recognized by T cells -1  
gp – glycoprotein 
CMV – cytomegalovirus 
EBV – Epstein-Bar virus 
IFNγ – interferon gamma 
pMHC – peptide major histocompatibility complex 
AIDS – acquired immunodeficiency syndrome 
GVHD – graft-versus-host-disease 
TH  – helper T cell 
CEA – carcinoembryonic antigen 
MAGE – melanoma-associated antigen 
IRES – internal ribosome entry site 
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TAA – tumor-associated antigen 
scFv – single chain variable fragment 
ASK1 – apoptosis signal-regulating kinase 1 
ATF2 – activating transcription factor 2 
CAN – calcineurin 
DAG – diacylglycerol 
LAT – linker for activation of T cells 
MMK – MAP kinase kinase 
NFAT – nuclear factor of activated T cells 
NF-κB – nuclear factor-κB 
PIP3 – phosphatidylinositol-(3,4,5)-trisphosphate 
PKCα – protein kinase Cα 
PLCγ – phospholipase Cγ 
SLP76 – SH2 domain-containing leukocyte protein of 76 kDa 
ICOS – inducible T cell co-stimulator 
TNFR – tumor necrosis factor receptor 
MDSC – myeloid-derived suppressor cell 
TRUCK – T cell redirected for universal cytokine-mediated killing 
NK – natural killer 
DC – dendritic cell 
HSC – hematopoietic stem cell 
CRS – cytokine release syndrome 
TN – naïve T cell 
TCM – central memory T cell 
TEM – effector memory T cell 
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TSP – thymus seeding prognitor 
DN – double negative 
DP – double positive 
cTEC – cortical thymic epithelial cell 
SP – single positive 
mTEC – medullary thymic epithelial cell 
TRA – tissue-restricted antigen 
DLL – delta like ligand 
DSL – Delta/Serrate/Lag 
ADAM – a disintegrin and metalloproteinase 
CBF1 – C-promoter binding factor 1 
HES – hairy enhancer of split 
ISP – intermediate single positive 
FTOC – fetal thymus organ culture 
RTOC – reaggregate thymus organ culture 
ESC – embryonic stem cell 
Flt3L – FMS-like tyrosine kinase 3 ligand 








RAG – recombination activating gene 
LCMV – lymphocytic choriomeningitis virus 
hTrp2 – human tyrosinase-related protein 2 
MLR – mixed lymphocyte reaction 
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Chapter 3: Generating Functional, Human Antigen-Specific CD8
+
 SP T 
Cells from CD34
+
 Cord Blood-Derived Hematopoietic Stem Cells 
[This chapter was adapted, with permission****, from I. Fernandez, T.P. Ooi, and 
K. Roy††††. Generation of Functional, Antigen-Specific CD8+ Human T Cells from Cord 
Blood Stem Cells Using Exogenous Notch and Tetramer-TCR Signaling. Stem Cells. 
(2014) 32(1) 93-104. doi: 10.1002/stem.1512] 
3.1 BACKGROUND AND MOTIVATION 
T cells, unlike other lymphocyte subsets that mature in the bone marrow, develop 
exclusively in the thymus. It is well established that in addition to soluble cytokines, T 
lineage commitment is critically dependent on two temporally- and spatially-controlled 
signals provided by direct contact with thymic stromal cells: (i) Notch receptor-Delta like 
ligand (DLL) signaling and (ii) T cell receptor (TCR)-major histocompatibility complex 
(MHC)/human leukocyte antigen (HLA) signaling. Notch signaling is required for T 




 early T 
cells.
1,2
 DP cells undergo positive selection by interacting with antigen-loaded 
MHC/HLA molecules presented by cortical thymic epithelial cells. Specifically, cells 
with TCRs that are capable of interacting with self-antigen Class I or Class II MHC/HLA 









 T cells, respectively. Subsequent negative selection in the thymic medulla 
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eliminates SP T cells with TCRs that bind with high affinity to self-antigen MHC/HLA 
molecules, resulting in a diverse repertoire of mature, functional T cells.
1,2
  
Fully mature T cells are characterized by the surface expression of an αβTCR 
heterodimer, which recognizes foreign-antigen MHC/HLA complexes on target cells. In 
particular, mature CD8
+
 T cells, also known as cytotoxic T lymphocytes (CTLs), are 
responsible for eliminating pathogen-infected cells and tumor cells, thereby playing an 
essential role in immune function. This unique ability of CD8
+
 T cells provides much 
promise for the field of cellular immunotherapy. The use of CTLs for autologous 
adoptive transfer has shown promise in treating many cancers including melanoma, renal 
cancer, leukemia, multiple myeloma, prostate cancer, Hodgkin’s disease, and 
nasopharyngeal cancer, as well as post-transplant lymphoproliferative diseases 
(PTLDs).
3-9
 Currently, T cells for such therapies are isolated from a patient’s peripheral 
blood, expanded ex vivo for several weeks, and selected for antigen-specificity before 
being transplanted into the recipient.
3
 Despite its immense clinical promise, adoptive T 
cell transfer is constrained by the difficulty and inefficiency of patient cell isolation, 
problems with expansion of primary cells ex vivo, a limited availability of HLA-matched 
donor cells, and the time required to process patient-isolated cells. Thus, scalable 
technologies for providing efficient, high throughput and readily available sources for 
antigen-specific, therapeutic T cells are needed.  
In vitro T cell generation from stem cells has been explored extensively using co-
culture with stromal cells known to support hematopoiesis. Retrovirally-transduced 
mouse bone marrow-derived stromal cells (OP9) that stably express the Notch ligands, 
DLL1 (OP9-DL1) or DLL4 (OP9-DL4), are capable of supporting the differentiation of 
mouse hematopoietic, embryonic, and induced pluripotent stem cells, as well as human 
hematopoietic stem cells (HSCs), into early T cells and CD8
+




studies have also shown that plate-bound Notch ligands and a defined combination of 











 Taqvi et al. have previously shown that culturing 
mouse LSK cells with DLL4-functionalized microbeads in an insert co-culture system 
using OP9 cells can induce early T lineage commitment and differentiation without direct 
stromal cell contact.
18
 However, generation of mature, functional antigen-specific SP T 
cells from these in vitro culture systems has not been reported extensively. Recently, 
antigen-specific T cells were expanded from a bulk population of OP9-DL1-derived 
murine CD8
+
 SP T cells using bone marrow-derived dendritic cells (DCs) expressing 
various epitopes.
19
 Lin et al. have also demonstrated the ability of antigen-loaded MHC 
Class I tetramers to generate, from mouse DP cells or embryonic stem cells (ESCs), a 
population of CD8
+
 T cells specific for that particular antigen and capable of in vitro 
cytotoxic killing of target cells.
20
 However, to date, direct in vitro generation of antigen-
specific, functional human T cells from any stem cell population has not been achieved, 




It was hypothesized that the thymic TCR-HLA interaction could be recreated in 
vitro using foreign antigen-loaded HLA tetramers to induce the differentiation of Notch-
directed, human stem cell-derived early T cells into SP T cells specific for the same 














 early T cells. Further culture with cytomegalovirus (CMV) or influenza 
(GIL) epitope-loaded HLA-A*0201 tetramers resulted in the generation of CMV-specific 
or GIL-specific CD8
+
 T cells, respectively. These cells exhibited activation and in vitro 
cytotoxic functionality against peptide-loaded target cells as demonstrated by surface 
 62 
presentation of the degranulation marker CD107a, production interferon gamma (IFNγ), 
and granzyme B secretion.  
  
 63 
3.2 MATERIALS AND METHODS 





 human cord blood mononuclear (CB-MN) cells (StemCell 
Technologies) were expanded in T25 tissue culture-treated flasks (Corning) using 
StemSpan® Serum Free Expansion Medium (StemCell Technologies) supplemented with 
the following human recombinant cytokines from Peprotech: FMS-related tyrosine kinase 
3 ligand (Flt3L) (100 ng/mL), stem cell factor (SCF) (100 ng/mL), interleukin (IL)-3 (20 
ng/mL), IL-6 (20 ng/mL), granulocyte-colony stimulating factor (G-CSF) (20 ng/mL), 
thrombopoietin (TPO) (50 ng/mL), and human low density lipoprotein (hLDL) (40 
µg/mL) (StemCell Technologies). Cells were grown at 37°C and 5% CO2. After 3 days, 
cells were transferred to T150 tissue culture treated flasks (Corning) and fresh media and 
cytokines were added to the cultures. Cells were expanded for a total of 7 days. 
3.2.2 CD34+CD38-/low Cell Sorting 
Expanded CB-MN cells were collected and centrifuged at 300 x g for 5 minutes at 
4°C. Cells were resuspended in phosphate buffered saline (PBS) containing 1% bovine 
serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid (EDTA). CD34
+
 cells 
were enriched using MACS CD34
+
 Microbead Kit and MS Columns (Miltenyi Biotec) 
according to the manufacturer’s protocols. Resultant cells from CD34 positive selection 
were stained with PE-conjugated anti-CD34 monoclonal antibody (mAb) (Miltenyi 





 cells were sorted by flow cytometry (BD FACSAria™ II, BD 
Biosciences) to obtain maximal purity. 
 64 
3.2.3 Collection of OP9-DL1 Conditioned Medium 
OP9-DL1 cells were kindly provided by Dr. Zúñiga-Pflücker (Toronto, Canada). 
3.5 x 10
5
 OP9-DL1 cells were seeded in T75 tissue culture-treated flasks and expanded in 
alpha minimum essential media (α-MEM) supplemented with 20% fetal bovine serum 
(FBS) (StemCell Technologies), sodium bicarbonate (2.2 g/L), penicillin (100 U/mL), 
and streptomycin (100 µg/mL). Cells were grown at 37°C and 5% CO2. Media was 
replaced when the cells were 80% confluent. For the next 3 days thereafter, OP9-DL1 
conditioned media (CM) was collected, filtered through a 0.22 µm sterile membrane, and 
stored at 4°C. 
3.2.4 Functionalization of Microplates with Notch Ligand Fc-DLL1 
Protein A (10 µg/mL) (Sigma), diluted in PBS, was adsorbed on Corning® Not 
Treated Tissue Culture clear, flat-bottom 96-well plates (100 µL/well) for 30 minutes at 
37°C and 5% CO2. Wells were washed twice with PBS and blocked with HBSS/2% BSA 
at 25°C for 45 minutes.  Residual blocking buffer was removed by washing twice with 
PBS. Human Fc-DLL1 (Enzo Life Sciences, 2.5 µg/mL or 5.0 µg/mL diluted in PBS), 
was incubated with Protein A-coated wells for 2 hours at 37°C and 5% CO2. Wells were 
washed twice with PBS prior to cell seeding. 





 cells were seeded onto Fc-DLL1 coated plates at a density 
of 3.0 x 10
4
 cells/well in OP9-DL1 CM supplemented with human recombinant Flt3L (10 
ng/mL) and IL-7 (5.0 ng/mL) (Peprotech).  After 13 days, all cells were collected and 
transferred to 24-well plates coated with Fc-DLL1 (5 x 10
5
 cells/well).  Cells were 
cultured with DLL1 plates for a total of 25 days. Media and cytokines were replenished 
every 3 days. 
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3.2.6 Antigen-Specific T Cell Differentiation 
At day 25 of differentiation on DLL1-coated plates, CMVpp65 (NLVPMVATV)  
peptide (3 µg/mL), CMV (NLVPMVATV) HLA-A*0201 tetramers (3.0 µg/mL), or 
irrelevant control Influenza (GIL) (GILGFVFTL) tetramers (3.0 µg/mL) (Baylor College 
of Medicine) were added to the cultures in OP9-DL1 CM supplemented with human 
recombinant Flt3L (10 ng/mL), IL-7 (5.0 ng/mL), IL-2 (10 ng/mL) and co-stimulatory 
molecules anti-CD3 (1.0 µg/mL, Biolegend, 317304) and anti-CD28 (1.0 µg/mL, 
Biolegend, 302914). Cells were cultured with tetramers for a total of 7 days.  Tetramers, 
peptide, media, cytokines, and co-stimulatory molecules were replenished every 3 days. 
3.2.7 Flow Cytometry 
At days 16, 22, and 25 of differentiation, cells were collected to quantify the 
expression of lymphoid and myeloid markers. Briefly, cells were harvested and 
resuspended in PBS containing 1% BSA and 2 mM EDTA.  FcR blocking reagent 
(Miltenyi Biotec, 130-059-901) was added at a 1:100 dilution for 15 minutes at 4°C prior 
to staining.  Cells were then labeled with a combination of mAbs against the lymphoid 
markers CD1a, CD7, CD4, CD8 and CD3 (CD1a-APC (BD Biosciences, 555807), CD7-
PECy5 (BD Biosciences, 555362), CD4-PerCP (BD Biosciences, 550631), CD8-FITC 
(BD Biosciences, 555366), CD3-APC (BD Biosciences, 555335)) and myeloid markers  
CD11c, HLA-DR and HLA-ABC (CD11c-FITC (eBioscience, 11-0116-71), HLA-DR-
APC (BD Biosciences, 559866;), HLA-ABC-PECy5 (eBioscience15-9983-41)) for 30 
minutes at 4°C.  
Seven days after adding HLA tetramers to the differentiation cultures (day 32), 
cells were harvested to determine the percentage of CMV-antigen specific CD8
+
 cells in 
the cultures. Similarly, cells were stained with mAbs against CD8, CD3, CD4, and for 
antigen-specificity using APC-conjugated tetramers (CMVpp65 or GIL HLA-A*0201) 
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(Baylor College of Medicine Tetramer Production Facility). Isotype controls were 
included for each staining. To determine whether CMV-specific CD8
+
 T cells generated 
from this system were monoclonal or polyclonal, staining was done at day 32 using 
IOTest® Beta Mark TCR Vβ Kit (Beckman Coulter).  All samples were analyzed on a 
BD Accuri™ C6 Flow Cytometer (BD Biosciences) or BD FACSAria™ II (BD 
Biosciences).  Data was analyzed using FlowJo Software (Tree Star, Inc.). 
3.2.8 T Cell Functionality Assays: CD107a Mobilization and IFNγ Production 





HSCs was assessed with a CD107a mobilization assay as previously described.
23
 
Differentiated cells were harvested and co-cultured with CMVpp65 peptide-loaded T2 
target cells (174xCEM.T2; ATCC CRL-1992) in a CTL assay. All viable cells obtained 
from differentiation cultures were used as effector cells. T2 cells were loaded with 50 
µg/mL of CMVpp65 peptide for 2 hours at 37°C in RPMI 1640 containing 10% human 
serum (Sigma Aldrich). Cells were washed twice with PBS to remove un-bound peptide. 
Incubation of effector and target cells was carried out for 5 hours at 37°C at a 5:1 effector 
to target (E:T) ratio. PE-conjugated anti-CD107a mAb (BD Biosciences, 555801) was 
added at the beginning of co-culture. Brefeldin A (BD Biosciences), a secretion inhibitor, 
was added after the first hour. Cells were collected and then surface-stained with FITC-
conjugated anti-CD8 mAb and APC-conjugated tetramers (CMVpp65 or GIL HLA-
A*0201) (Baylor College of Medicine). In some experiments, following surface staining, 
cells were fixed in Cytofix/Cytoperm solution (BD Biosciences) and stained with PECy7-
conjugated anti-mouse IFNγ (BD Biosciences, 557844). Finally, cells were analyzed on a 
BD Accuri™ C6 Flow Cytometer (BD Biosciences). Data was analyzed using FlowJo 
Software (Tree Star, Inc.). 
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3.2.9 CD8+ T Cell-Mediated Granzyme B Assay: 
CD8
+
 T cell-mediated granzyme B activity was analyzed using the GranToxiLux 
PLUS! Kit (OncoImmunin, Inc.). Briefly, target T2 cells were loaded with 50 µg/mL of 
CMVpp65 peptide for 2 hours at 37°C in RPMI 1640 containing 10% human serum. The 
fluorescent cell TFL2 dye (red) was added to the cells during the last 15 minutes of 
incubation. Cells were washed twice with PBS to remove un-bound peptide and TFL2 
dye. Co-incubation of effector and target cells was carried out for 2 hours at 37°C at a 5:1 
E:T ratio in the presence of the cell-permeable fluorescent (green) granzyme B substrate 
(OncoImmunin, Inc.). Cells were then collected and analyzed using FACSAria™ II (BD 









 HSCs Using Surface Immobilized Fc-DLL1 and 
OP9-DL1 Conditioned Media 
The ability of surface-immobilized DLL1 and OP9-DL1 CM to induce T lineage 





derived HSCs were cultured on DLL1-functionalized plates in the presence of stromal 
cell-secreted factors (Figure 3.1). Briefly, CD34
+
 UCB cells were expanded for 7 days. 
CD34
+









 cells were then plated on 
non-tissue culture-treated wells containing 2.5 µg/mL or 5 µg/mL of immobilized Fc-
DLL1 supplemented with Flt3L and IL-7. 









hematopoietic cells, independent of Notch-induced signaling (results not shown). There 




 cells in all culture conditions (approximately 
5.0-7.0%) that remained CD34
+









 cells from the Notch-induced cultures (either 2.5 or 5.0 µg/mL Fc-




 cells compared to no ligand control 




 cells (Figure 3.2A). These 
results indicate that there was more rapid induction of hematopoiesis in the presence of 
Notch ligands, consistent with previous results from other groups.
14-17 
By day 25, the 









Figure 3.1: Schematic for the generation of antigen-specific CD8
+










HSC population was enriched, sorted, and seeded onto 
DLL1-coated plates. HLA-TCR signaling was induced using CMVpp65 
peptide, CMV epitope-loaded HLA-A*0201 Class I tetramers, or GIL 
epitope-loaded HLA-A*0201 Class I tetramers. 
At days 16, 22, and 25, the ability immobilized Notch ligands to direct T lineage 
differentiation and generate early T lymphocytes was evaluated. Cultures were analyzed 









 DP T cells (Figure 3.2B, 3.2C, and Figure 3.3B, 3.3C).
10,12
 At day 16, 





 cells compared to the no ligand control (Figure 3.2B). After 25 days of 
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compared to the control (Figure 3.3B). Furthermore, it was observed that a significantly 
higher percentage of CD7+ lymphoid-committed cells were generated in Notch ligand 
cultures compared to the control at both time points. As expected, the CD7
+
 population 
was much higher in peripheral blood mononuclear cells (PBMCs) (Figure 3.3B).  
To investigate whether more mature T cells were present in the culture, cells were 
analyzed for the expression of CD4 and CD8 (Figure 3.2C and Figure 3.3C). At day 22, 




cells compared to the no 
ligand control, indicating progression through the double negative stages to the DP stage 




 early T 
cells were found in the DLL1 cultures compared to the control (Figure 3.3C). At day 22, 




 cells were observed in the no ligand control 





 cells in the Notch ligand culture was similar to that of the no ligand control 




 cells differentiated due to the presence 





 cells in all conditions (Figure 3.4). 
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cells in Notch signaling-induced differentiation cultures. Flow cytometry 
analysis of A) CD34 and CD38 and B) CD1a and CD7 expression at day 16 




In order to gauge T cell differentiation in the presence of immobilized DLL1, 
CD3 and TCRαβ expression was evaluated. Although CD4+CD8+ populations were 
present in all conditions at day 22, DP cells from the no ligand cultures expressed lower 
levels of CD3 compared to cells differentiated with Fc-DLL1 (Figure 3.2D). It was 
hypothesized that the DP cells from the the no ligand control differentiated due to the 
presence of Notch ligands on other cells within the culture. Indeed, it has been shown by 




 cells, myeloid cells, and mature CD3
+
 T cells 
express DLL1 and/or DLL4.
24





cells generated from DLL1 and control cultures expressed CD3 and TCRαβ (Figure 3.3D 







TCRαβ+, compared to only 1.3% from the no ligand 
control. The expression of CD3 and TCRαβ on CD8+CD4- PBMCs are shown as staining 




 PBMCs express CD3 and TCRαβ, 
as these cells are mature T cells (Figure 3.3D and 3.3E).  
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cells in Notch 
signaling-induced differentiation cultures. Flow cytometry analysis of A) 
CD34 and CD38, B) CD1a and CD7, C) CD4 and CD8 expression, and D) 
CD3 and TCRαβ expression. E) Table indicating the percentage of the total 


















in Notch signaling-induced differentiation cultures. Flow cytometry analysis 
of CD11c, HLA-ABC and HLA-DR expression. 
3.3.2 Peptide-Loaded HLA-A*0201 Tetramers Induce the Generation of Antigen-
Specific CD8
+
 T Cells 
On day 25, 3.0 µg/mL of CMVpp65 peptide, CMVpp65 HLA-A*0201 Class I 
tetramers, or GIL HLA-A*0201 Class I tetramers were added to the culture along with 
exogenous co-stimulatory molecules, anti-CD3 and anti-CD28 (Figure 3.5A). Seven days 
after peptide or tetramer addition, cells were analyzed for antigen-specificity and 
functionality. After 7 days of culture with peptides or tetramers, CD8
+
 cells were found to 
be primarily CD4
-




 cells was observed (Figure 3.6). It 




 cells found in the culture 
differentiated due to the presence of HLA Class II-presenting myeloid cells (Figure 3.4).  
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Figure 3.5: Generation of CMV antigen-specific CD8
+
 T cells in the presence of 
CMVpp65 tetramer or peptide. A) Experimental design. B) CMV antigen-
specific CD8
+
 T cells were generated by adding CMVpp65 tetramers, 
CMVpp65 peptide, or an irrelevant control tetramers (GIL tetramer) at day 
25 of differentiation. C) Bar graphs represent percentage of CD8
+
 T cells 




 cells (gated on CD8
+
 






 T cells generated with CMVpp65 tetramer or peptide are predominantly 
CD4
-














cells may have differentiated due to the presence of Class II-presenting cells 
in culture. 
Of the cells differentiated with CMV tetramer or CMVpp65 peptide, 
approximately 5.64%-26.90% were found to be CD8
+
 T cells. Of the CD8
+
 T cells, 
2.91%-21.60% were CMV-specific. Cells differentiated with CMVpp65 peptide or 
tetramer consistently had higher percentages of CMV-specific CD8
+
 T cells compared to 
the cells cultured with the GIL irrelevant control tetramer (Figure 3.5B, 3.5C). These 
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results were consistent over 5 independent samples (Figure 3.5C). Similarly, GIL-specific 
CD8
+ 
T cells could be generated by incorporating GIL tetramers into the differentiation 
cultures (Figure 3.7).  These results indicate that for the generation of antigen-specific T 
cells, the described system is not restricted to a specific tetramer. Interestingly, 
incubation of differentiating cells with CMVpp65 peptide also initiated antigen-specific T 
cell development (Figure 3.5B). This may be attributed to the presence of DCs, as well as 
presentation of the epitope via HLA Class I molecules expressed by nucleated cells in the 
differentiation cultures (Figure 3.4). 
 
Figure 3.7: Generation of Influenza antigen-specific CD8
+
 T cells in the presence of 




 cells were generated when GIL HLA-
A*0201 tetramers were added to differentiation cultures for 7 days. 48.9% 
of these cells expressed CD107a when cultured with GIL epitope-loaded 
target cells at an effector to target ratio of 5:1.  
3.3.3 Human HSC-Derived Antigen-Specific CD8+ T Cells are Functional 
Functionality of CMV-specific CD8
+
 T lymphocytes was determined by CD107a 
surface mobilization, intracellular IFNγ production, and granzyme B-mediated 
cytotoxicity in the presence of antigen-loaded target cells.
23,25-27 




 effector T cells release cytotoxic mediators such as perforins and 
granzymes upon antigen engagement. CD107a, also known as lysosomal-associated 
membrane protein-1, is a vesicle membrane protein that becomes transiently mobilized to 
the cell surface during degranulation, the initial event that takes place during target cell 
lysis. Upon co-culture of differentiated effector T cells with peptide-loaded target cells, 
CD107a mobilization was quantified. Additionally, expression of IFNγ, a critical 
cytokine that is produced by CD8
+
 T cells upon antigen recognition, was evaluated by 
intracellular staining. Lastly, granzyme B activity in target cells was measured, as this 
provides a quantitative assessment of T cell-mediated cellular cytotoxicity.
28 
 
Figure 3.8: CMV antigen-specific CD8
+
 T cells express CD107a and produce IFNγ after 
culture with epitope-presenting target cells. 
For the functional assays, all cells from differentiation cultures were harvested 
and used as effector cells. T2 target cells were loaded with CMVpp65 peptide for 2 
hours. For CD107a/IFNγ assays, effectors and peptide-loaded target cells were co-
cultured for 5 hours at an E:T ratio of 5:1, in the presence of Brefeldin A and anti-
CD107a mAb. For granzyme B assays, effectors and peptide-loaded targets were co-
cultured for 2 hours in the presence of a fluorescent granzyme B substrate. Following 
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stimulation, the ability of CMV-specific cells to degranulate and produce IFNγ was 
examined (Figure 3.8).  
Approximately 13% of CD8
+
 T cells generated from CMV tetramer 
differentiation cultures in this experiment were CMV-specific (Figure 3.8, top panel). 
After stimulation with target cells, about 40% of the tetramer-differentiated CMV
+ 
cells 





 cells were generated from CMVpp65 peptide differentiation cultures (Figure 
3.8, bottom panel). About 25% of those cells expressed CD107a upon co-culture with 
target cells, but less than 5% produced IFNγ. Although stimulation with CMVpp65 
peptide for 7 days resulted in a high number of antigen-specific CD8
+
 T cells, peptide-
stimulation may not be sufficient to induce CTL effector functionality. It is possible that 
more than 7 days of peptide stimulation is needed for activation.  








 cells generated 
from CMV tetramer cultures and CMV peptide cultures was compared (Figure 3.8). 













 cells still expressed CD107a non-specifically. 
This could be due to several confounding factors. First, due to cell number limitations, all 
cells from the differentiation cultures were used as effector cells. In addition, the use of 
co-stimulatory molecules anti-CD3 and anti-CD28, as well as IL-2, to stimulate T cell 
proliferation may induce a background level of activation, resulting in CD107a 
expression. It is also possible that some of the non-CMV-specific CD8
+ 
T cells 
recognized self-antigens presented by T2 cells. 
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Figure 3.9: Tetramer-differentiated CMV-specific CD8
+
 T cells express activation 
markers CD25 and CD28. 
The expression of CD28 and CD25, a co-stimulation and activation marker 
relevant in the cytotoxic process initiated by CD8
+
 T cells, on the antigen-specific in 
vitro-generated T cells was determined. The results (Figure 3.9) show that approximately 






 in vitro-differentiated T cells were CD28
+
 and the majority 






 in vitro-differentiated T cells 
were CD28- and a lower percentage expressed CD25.  
 81 
 
Figure 3.10: CMV antigen-specific CD8
+
 T cells facilitated granzyme B-mediated killing. 
CMVpp65 peptide-loaded targets were labeled with a red dye and incubated, 
in the presence of granzyme B substrate (green), with CMVpp65 tetramer-
differentiated cells (effector cells) at a 5:1 E:T ratio for 2 hours. No peptide-
loaded target cells, target cells alone, and effector cells alone are shown as 
controls. Target cells were gated on FSC
hi






 T cell-mediated killing of target cells was evaluated by 
measuring granzyme B activity inside target cells (Figure 3.10). T2 target cells were 
fluorescently labeled and then co-incubated with CMVpp65 tetramer-differentiated cells 
in the presence of a fluorescent granzyme B substrate. Cleavage of the substrate results in 
increased green fluorescence in target cells. Granzyme B activity was detected in about 
44.9% of the CMVpp65 peptide-loaded target cells after incubation with effector cells 
containing CMV antigen-specific CD8
+
 T cells (Figure 3.10, upper panel), compared to 
41.7% and 41% background levels detected in no peptide-loaded target cells and no 
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effector conditions, respectively (Figure, 3.10 middle panels). There did not appear to be 
significant differences in the percentages of granzyme B
+
 targets in the different 
conditions, but the data demonstrate that a significant proportion of the ex vivo 
differentiated CD8
+
 cells exhibit effector function. Staining of effector cells alone was 
evaluated as a control. As expected there was no significant detection of granzyme B, as 
it exists in an inactive form in effector cells (Figure 3.10, right panel). The relatively high 
level of background staining may be attributed to prolonged culture with the tetramers 
and co-stimulatory molecules, as well as possible cross-reactivity of effector T cells.  The 
presence of dead target cells at beginning of the CTL experiment, prior to incubation of 
targets with effectors, may have also contributed to the high background.  
3.3.4 Antigen-Specific CD8+ T Cells are Polyclonal 
 
Figure 3.11: Clonogram showing TCR Vβ repertoire of CMV antigen-specific CD8+ T 
cells after differentiation with CMVpp65 tetramers for 7 days. 
To provide insight about the clonality of the CMV-specific CD8
+
 T cells 
generated from differentiation cultures, TCR Vβ analysis via flow cytometry was 




 T cell population (Figure 3.11). This finding was consistent over two independent 




The ability of HSCs to differentiate into various blood lineages, as well as their 
unique capacity to self-renew, makes them an attractive source from which therapeutic T 
cells can be generated.
29,30
 HSCs are isolated from the bone marrow, peripheral blood, or 
umbilical cord blood (UCB) and can be expanded, thereby providing a large, readily-
available cell source that could be differentiated into lineage-specific therapeutic cells as 
needed. In addition, problems associated with allogeneic T cell transfer, such as the 
shortage of donors and the difficulty of finding HLA-matched donor cells, may be 
overcome through the use of HSCs as a source for adoptive transfer T cells.
31
 In 
particular, human umbilical cord and placenta, which support the developing fetus during 
pregnancy, are delivered with the baby and can be easily retrieved after birth. Numerous 
public cord blood banks have been developed worldwide to collect, type, and 
cryopreserve cord blood for potential future transplant.
32
 The development of an efficient 
and scalable differentiation system that could generate antigen-specific, functional T cells 
from cord blood HSCs could enable important therapeutic opportunities in a variety of 
diseases.  
With advancements in in vitro stem cell differentiation technologies, stem cell-
derived therapies are becoming more of a reality. To specifically induce T lymphoid 
lineage commitment, ESCs or HSCs can be co-cultured with OP9-DL1 cells, bone 
marrow-derived stromal expressing the Notch ligand, DLL1.
10-13
 The OP9-DL1 co-
culture system is now an established method for generating early T cells and CD8
+
 SP T 
cells; however, the directed differentiation of human antigen-specific T cells, without 
retroviral transduction of specific TCRs, has not been reported.
10-13,21,22,33
 Furthermore, 
large scale production of therapeutic T cells for eventual clinical application via co-
culture with genetically modified cells is difficult, both from pharmaceutical and 
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regulatory perspectives. Therefore, in order for in vitro T cell differentiation to become 
clinically applicable, a system that is capable of producing antigen-specific T cells on a 
large scale, without relying on complicated co-culture methods or genetic modification, is 
necessary. 
The development of a stromal cell contact-free system that facilitates the 
differentiation of human cord blood-derived HSCs into functional, antigen-specific T 
cells was described in this chapter. Notch signaling for the generation of early T cells was 
mediated by plate-immobilized Notch ligands in the presence of soluble factors from 
stromal cell CM. Recent studies have indicated the importance of Notch ligand 
endocytosis in Notch signaling and T cell development.
34,35
 In the context of OP9-DL1 or 
OP9-DL4 co-culture, mutants that are unable to undergo Notch ligand endocytosis or 
recycling have a reduced capacity to induce Notch signaling and support T cell 
development.
34,35
 While the system detailed in this chapter utilizes plate-immobilized 









 early human T cells was still observed. This finding is consistent with that of 
other groups utilizing immobilized Notch ligands for HSC expansion.
13-17
 The frequency 
of T cell progenitors may increase by using Notch ligand-presenting cells; however, the 
goal here is to develop a stromal cell contact-free system for inducing T cell development 
that can be easily scaled up and is clinically translatable. 
TCR signaling, induced by antigen-loaded HLA-A*0201 Class I tetramers, 
provided sufficient signals to generate a population of polyclonal, antigen-specific CD8
+
 
T cells. The results demonstrate that the antigen-specific T cells developed from this 
differentiation system exhibited effector function against peptide-loaded target cells, as 
indicated by the surface presentation of activated cytotoxic-specific marker, CD107a, 
production of intracellular IFNγ, and granzyme B activity, albeit with some non-
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specificity and high background killing. For CD8
+
 T cell immunotherapy to be 
successful, efficient T cell activation and cytotoxic activity in response to foreign antigen 
is crucial. While the affinities of the T cells generated through the described system may 
vary depending on the antigen, the continued presence of HLA Class I tetramers, and the 
exogenous use of anti-CD28 and IL-2 may prime and increase the functional avidity of 




 Furthermore, antigen-specific T 
cells could be sorted from the bulk population and expanded with several rounds of 
tetramer stimulation to increase specificity. Thus, the described system is a promising 
platform for the in vitro generation of cytotoxic T cells with therapeutic efficacy. 
The TCRVβ repertoire of the antigen-specific CD8+ T cells was evaluated in 
order to elucidate how TCR-MHC/HLA signaling, induced by antigen-loaded HLA 
tetramers, facilitates the development of antigen-specific T cells in vitro. It was 
hypothesized that two possible mechanisms contributed to the in vitro generation of 
antigen-specific T cells (Figure 3.12): (1) Proliferation of a single random antigen-
specific CD8
+
 T cell clone or (2) TCR gene rearrangement induced by co-stimulatory 
molecules and/or soluble factors within the differentiation system that increase the 
probability of generating antigen-specific T cells, which are further expanded by the 






Figure 3.12: Schematic overview of how tetramer-differentiated, antigen-specific T cells 
are being generated in vitro. 
Recent studies indicate that in vitro T cell differentiation systems using OP9-DL1 
co-cultures are capable of producing populations of antigen-specific CD8
+
 T cells that 
can be expanded by epitope-presenting DCs.
19
 Since CMV or GIL epitope-loaded HLA 
tetramers were added to the all differentiated cells, it is possible that randomly generated 
T cell clones, specific for either antigen, are expanded. If this were the case, the clonal 
diversity of antigen-specific cells would be low. The data indicate that several unique Vβ 
families were highly represented in the antigen-specific T cell repertoire, suggesting that 
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the primary mechanism of tetramer-mediated generation of antigen-specific T cells may 
not be limited solely to expansion of a single or few clones. 
Given the diverse clonality of CMV-specific T cells generated from the 
differentiation system, it was hypothesized that another, or an additional mechanism, may 
be responsible for the generation of antigen-specific T cells. In the periphery, if a T cell 
cannot recognize a presented antigen, it can either undergo anergy and death or TCR 
revision, which may allow the cell to respond to an antigen.
40
 During TCR revision, T 
cells lose surface expression of the TCR, upregulate recombinase machinery, and 
rearrange genes to produce an extrathymically generated TCR that is then expressed on 
the cell surface.
41-43
 This phenomenon was first identified in Vβ5 transgenic mice that 
lost Vβ5 expression and gained an endogenous Vβ repertoire similar to that of wild type 




Vβ5low peripheral T cells were found to have downregulated surface 
TCR expression and high levels of RAG1, RAG2, and TdT indicating gene 
rearrangement of the TCR loci.
44
  
Recently, it was demonstrated that treatment of mouse DP thymocytes with 
antigen-loaded H-2K
b
 MHC Class I tetramers, anti-CD28, anti-CD3, IL-2, and IL-7 
results in RAG-1 upregulation, suggesting that TCR gene rearrangement is initiated or 
continued due to the presence of MHC tetramers.
20
 Furthermore, an in vitro model of 
TCR revision in mature human CD8
+
 T cells, induced by the presence of anti-CD3 and 
IL-7, was recently described.
45
 IL-7 has been shown to induce T cell survival and 
facilitate chromatin remodeling at the TCR loci in developing, immature T cells.
46-48
 
Thus, due to the presence of HLA-A*0201 Class I tetramers and other soluble 
stimulatory factors within the culture, the possibility that TCR gene rearrangement may 
be occurring in vitro cannot be eliminated. While more in-depth studies on clonality are 
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required to confirm this hypothesis, the reported findings present important insights into 
the mechanism behind in vitro T cell development. 
One concern with this in vitro differentiation system is that while it provides a 
means for selection of T cells specific for one antigen, there is no mechanism that ensures 
negative selection to eliminate self-reactive cells. In addition, the data indicates that 
CMV-specific T cells displayed only slightly more cytotoxic activity against CMVpp65 
peptide-displaying target cells compared to target cells loaded with no peptide. It is 
hypothesized that a pure, antigen-specific CD8
+
 T cell population could be easily sorted 
at the end of the differentiation to increase specificity and reduce the possibility of 
recovering self-reactive T cells. To increase the yield of the desired antigen-specific 
CD8
+
 T cells, several rounds of tetramer stimulation could be done by continuously 
pulsing the cells with Class I tetramers and co-stimulatory molecules, anti-CD3, anti-
CD28, and IL-2. It has been shown that bead-based artificial antigen-presenting cells, 
displaying pMHC tetramers and co-stimulatory molecules, anti-CD3, anti-CD28, and 4-
1BB, can activate and expand antigen-specific T cells.
49
 Furthermore, Savage et al. have 
shown that soluble Class I MHC tetramers can be used to expand CD8
+
 T cells in vitro.
50 
Given the previous success of these groups, it is speculated that the antigen-specific 
CD8
+
 T cells generated from the described in vitro differentiation system can be 




In this chapter, a novel, in vitro system which can be used to generate antigen-
specific T cells from human hematopoietic progenitors, was detailed. By utilizing plate-
immobilized and soluble ligands, the need for feeder cells and retroviral transfection was 
eliminated, thereby providing a practical and scalable technology that could facilitate the 




MHC – major histocompatibility complex 
DLL – Delta like ligand 
HLA – human leukocyte antigen 
TCR – T cell receptor 
DP – double positive 
SP – single positive  
CTL – cytotoxic T lymphocyte 
PTLD – post-transplant lymphoproliferative disease 
OP9 – bone marrow derived stromal cell 
OP9-DL1 – bone marrow derived stromal cell expressing delta like 1 
OP9-DL4 – bone marrow derived stromal cell expressing delta like 4 








DC – dendritc cell 
ESC – embryonic stem cell 
UCB – umbilical cord blood 
CMV – cytomegalovirus  
GIL – influenza  
CB-MN – cord blood mononuclear cell 
Flt3L – FMS-related tyrosine kinase 3 ligand 
SCF – stem cell factor 
IL - interleukin 
G-CSF – granulocyte colony-stimulating factor 
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TPO – thrombopoietin  
hLDL – human low-density lipoprotein 
PBS – phosphate buffered saline 
BSA – bovine serum albumin 
EDTA – ethylenediaminetetraacetic acid 
mAb – monoclonal antibody 
PE – phycoerythrin  
Cy – cyanine  
a-MEM – alpha minimum essential media 
FBS – fetal bovine serum 
FcR – Fc receptor 
APC – allophycocyanin  
FITC – fluorescein isothiocyanate 
PBMC – peripheral blood mononuclear cell 
NLVPMVATV – (asparagine – leucine – valine – proline – methionine – valine – 
alanine – threonine – valine) 
GILGFVFTL – (glycine – isoleucine – leucine – glycine – phenylalanine – valine – 
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Chapter 4: Enrichment and Expansion of Progenitor-Derived Antigen-
Specific CD8
+
 T Cells for Adoptive Transfer Immunotherapy 
4.1 INTRODUCTION 
In the previous chapter, a novel method to differentiate human CD34
+
 cord blood 
hematopoietic stem cells (HSCs) into functional, antigen-specific CD8
+
 T cells was 
presented. While a population of antigen-specific T cells was generated using this system, 
the resulting efficiency and cell yield were low. Approximately 0.5-1.0% of the starting 
CD34
+
 population differentiated into functional, antigen-specific CD8
+
 T cells. During 




 CTLs are needed for each infusion in order to ensure 
an effective response against the tumor or viral load, and a pure, antigen-specific T cell 
population is needed to minimize graft-versus-host response. Background killing levels 
of differentiated T cells in cytotoxic T lymphocyte (CTLs) assays were high, possibly due 
to the use of bulk mixed populations as effectors. To address these issues, it was 
hypothesized that the enrichment and expansion of stem cell-derived or progenitor-
derived antigen-specific CD8
+
 T cells would yield a pure population of antigen-specific T 
cells in clinically relevant numbers. In this chapter, the enrichment and expansion of 
progenitor-derived antigen-specific CD8
+
 T cells, using Class I tetramers, co-stimulatory 
molecules, and proliferative cytokines is described. 
4.1.1 Antigen-Presenting Cells for T Cell Activation and Expansion 
Classically, T cell immunotherapy involves the ex vivo stimulation and expansion 
of antigen-specific T cells using professional antigen-presenting cells (APCs), in 
particular dendritic cells (DCs), which are equipped with the machinery to activate naïve 
T cells. APCs provide three signals that induce T cell activation and proliferation:
1-3
  
• Signal 1: Antigen presentation 
• Signal 2: Co-stimulation 
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• Signal 3: Cytokine release 
The first signal, antigen recognition, occurs through the interaction of a T 
lymphocyte’s T cell receptor (TCR) with a peptide major histocompatibility complex 
(pMHC in mice, peptide human leukocyte antigen (pHLA) in humans) presented by 
professional APCs, which express MHC Class I and Class II molecules.
1-3
 Class I 
molecules present antigens derived from intracellular proteins and engage CD8
+ 
T cells, 












 cells, or T helper (TH) cells, release 
cytokines to stimulate CTL activation and B cell-dependent antibody production.
1-3
 TCR 
ligation can also be induced using agonistic antibodies against CD3, which trigger the 




Signal 2, or co-stimulation, is an antigen-independent signal needed for full T cell 
activation.
1-3
 Upon encounter with infection or cellular damage, APCs up-regulate 
molecules B7-1 (CD80) and B7-2 (CD86) which interact with CD28 on the T cell surface 
to induce full activation.
1-3
 Interaction of CD80 or CD86 with inhibitory molecule, 
cytotoxic T lymphocyte associated protein 4 (CTLA-4), can have immunosuppressive 
effects on T cell function and differentiation.
1-3
  
Lastly, cytokines released by APCs or CD4
+
 TH cells, or in an autocrine fashion 
by CTLs, further direct effector differentiation and function by binding to cytokine 
receptors.
1-3
 These cytokines are essential for the survival, proliferation, and function of 
CD8
+
 T cells. In particular, interleukin (IL)-2 is produced by T cells upon initial contact 
with the APC and promotes expansion and effector cell differentiation.
1-3
 Activating 
cytokines secreted by APCs such as IL-12, IL-15, IL-21, and type I interferons (IFNα/β) 
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are necessary for proper T cell function and crucial for T effector differentiation. 
Inhibitory cytokines such as IL-4, IL-5, and IL-10 are known to reduce the immune 
response and can induce tolerance.
1-3
   
The use of APCs, such as DCs, for ex vivo T cell expansion is constrained by the 
inherent disadvantages of using primary cells. The isolation of autologous DCs is often 
inefficient and time-consuming, rendering the procedure impractical for patients with 
advanced stages of disease.
6
 The quality of patient-derived autologous DCs can be 
variable due to sub-optimal antigen loading and the immunosuppressive tumor 
microenvironment.
6
 The reagents required for stimulation of DCs are also expensive. To 
overcome the difficulties with using autologous DCs, artificial antigen-presenting cells 
(aAPCs) that display antigens and/or co-stimulatory molecules in a controlled manner, 
have been produced or fabricated.
7
 To date, numerous groups have successfully used 
aAPCs to expand adoptive transfer tumor- or virus-specific T cells in vitro. 
4.1.2 T Cell Expansion Using Cell-Based aAPCs  
4.1.2.1 Insect Cells 
Insect cells were first used to investigate the molecular mechanisms of antigen 
processing and presentation. D. melanogaster cells lack the Transporter Associated with 
Antigen Presentation 1 (TAP1) and TAP2 peptide transporters needed to load 
endogenous peptides on nascent MHC Class I molecules, and are therefore good 
candidates with which to study exogenously loaded epitopes.
8
 Cai et al. found that D. 
melanogaster cells, transfected with murine Class I molecules alone, were not able to 
stimulate naïve T cells.
9,10
 However, co-transfection of B7-1 and intracellular adhesion 
molecule 1 (ICAM-1) turned Class I-expressing D. melanogaster cells into potent APCs 
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with the ability to induce naïve transgenic 2C CD8
+




In a phase I adoptive transfer clinical trial, D. melanogaster aAPCs expressing 
HLA-A2.1, CD80, and I-CAM were loaded with the HLA.A2.1-restricted tyrosinase 369-
377 peptide and used to expand antigen-specific CTLs from patient-isolated CD8
+
 T 
cells; subsequent re-stimulation was done using autologous peripheral blood 
mononuclear cells (PBMCs) and supplemental IL-2 and IL-7. After 1 month, 10
9
 CTLS 
were generated, with 10-30% being specific for the melanocyte antigen.
11
 The problem 
with using D. melanogaster cells for applications requiring extended culture is that they 
are optimally viable at 27°C.
11
 When cultured at 37°C, D. melanogaster cells experience 
a drastic loss in viability by 12 hours. Cell death results in a reduced number of TCR-
pMHC contacts and a release of antigens from dying cells. Therefore, despite being 
seminal tools for studying antigen-presentation, D. melanogaster cells are not practical 
aAPCs for clinical applications.   
4.1.2.2 Murine Fibroblasts 
Murine fibroblasts were used in experiments to investigate the role of co-
stimulatory molecules directly involved in murine or human CTL activation.   Latcouhe 
et al. co-transfected mouse fibroblasts with genes encoding B7.1, ICAM-1, leukocyte 
function antigen (LFA)-3, a single pHLA Class I complex, and human β2-
microglobulin.
12
 They found that these aAPCs elicited robust stimulation and expansion 
of the antigen-specific human CTLs when they presented individual epitopes derived 
from influenza matrix, melanoma antigen recognized by T cells-1 (MART-1) or 
glycoprotein (gp)100 proteins.
12
 In subsequent experiments, Papanicolaou and colleagues 
demonstrated that murine HLA-A2.1 aAPCs expressing the cytomegalovirus (CMV) 
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P495 epitope or full-length pp65 protein rapidly stimulated and expanded P495-specific 
CTLs as effectively as autologous PBMCs.
13
  
4.1.2.3 Human Erythroleukemia Cells 
June and colleagues recently engineered an aAPC system for rapid, polyclonal 
expansion of human CTLs. The K562 erythromyeloid cell line was stably transfected to 
express human Fcγ receptor (CD32), and human 4-1BB co-stimulatory molecules.  These 
cells, named K32/4-1BB, could then be coated with anti-CD3 and anti-CD28 (K32/4-
1BB/CD3/28) and used to non-specifically expand CTLs.
14
 It was found that K32/4-
1BB/CD3/28 cells could induce reproducible, long-term proliferation with an average of 
410-fold higher T cell numbers compared to anti-CD3/28 beads.
14
 K32/4-1BB/CD3/28 
cells were also able to expand MHC tetramer-sorted primary influenza matrix protein 
(MP) peptide-specific CD8
+
 T lymphocytes for up to 60 days, without loss of cytotoxicity 
for flu MP peptide-pulsed target cells.
14
 Similar studies indicate that K32/4-1BB/CD3/28 





4.1.3 T Cell Expansion Using Acellular aAPCs 
Cellular APCs have provided much insight about the requirements for T cell 
activation and expansion; however, the use of cell-based APCs is not ideal or 
economically viable for clinical applications. The lack of reproducibility and consistency 
of cell-derived APCs has warranted the need for “off the shelf” acellular APCs that can 
be made with Good Manufacturing Practices. Additionally, such acellular systems 
eliminate the need for allogeneic culture or the use of virally infected cells. As a result, 





 T cell expansion.  
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4.1.3.1 Anti-CD3/Anti-CD28 Microbeads  
The use of magnetic microbeads for ex vivo T cell expansion was initially 
pioneered by Levine and colleagues. They demonstrated that beads, covalently modified 
with anti-CD3 and anti-CD28, could exponentially expand CD4
+
 T cells for over 60 days 
without the use of additional feeder cells. This expansion was enhanced by the addition 
of exogenous IL-2.
16
 Later studies have shown that CD8
+
 T cells can also be expanded 
using anti-CD3/anti-CD28 beads, albeit with a lower proliferative capacity and greater 




 Anti-CD3/anti-CD28 beads are commercially 
available,
5
 and have been shown to expand CD4+ and CD8+ T cells to levels comparable 




4.1.3.2 MHC/HLA Multimers 
Oelke et al. have fabricated aAPC microbeads with immobilized pHLA.A2-Ig 
dimers and anti-CD28 antibodies.
19-21
 Microbeads presenting pHLA.A2-Igs loaded with 
high-affinity CMVpp65 peptide or low-affinity MART-1 peptide were able to induce 
robust expansion of the respective antigen-specific CTLs. Cells cultured with these beads 
expanded 10
6
-fold after two months and maintained antigen-specificity of greater than 
85%.
19-21
 Antigen-specific human CD4
+
 T cell expansion has also been achieved using 
microbeads, conjugated with pHLA tetramers and anti-CD28 molecules, as aAPCs.
22
 In 
addition to bead-immobilized Class I molecules, soluble Class I MHC tetramers have 
shown success in expanding CD8
+
 CTLs in vitro.
23
 Savage and colleagues have shown 
that cytotoxic T cells recognizing HLA-2/Melan-A and HLA-A2/Gag complexes could 






In this chapter, the enrichment and expansion procedures used to generate 
clinically relevant numbers of progenitor-derived antigen-specific CD8
+
 T cells are 
presented. While work described in the previous chapter was done using human stem 
cells, this chapter focuses on the use of mouse T cell progenitors as the starting cell 
source. Because murine thymocytes are easily retrievable and readily available in large 
quantities, they were useful tools for these proof-of-concept experiments. It was 
hypothesized that robust expansion of progenitor-derived antigen-specific CD8
+
 single 
positive (SP) T cells could be initiated by mimicking the three signals provided by APCs: 
i.) antigen-presentation, ii.) co-stimulation, and iii.) proliferative cytokines.  
Based on the success of other groups in expanding antigen-specific CTLs using 
MHC multimers, it was hypothesized that signal 1, antigen-presentation, could be 
induced using soluble, cognate pMHC Class I tetramers. Anti-CD3 antibodies, which can 
trigger the TCR signaling pathway, were included to enhance stimulation.
19,21,23
 The 
second signal, co-stimulation, was provided by incorporating anti-CD28 antibodies into 
the expansion media. Lastly, the proliferation-inducing cytokine, IL-2, was used to 
induce the third signal needed for T cell expansion. It was hypothesized that cognate 
Class I tetramers, together with anti-CD3, anti-CD28, and IL-2, would act synergistically 
to induce the robust expansion of progenitor-derived antigen-specific CD8
+
 SP T cells. A 
schematic of the experimental procedure can be found below (Figure 4.1). Briefly, double 
positive (DP) thymocytes from C57BL/6 mice were sorted and cultured with ovalbumin 
(OVA)257p- or lymphocytic choriomeningitis virus (LCMV).GP34p-MHC Class I 
tetramers, anti-CD3, anti-CD28, IL-2, and IL-7 for 7 days. Antigen-specific CD8
+
 SP T 
cells were then sorted and expanded using the respective Class I tetramers, anti-CD3, 
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anti-CD28, and IL-2 for an additional 7 days. Following expansion, CTL functionality 
was determined via granzyme B activity assays (Figure 4.1). 
 
 




 DP thymocytes from C57BL/6 mice 
were differentiated with OVA257p- or LCMV.GP34p-MHC Class I 
tetramers, anti-CD3, anti-CD28, IL-2, and IL-7 for 7 days. OVA257- or 
LCMV.GP34-specific CD8
+
 T cells were sorted and expanded for 7 days 
using the respective Class I tetramers, anti-CD3, anti-CD28, and IL-2. CTL 
functionality was determined via granzyme B activity. 
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4.3 MATERIALS AND METHODS 
4.3.1 Thymocyte Isolation 
Thymi from C57BL/6 mice (The Jackson Laboratory) were isolated. Thymi were ground 
on top of BD Falcon Blue Nylon Mesh 40 µm Cell Strainers (BD Biosciences, 352340) 
to release thymocytes into a single cell suspension. Red blood cells were lysed using 1X 
RBC Lysis Buffer (eBioscience, 00-4333-57) at a concentration of 2 mL/thymus for 15 
minutes at 20°C (room temperature). Cells were counted and washed with phosphate 
buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and 2 mM 
ethylenediaminetetraacetic acid (EDTA) and centrifuged at 300 x g for 5 minutes at 4°C. 
Thymocytes were resuspended at a concentration of 10
7
 cells/mL in PBS containing 0.1% 
BSA and 2 mM EDTA and processed for cell sorting.  
4.3.2 Double Positive Thymocyte Sorting 
Thymocytes were treated with FcR Block (eBioscience, 16-0161) at a 1:100 dilution for 
15 minutes on ice, then labeled with FITC-conjugated anti-CD8a (clone 53-6.7, 
eBioscience, 11-0081) and PECy7-conjugated anti-CD4 (clone RM5-4, eBioscience, 25-
0042) at a 1:100 dilution for 30 minutes on ice. Cells were then washed with 10-fold 
excess of PBS containing 0.1% BSA and 2 mM EDTA and centrifuged at 300 x g for 5 
minutes at 4°C. Pellets were resuspended at 107 cells/mL in PBS containing 0.1% BSA 





 DP thymocytes were sorted using FACSAriaIIIu (BD Biosciences) and 
FACSDiva Software (BD Biosciences).  
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4.3.3 Antigen-Specific CD8+ T Cell Differentiation Using OVA257p-MHC or 
LCMV.GP34p-MHC Class I Tetramers 
Sorted C57BL/6 DP thymocytes were seeded in Corning® Not Treated Tissue Culture 
clear, flat-bottom 12-well plates with OVA257p-MHC (10 µg/mL) or LCMV.GP34p-
MHC tetramers (10 µg/mL, Baylor College of Medicine Tetramer Production Facility) at 
a concentration of 10
6
 cells/well in RPMI 1640 supplemented with 10% fetal bovine 
serum (FBS), penicillin (100 U/mL), and streptomycin (100 µg/mL). All wells were 
supplemented with anti-CD28 (1.0 µg/mL, clone 37.51, eBioscience, 16-0281), anti-CD3 
(1.0 µg/mL, clone 17A2, eBioscience, 16-0032), IL-2 (10 ng/mL), and IL-7 (10 ng/mL) 
at a 1.0 mL working volume. Cells were cultured for a total of 7 days. Media and 
supplemental factors were replenished every 3 days.  
4.3.4  OVA257 and LCMV.GP34 Antigen-Specific CD8+ T Cell Sorting 
Differentiated cells were collected and washed with a 10-fold excess of PBS containing 
0.1% BSA and 2mM EDTA to remove excess media. Cells were counted using trypan 
blue exclusion and pelleted at 300 x g for 5 minutes at 4°C. The cell pellet was 
resuspended in PBS containing 0.1% BSA and 2 mM EDTA using gentle vortexing at a 
concentration of 10
7
 cells/100 µL. Following resuspension, the cells were stained with 
APC-conjugated LCMV.GP34p- or OVA257p-MHC tetramers at a 1:100 dilution on ice 
for 30-45 minutes. The cells were then treated with FcR Block (eBioscience, 16-0161) at 
a 1:100 dilution for 15 minutes on ice, then labeled with FITC-conjugated anti-CD8a 
(clone 53-6.7, eBioscience, 11-0081) and PE-conjugated or PECy7-conjugated anti-CD4 
(clone RM5-4, eBioscience, 12-0042 or 25-0042, respectively) at a 1:100 dilution for 30 
minutes on ice. Cells were then washed with 10-fold excess of PBS containing 0.1% BSA 
and 2 mM EDTA and centrifuged at 300 x g for 5 minutes at 4°C. Cell pellets were 
resuspended at 10
7
 cells/mL in PBS containing 0.1% BSA and 2 mM EDTA and 
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cells/100 µL. Tetramer-specific CD4-CD8+ SP thymocytes were sorted using 
FACSAriaIIIu (BD Biosciences) and FACSDiva Software (BD Biosciences).  
4.3.5 Expansion of OVA257- or LCMV.GP34-specific CD8+ SP T cells Using 
OVA257p-MHC or LCMV.GP34p-MHC Class I Tetramers 
The sorted OVA257- or LCMV.GP34-specific CD8
+
 SP T cells were cultured for 7 days 
in RPMI 1640 supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 
µg/mL), anti-CD28 (1.0 µg/mL, clone 37.51, eBioscience, 16-0281), anti-CD3 (1.0 
µg/mL, clone 17A2, eBioscience, 16-0032), IL-2 (10 ng/mL), and OVA257p- (10 
µg/mL) or LCMV.GP34p-MHC tetramers (10 µg/mL), respectively, in Corning® Not 
Treated Tissue Culture clear, flat-bottom 96-well plates at 200 µL working volumes. 
Seeding density ranged from 30,000 – 100,000 cells/well. Media and supplemental 
factors were replenished every 3-4 days.  
4.3.6 Characterization of T Cells after 7 Days of Expansion with OVA257p-MHC 
or LCMV.GP34p-MHC Class I Tetramers 
After expansion, cells were counted and characterized by flow cytometry to confirm 
enrichment and expansion. Cells were collected in polystyrene 12 x 75 mm test tubes and 
washed with 10-fold excess of PBS containing 0.1% BSA and 2 mM EDTA. The cell 
pellet was resuspended in PBS containing 0.1% BSA and 2 mM EDTA using gentle 
vortexing (100 µL working volume).  Following resuspension, the cells were stained with 
APC-conjugated LCMV.GP34p-MHC tetramers at a 1:100 dilution on ice for 30-45 
minutes. The cells were then treated with FcR Block (eBioscience, 16-0161) at a 1:100 
dilution for 15 minutes on ice, then labeled with FITC-conjugated anti-CD8a (clone 53-
6.7, eBioscience, 11-0081) and PE- or PECy7-conjugated anti-CD4 (clone RM5-4, 
eBioscience, 12-0042 or 25-0042, respectively) at a 1:100 dilution for 30 minutes on ice. 
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Cells were then washed with 10-fold excess of PBS containing 0.1% BSA and 2 mM 
EDTA and centrifuged at 300 x g for 5 minutes at 4°C. Cell pellets were resuspended at a 
200-300 µL working volume and were analyzed using FACSAria™IIIu (BD 
Biosciences) and FACSDiva Software (BD Biosciences). 
4.3.7 T Cell-Mediated Granzyme B Activity of Enriched LCMV.GP34-Specific 
CD8
+
 T Cells Against LCMV.GP34 Peptide-Loaded EL-4 Target Cells 
T cell-mediated granzyme B activity was determined using GranToxiLux PLUS! 
(OncoImmunin). Briefly, target EL-4 (ATCC
®
TIB-39™) lymphoblast cells were 
resuspended at a concentration of 2 x 10
6
 cells/mL in RPMI 1640 containing 10% FBS 
(complete RPMI1640). Cells were loaded with LCMV.GP34 peptide (50 µg/mL) for 1 
hour at 37°C. Cells were loaded with the cell-permeable fluorescent TFL4 dye (provided 
by the manufacturer) at a 1:1000 dilution during the last 15 minutes of incubation. The 
cells were washed with 10-fold excess of complete RPMI 1640, pelleted, and 
resuspended in complete RPMI 1640. Effector T cells from expansion cultures were 
counted and resuspended in 100 µL of complete RPMI 1640. Target cell volume was 
adjusted to yield 100 µL working volumes, and to yield a final effector to target (E:T) 
ratio of 5:1. Effector cells (in 100 µL) were added to round-bottom 96-well plates, and 
target cells (in 100 µL) were added immediately to those wells. The plate was centrifuged 
for 5 minutes at 300 x g and the media was removed by deftly flicking the plate. 75 µL of 
granzyme B substrate (provided by manufacturer) was added to the pelleted cells. 
Effectors and targets were co-cultured for 1 hour at 37°C in 5% CO2. Cells were 
transferred to 12 x 75 mm test tubes, washed with PBS containing 0.1% BSA and 2 mM 
EDTA, and centrifuged at 300 x g for 5 minutes at 4°C. Flow cytometric analysis was 
done on a FACSAriaIIIu (BD Biociences). Voltages were adjusted so that background 






 random fluorescence units (RFUs). Further analysis was performed using 




4.4.1. DP Thymocyte Sorting  
For all experiments, DP thymocytes were sorted using FITC-conjugated anti-CD8 
and PE-conjugated or PECy7-conjugated anti-CD4 antibodies. DP cells consistently 
ranged from 70-80% of the live thymocyte population (Figure 4.2).  
 
Figure 4.2: Sorted DP thymocytes consistently represented 70-80% of the live thymocyte 
population. This figure is representative of all DP cell sorts. 
4.4.2. CD8+ SP T Cell Generation in the Presence or Absence of Class I Tetramers  
After 7 days of differentiation, the percentage of CD8
+
 SP T cells obtained was 
consistently over 50% of the total live population, regardless of the presence or type of 
Class I tetramers (Figure 4.3). In all experiments, negligible amounts of CD4
+
 SP T cells 
were found (< 1% of the live cell population). Of the CD8
+
 SP T cells, generation of an 
antigen-specific population was variable and appeared to be dependent on the type of 





 SP T cells consistently made up over 50% of the differentiated T cell 
population, regardless of the presence (right) or absence (middle) of 
tetramers. Minimal CD4
+
 SP T cells were generated. These plots are 
representative of all experiments performed. 
4.4.3. Generation of OVA257-Specific CD8+ T Cells from DP Thymocytes Using 
OVA257p-MHC Class I Tetramers 
Due to the wide use of OVA as a model antigen and the accessibility of OVA 
epitope-specific TCR transgenic mice and tumor models, initial experiments to generate 
OVA257-specific CD8
+
 SP T cells from C567BL/6 T cell progenitors were attempted. It 
was hypothesized that the presence of OVA257p-MHC Class I tetramers would induce 
the generation of OVA257-specific CD8
+
 T cells that could be further expanded. After 7 
days of being “trained” with or without OVA257p-MHC Class I tetramers, the majority 
of DP thymocytes differentiated into SP CD8
+
 T cells (70.8% and 91.2%, respectively); 
however, the percentage of OVA257-specific CD8
+ 
T cells generated using OVA257p-
MHC Class I tetramers (2.07%) was slightly lower compared to the DP thymocytes 





 SP cells (left column) and OVA257-specific CD8
+
 SP T cells (right 
column) generated using OVA257p-MHC Class I tetramers (top row) or no 
tetramers (bottom row).  
4.4.4. Differentiation of OVA257- or LCMV.GP34-Specific CD8+ T Cells from DP 
Thymocytes Using OVA257p-MHC or LCMV.GP34p-MHC Class I Tetramers 
This data was discouraging, as it suggested that OVA257p-MHC tetramers were 
not inducing antigen-specific differentiation, and might even be deleting high-avidity 
OVA257-specific cells. To determine whether this phenomenon would occur with other 
tetramers, DP thymocytes were differentiated with OVA257p-MHC or LCMV.GP34p-
MHC tetramers (Figure 4.5).  
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Figure 4.5: OVA257- and LCMV.GP34-specific CD8
+
 T cells generated from culture 
with OVA257p-MHC or LCMV.GP34p-MHC Class I tetramers. The 
antigen-specific populations were sorted and expanded with the respective 
tetramers.  
Unexpectedly, when DP thymocytes were trained with OVA257p-MHC for 7 
days, a higher percentage of the CD8
+
 SP cells were LCMV.GP34-specific 
(approximately 3.02%, Figure 4.5 lower left) compared to OVA257-specific 
(approximately 0.172%) (Figure 4.5 upper left). Interestingly, this trend was not seen 
when LCMV.GP34p-MHC tetramers are used to differentiate the DP thymocytes. After 7 
days of culture with the LCMV.GP34 tetramers, a higher percentage of cells were 
LCMV.GP34-specific (approximately 2.04%, Figure 4.5 lower right) compared to 
OVA257-specific (approximately 0.318%, Figure 4.5 upper right). Similar results have 
been observed using OVA257p- and LCMV.GP34p-MHC-functionalized microbeads for 
differentiation (detailed in Chapter 5). 
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4.4.5. Expansion of OVA257- or LCMV.GP34-Specific CD8+ T Cells Using 
OVA257p-MHC or LCMV.GP34p-MHC Class I Tetramers 
Despite the puzzling differentiation results, expansion of SP CD8
+
 T cells was 
attempted. OVA257- and LCMV.GP34-specific CD8
+
 SP cells from all groups were 
sorted and expanded for 7 days with the respective tetramers and co-stimulatory factors 
(Figure 4.6). Flow cytometry analysis indicates that the majority of the sorted OVA257-
specific CD8
+ 
SP T cells that were expanded with OVA257p-MHC Class I tetramers 
retained OVA257-specificty (88.7% and 78.7%, Figures 4.6A, C), but were also 
LCMV.GP34-specific (93.8% and 82.9%, Figures 4.6E, G). After expansion of the sorted 
LCMV.GP34-specific CD8
+
 T cells with LCMV.GP34p-MHC Class I tetramers, almost 
all of the CD8
+
 SP cells were LCMV.GP34-specific (95.3% and 93.2%, Figures 4.6F, H) 
compared to OVA257-specific (41.4% and 13.6%, Figures 4.6B, D). Due to the cross-
reactivity of cells expanded with OVA257p-MHC tetramers, only LCMV.GP34 tetramers 
were used in further experiments. Cells counts indicated that cell number did not increase 






Figure 4.6: OVA257- (A-D) or LCMV.GP34- (E-H) specificity of DP thymocytes after 
differentiation with OVA257p-MHC (A,B,E,F) or LCMV.GP34p-MHC 
tetramers (C, D, G, H) followed by expansion with OVA257p-MHC 
tetramers (A,C,E,G) or LCMV.GP34pMHC tetramers (B, D, F, H). 
4.4.6. Generation of LCMV.GP34-Specific CD8+ T Cells Using LCMV.GP34p-
MHC Class I Tetramers 
In a separate experiment, using only LCMV.GP34p-MHC Class I tetramers to 
induce differentiation, approximately 46.4% of CD8
+
 SP T cells were LCMV.GP34-
specific after 7 days of differentiation (Figure 4.7). Live LCMV.GP34-specific CD8
+
 T 
cells and non-specific CD8
+
 SP T cells from cultures differentiated with LCMV.GP34p-




Figure 4.7: CD4 and CD8 expression and LCMV.GP34-specificity of DP thymocytes 
differentiated with LCMV.GP34p-MHC Class I tetramers (top row) or no 
tetramers (bottom row). LCMV.GP34-specific and non-specific cells from 
LCMV.GP34 tetramer-trained cultures were sorted.  
4.4.7. Expansion of LCMV.GP34-Specific CD8+ T Cells Using LCMV.GP34p-
MHC Class I Tetramers 
The sorted LCMV.GP34-specific and non-specific CD8
+
 T cells were expanded 
in media with or without LCMV.GP34p-MHC Class I tetramers, respectively, 
supplemented with anti-CD3, anti-CD28, and IL-2. After expansion, cells were analyzed 
by flow cytometry to confirm maintenance of tetramer specificity (Figure 4.8). 
Interestingly, two separate populations appeared in the FSC versus SSC of cells expanded 
without tetramers. The larger (higher FSC) population contained mostly dead cells, as 
confirmed by 7AAD
+
 staining. As expected, the majority of the LCMV.GP34-specific 
CD8
+
 SP T expanded with LCMV.GP34p-MHC Class I tetramers retained their antigen-
specificity. Non-specific CD8
+
 SP T cells expanded without tetramers showed minimal 
levels of LCMV.GP34p-MHC tetramer staining. 
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Figure 4.8: A) LCMV.GP34-specificity of non-specific CD8
+
 SP T cells expanded 
without tetramers and B) LCMV.GP34-specificity of LCMV.GP34-specific 
CD8
+
 T cells expanded with LCMV.GP34p-MHC Class I tetramers.  
During all differentiation experiments utilizing LCMV.GP34p-MHC tetramers, 
30,000 to 100,000 antigen-specific CD8
+
 SP T cells were consistently obtained. Despite 
the enrichment of antigen-specific CD8
+
 T cells and the use of Class I tetramers, anti-
CD28, anti-CD3, and IL-2 to induce expansion, cell numbers remained the same at the 
end of the 7 day expansion culture. 7AAD staining confirmed that the antigen-specific 
CD8
+
 T cells were viable after 7 days of culture in expansion media containing tetramers, 
anti-CD28, anti-CD3, and IL-2 (Figure 4.8).  
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4.4.8. Progenitor-Derived LCMV.GP34-Specific CD8+ T Cells Differentiated and 
Expanded with LCMV.GP34p-MHC Class I Tetramers Remain Functional 
To determine if LCMVp.GP34-specific T cells remained functional after 14 days 
of differentiation and expansion, T cell-mediated granzyme B activity was evaluated. 
Following the 14 days of culture detailed above, LCMV.GP34-specific or non-specific 
CD8
+
 SP T cells were co-cultured with LCMV.GP34 peptide-loaded EL-4 target cells for 
1 hour. Prior to co-culture, the EL-4 targets were labeled with a TFL4 dye and loaded 
with LCMV.GP34 peptide. Addition of cell-permeable granzyme B substrate was added 
immediately upon co-culture. The substrate fluoresces when cleaved by granzyme B.  
Non-specific CD8
+
 T cells, co-cultured with LCMV peptide-loaded EL-4 target 
cells, exhibited minimal levels of granzyme B activity (2.39%, Figure 4.9 middle row). 
However, approximately 28.8% of EL-4 target cells cultured with LCMV.GP34-specific 
effector T cells contained active granzyme B (Figure 4.9 bottom row), confirming that 
the LCMV.GP34-specific CD8
+
 T cells, but not the non-specific CD8
+
 T cells, can 
induce the killing of LCMV.GP34 peptide-loaded target cells. This data suggests that 
although the antigen-specific T cells appear to have lost expansion and/or proliferative 
capacity, they retained cytotoxic functionality. 
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Figure 4.9: T cell-mediated granzyme B activity of non-specific (middle row) and 
LCMV.GP34-specific (bottom row) CD8
+
 SP T cells against LCMV.GP34 




One surprising finding from these studies was the quantitative difference in 
antigen-specific differentiation induced by OVA257p- and LCMV.GP34p-MHC Class I 
tetramers. While both tetramers induced CD8
+
 SP T cell generation with equal efficiency, 
differentiation with OVA257p-MHC tetramers resulted in a higher percentage of 
LCMV.GP34-specific CD8
+ 
SP T cells than OVA257-specific CD8
+
 T cells. However, 
differentiation with LCMV.GP34p-MHC tetramers resulted in a higher percentage of 
LCMV.GP34-specific CD8
+
 SP T cells than OVA257-specific CD8
+
 T cells. From the 
results, it was hypothesized that instead of inducing OVA257-specific differentiation, the 
OVA257p-MHC tetramer, but not the LCMV.GP34p-MHC tetramer, skewed the T cell 
population to other antigen-specificities. In the following section, reasons for how and 
why this could happen are presented. 
4.5.1 Thymocyte Population Bias for OVA257p-MHC Class I Tetramers 
It was hypothesized that C57BL/6 DP thymocytes undergo higher levels of 
negative selection when cultured with OVA257p-MHC tetramers compared to the 
LCMV.GP34p-MHC tetramers. This may attributed to the inherent repertoire of 
C57BL/6 mice if it contains a population of thymocytes with TCRs that bind with high 
avidity to the OVA257p-MHC tetramer. Indeed, staining of freshly isolated C57BL/6 
thymocytes shows that approximately 7% of the thymocytes bind to the OVA257p-MHC 
tetramer, compared to minimal binding to the LCMV.GP34p-MHC tetramer (< 0.5% of 
thymocyte population) (Figure 4.10). Further analysis indicates that the majority (97.4%) 




Figure 4.10: OVA257- (upper left) and LCMV.GP34- (lower left) specificity of C57BL/6 
thymocytes. The majority of tetramer-binding cells are DP thymocytes 
(right column). 
TCR repertoire analysis of C57BL/6 mice indicates that Vβ1-1, Vβ5-2, Vβ12-1, 
and Vα2-1 are more highly represented in DP and CD8+ SP T cells over other Vα or β 
families.
24
 Interestingly, naïve CD8
+
 T cells from Vβ5-2 transgenic mice generate very 
strong immune responses to OVAp-H-2K
b
 complexes in vitro, and oligoclonal CTLs 
derived from non-transgenic mice have dramatically skewed expression of Vβ5-1 and 
Vβ5-2.25 In addition, Vβ5-2 transgenic mice express 30-fold more OVAp-H-2Kb specific 
CD8
+
 T cells compared to their non-transgenic littermates.
25
 Indeed, OT-1 transgenic 
mice, which express TCRs that recognize OVA257p-MHCs, contain TCR-Vα2 and 
TCR-Vβ5 transgenic inserts. Studies have also shown that OVA257-specific CD8+ 
memory T cells are found in germ-free, unprimed C57BL/6 mice.
26
 Collectively, these 
data suggest the C57BL/6 mice naturally contain a population of thymocytes with TCRs 
that bind with high avidity to OVA257p-MHC tetramers.  
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Results indicate that culture with OVA257p-MHC tetramers yields a distinct 
population of LCMV.GP34-specific cells. It is suspected that the OVA257p-MHC 
tetramers enriched the LCMV.GP34-specific cells by deleting the population of 
thymocytes which bind with high avidity to OVA257p-MHC, and simultaneously 
providing a positively selecting signal for thymocytes with weak to high avidities for 
LCMV.GP34-H-2K
b
 molecules. Interestingly, culture of DP thymocytes with 
LCMV.GP34p-MHC tetramers yielded more LCMV.GP34-specific T cells compared to 
OVA257-specific T cells. It was hypothesized that the LCMV.GP34p-MHC tetramers 
enriched for cells with weak to medium avidities for LCMV.GP34-H-2K
b
 molecules, 
while cells with avidities for OVA257p-H-2K
b
 molecules underwent death-by-neglect.  
Further studies need to be done to fully understand why LCMV.GP34p-MHC and 
OVA257p-MHC tetramers affected the C57BL/6 DP thymocyte population differently. 
One interesting experiment to determine how tetramer avidity affects antigen-specific 
differentiation could be done using cohorts of OVA-tetramers bearing peptide variants of 
the SIINFEKL epitope. These tetramers could be used to differentiate antigen-specific T 
cells with varying avidities for the SIINFEKL pMHC, which could then be sorted and 
tested for functionality. If the thymocyte population of C57BL/6 mice is truly biasing 
differentiation, differentiation with low-avidity tetramers should yield high avidity 
SIINFEKL pMHC-specific T cells. Additional differentiation experiments using 
tetramers with diverse epitopes should also be done to confirm if antigen-specific T cells 
can be generated for multiple epitopes in a tetramer-directed fashion. 
It also should be noted that the OVA257-specific T cells obtained from expansion 
cultures were cross-reactive with LCMV.GP34p-MHC tetramers. This finding is 
important because it confirms that in vitro-differentiated T cells must be screened for 
unexpected cross- or self-reactivity before transplantation. This could be done by 
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culturing differentiated/expanded cells with autologous PBMCs and screening for cells 
that undergo proliferation.  
4.5.2 T Cell Dysfunction May Prevent Expansion 
Another concern of these experiments is that the antigen-specific cells did not 
efficiently expand after sorting. Adoptively transferred cells must be expanded to the 
order of billions (approximately 27 doublings of 1 naïve T cell) before being infused into 
a recipient.
27
 Live/dead staining using 7AAD indicates that the LCMV.GP34-specific 
CD8
+
 T cells are still alive after 14 days of culture, and the T cells remained functional, 
as they mediated granzyme B activity in peptide-loaded EL-4 targets. While further 
studies are needed to determine why the cells did not expand, it is hypothesized that the 
antigen-specific T cells entered a state of dysfunction. Possible states of dysfunction are 
discussed in the following sections. 
4.5.2.1 T Cell Anergy 
One possibility for the failed expansion of the antigen-specific CD8
+
 T cells in 
vitro is that they became anergic. Anergy is a state of T cell hyporesponsiveness that 
results from suboptimal stimulation, such as the engagement of the TCR by antigen 
without co-stimulation from CD28 or pro-inflammatory cytokines such as IL-2. In the 
anergic state, T cells activate the expression of genes that produce proteins to block TCR 
signaling and inhibit cytokine production, in particular IL-2, and proliferation.  
Studies done by Redmond et al. indicate that ligand density and TCR signaling 
strength influence T cell tolerance and anergy.
28-30
 In the absence of inflammatory 
signals, high doses of cognate antigen can induce hyporesponsiveness in TCR transgenic 
mice, and can prevent clonal deletion during additional antigenic stimulation; however, T 
cells treated with consecutive low antigen doses are effectively deleted.
28,29
 In addition, 
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Smith and colleagues have shown that high affinity peptides can promote T cell 
unresponsiveness in TCR transgenic mice in the absence of inflammatory signals, while 
low affinity peptides induce T cell deletion.
31
 However, because anti-CD28 and IL-2 
were consistently and continuously used in the expansion media of the system described, 
lack of co-stimulation is most likely not a problem. 
4.5.2.2 T Cell Tolerization 
Due to the treatment of DP thymocytes with tetramers, it is possible that high-
avidity CD8
+
 T cells were negatively selected, resulting in a pool of “tolerant” weak-
avidity antigen-specific cells. In addition, the SP T cells derived from differentiation 
cultures may have become tolerized due to chronic stimulation with the tetramers, co-
stimulatory molecules anti-CD3, anti-CD28, and IL-2. It is known that tolerized T cells 
are antigen-experienced and enter a plastic, non-proliferative state. Peripheral tolerance 
can be induced by continual exposure of T cells to self-antigen, but does not necessarily 
disrupt effector functions and can be reversed in vitro by inducing proliferation with IL-
15 or in vivo via lymphopenia.
31-35
 The observed results, lack of expansion with retained 
functionality, suggest that antigen-specific T cells may have become tolerized during 
differentiation or expansion. 
Tolerized T cells are characterized by a tolerance-specific gene program that is 
unique from that of naïve or memory T cells. To determine the genome-wide differences 
between tolerized and non-tolerized T cells, Schietinger and colleagues “rescued” 
tolerized T cells by transferring them into lymphopenic mice.
34,36
 Genome-wide analysis 
of the tolerized and “rescued” T cells indicates that tolerant T cells have uniquely 
overexpressed genes modulating effector function, cell cycle, division, nucleosome 
assembly, mitosis, and DNA replication. Tolerized T cells have reduced expression of 
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genes controlling effector molecules interferon gamma (IFNγ), perforin 1 (PRF1), and 
granzyme M (GZMM), as well as increased gene expression of chemokine and 
chemokine receptors, CXCR3, CCR5, and CCL5.
36
 Compared to rescued T cells, 
tolerized T cells have lower expression of the master transcription factors, T-bet, 
EOMES, GATA3, and STAT4, and increased expression of the negative transcriptional 
regulators, early growth response protein 1 (EGR1) and EGR2.
36
 Schietinger et al. also 
showed that tolerized T cells are re-tolerized in non-tolerogenic hosts, suggesting that the 
regulation of tolerance-specific genes occurs on an epigenetic level. Indeed, it was found 
that tolerized and re-tolerized T cells have increased expression of genes regulating 
chromatin modification including DNA-methyltransferase 1 (DNMT1), histone acetyl 
transfer 1 (HAT1), histone deacetylase 2 (HDAC2), and HDAC3.
36
  
4.5.2.3 T Cell Exhaustion 
T cell exhaustion arises from chronic stimulation caused by prolonged infections 
or cancer and represents a terminal state of T cell differentiation characterized by 
hyporesponsiveness. Exhaustion can be induced by chronic antigenic stimulation; 
however, unlike anergy, which happens rapidly after stimulation, T cell exhaustion is a 




 T cells first lose 
their proliferative capacity and ability to produce IL-2. Severely exhausted CD8
+
 cells 
fail to produce IFNγ and are unable to degranulate.30,34,39 Distinct from memory T cells, 
which can persist without antigen, via IL-7 and IL-15-mediated homeostasis, exhausted T 
cells have low expression of CD122 (the IL-15 receptor β-chain) and CD127 (the IL-7 
receptor α-chain).30,34,39 They require tonic signaling from the cognate antigen to survive, 
a term coined “antigen addiction”.
30,34,39
  Exhausted T cells are characterized by loss of 
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PD-1 has been implicated as the main inhibitory receptor regulating T cell 
exhaustion. Persistent antigen stimulation causes epigenetic alterations in the Pdcd1 
locus, resulting in the long-term expression of PD-1 on antigen-specific T cells.
42
  The 
PD-1/PDL-1 signaling pathway has been shown to attenuate functional and proliferative 
capacities of T cells by repressing TCR signaling and inducing the expression of genes 
that impair T cell function.
42
 PD-1 signaling has also been shown to inhibit T cell 
motility, thus preventing CD8
+






















 T cells are a progenitor 













 T cells have 
higher inhibitory receptors and do not replicate but express high levels of cytotoxic 
activity.
39





 regulatory T (TREG) cells, which secrete immunosuppressive 
cytokines such as IL-10 and TGF-β, induce and maintain T cell exhaustion.39 
In addition to PD-1 overexpression, exhausted T cells co-express inhibitory 
receptors LAG-3, CD244, CD160, TIM-3, and CTLA-4, and have low expression of 
CD122 (the IL-2 and IL-15 β-chain receptor) and CD127 (the IL-7 α-chain receptor).34,39 
Genomic approaches have provided much insight into the molecular program of 
exhausted CD8
+
 T cells and have confirmed that they are transcriptionally distinct from 
naïve or memory T cells.
39
 The transcriptional repressor, Blimp-1, has been implicated in 
T cell exhaustion.
43,44
 In small amounts, Blimp-1 is found to promote the formation of 




 Blimp-1 is found in very high levels in exhausted T cells, and is 
associated with the upregulation of the previously described inhibitory receptors. 
Exhausted T cells also express higher levels of NFATc1, which has been shown to 
regulate PD-1 expression in vitro.
40,43,44
 
4.5.2.4 T Cell Senescence 
Lastly, it is possible that the T cells failed to expand because they were senescent. 
Senescent T cells are characterized by telomeric shortening, which ultimately results in 
permanent cell cycle arrest.
30,46-49
 While T cell senescence is naturally associated with 
aging, high levels of senescent T cells are found in young patients with autoimmune 
diseases, suggesting that chronic activation and proliferation may induce T cell 
senescence. Senescent T cells are characterized by the loss of the important co-
stimulatory receptor, CD28, which is essential for T cells functions such as lipid raft 
formation, IL-2 gene transcription, cell adhesion, and glucose metabolism.
30,46-49
 
Interestingly, although senescent CD8
+
 T cells cannot replicate in response to TCR 
stimulation, either by the cognate antigen or mitogens, they contain high levels of 




Senescent T cells are characterized by the loss of CD28 and re-expression of 
CD45RA. CD8
+



















 Diminished expression 
of CD28 results in decreased TCR signaling and reduced ability to secrete IL-2. In 









 T cells demonstrate enhanced expression of co-stimulatory molecules 4-
1BB, CD244, and SLAMF7.
46
 It is thought that the simultaneous loss and enhancement 
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of co-stimulatory receptors serves as a compensatory mechanism, but this phenomenon is 
not completely understood. Real-time polymerase chain reaction (RT-PCR) analysis and 




 T cells also express higher levels of NK cell 
stimulatory receptors such as CD16, CD56, KIR2DL2, CD94, NKG2D, and KLRG1 




 memory T cell counterparts.
50
 Cytokines, chemokines, 









 T cells. Gene expression analysis has shown that IL-3, IL-23A, IL-7R, and IL-




 T cells, while IL-12A and IL-13 mRNA 




 T cells, suggesting different proliferative requirements 
for both sets of memory T cells.
50












Senescent T cells are characterized by shortened telomeres.
46,50
 Telomere 
shortening is an inevitable process that occurs with cell replication. When the telomere 
shortens to its critical length, DNA damage signals result in cell cycle arrest and 
replicative senescence.
46,50
 This mechanism is thought to protect cells from malignant 
changes brought about by the chromosomal instability of dividing cells with shortened 
telomeres.
46,50
 The loss of CD28 parallels telomere shortening in senescent T cells.
46,50
 
Telomeric sequences can be restored by the action of telomerase. Lymphocytes have the 
ability to upregulate telomerase in response to proliferative stimuli such as acute viral 
infections or when activated by anti-CD3 or anti-CD28 antibodies; however, after 
repeated rounds of stimulation, telomerase activity in CD8
+





4.5.2.5 Preventing T Cell Dysfunction 
Progenitor-derived antigen-specific CD8
+
 T cells should be evaluated, both 
molecularly and cellularly, to determine the most appropriate way to prevent 
dysregulation. As described in the previous sections, tolerized, exhausted, and senescent 
T cells are characterized by unique phenotypic markers and transcriptional profiles. 
Before expansion, antigen-specific T cells should be screened by flow cytometry for 
various dysfunction markers. In addition, quantitative RT-PCR would provide a deeper 
understanding of the molecular state of the cells. 
The failure to increase cell number may be due to lack of proliferation; however, 
it is also possible that some cells are proliferating while similar numbers are dying, 
resulting in unchanged cell numbers after culture. To discriminate between these two 
possibilities, a proliferation assay could be done. Cells could be labeled with CFSE and 
monitored by flow cytometry over the course of 7 days to determine if the cells have 
proliferative capacity.  
As discussed in the previous sections, various forms of T cell dysregulation can 
be caused by chronic stimulation, resulting in the loss of proliferative capacity. The 
amounts of tetramers, co-stimulatory molecules, and cytokines used for differentiation 
and/or expansion might provide too much stimulation and hinder proliferation.
31,32,37,38
 
One solution is to adjust the concentrations of the tetramers, anti-CD3, anti-CD28, and 
IL-2 to provide optimal amounts that allow for antigen-specific CD8
+
 T cell expansion. 
Because the antigen-specific CD8
+
 SP T cells are sorted prior to expansion, it is not 
necessary to include Class I tetramers during expansion. Elimination of the antigen would 
reduce chronic TCR signaling and increase the proliferative capacity of the T cells. In 
addition, lowering the concentration of anti-CD3, anti-CD28, and/or IL-2 would lower 
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the level of tonic stimulation and might prevent any tolerization that is occurring during 
the expansion portion of the procedure. 
In addition to adjusting the amount of IL-2 in the expansion media, additional 
cytokines, in particular, IL-15, may need to be incorporated for the T cells to retain 
proliferative activity.
53-61
 Studies have shown that IL-15 induces proliferation of memory 
CD8
+
 T cells similar to TCR crosslinking, and is capable of inducing cytotoxic activity in 
memory CTLs.
55
 Gene expression profiling shows similarities between cells stimulated 




 Teague and 
colleagues have shown that IL-15 can rescue tolerant CD8
+
 T cells in vitro, and that these 
rescued T cells can be used effectively for adoptive transfer after stimulation.
58
  
PD-1 blockade has been very well-studied and is an effective way to reverse T 






 If the antigen-specific CD8
+
 T cells from 
the differentiation or expansion cultures express intermediate to high levels of PD-1, in 
vitro culture with antagonist antibodies might prevent exhaustion and help maintain 
proliferative capacity; however, since the described system only contains T cells, PD-
1/PDL-1 signaling is not expected to occur.  Additional methods such as blocking other 
inhibitory receptors such as Tim-3, LAG-3, and CTLA-4 might enhance the expansion 
capacity of in vitro-exhausted T cells.
64
 
The epigenetic changes associated with exhaustion or tolerance may be reversible. 
Studies indicate that CD8
+
 T cell exhaustion during chronic LCMV infection is 
associated with a downregulation of diacetylated histone H3 (diAcH3).
65
 Zhang and 
colleagues have found that in vitro treatment of exhausted T cells with valproic acid 
(VPA), an HDAC inhibitor, increases the level of diAcH3 at the Ifng and Il2 promoters 
by seven- and two-fold, respectively.
65
 VPA-treated T cells also produced 50-fold higher 
amounts of IFNγ and four-fold higher amounts of tumor necrosis factor alpha (TNFα) 
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mRNA compared to non-treated exhausted T cells.
65
 After adoptive transfer, VPA-treated 
CD8
+
 T cells survived and differentiated into functional memory T cells that were 
capable of mounting a response against LCMV challenge.
65
 These studies suggest that 
exhaustion may be prevented or reversed with the use of HDAC inhibitors. 
Preventing replicative senescence using gene transduction of human telomerase 
reverse transcriptase (hTERT), an important component of telomerase, has been well-
studied in human fibroblasts, epithelial cells, and keratinocytes.
66-69
 Cells transduced with 
hTERT exhibit telomere stabilization and unlimited proliferation with no evidence of 
abnormal growth or tumorogenicity in severe combined immunodeficiency (SCID) 
mice.
66-69
 Expressing exogenous hTERT has been attempted with HIV-specific CD8
+
 T 
cells using a number of viral vectors; however, these approaches fail to prevent the loss 
of CD28, indicating that expression of telomerase in combination with CD28 may be 
required.
70
 Potential non-genetic approaches to modulate T cell replicative senescence 
center on the use of estrogen. Studies show that an estrogen-responsive element is found 
in the promoter region of IFNγ, a cytokine that has been shown to upregulate telomerase 
in T cells.
48,71-73
 The promoter region of hTERT contains an estrogen-responsive element 
in various reproductive tissues, and estrogen has been shown to modulate calcium 
mobilization in T cells.
71
 Collectively, these data suggest the potential use of estrogen for 
preventing T cell senescence. 
  
 133 
4.6 CONCLUSION  
In this chapter, a method to enrich and expand progenitor-derived CD8
+
 SP T 
cells was presented. The studies detailed here indicate that progenitor-derived 
LCMV.GP34-specific CD8
+
 T cells can be enriched and cultured for 7 days in expansion 
media containing tetramers, co-stimulatory molecules, and cytokines. Despite the lack of 
T cell expansion, enriched antigen-specific T cells retained their cytotoxic functionality. 
Optimization of differentiation and expansion conditions, by lowering the amounts of 
tetramers, co-stimulatory molecules, and cytokines used for culture, or by including IL-
15 in the expansion media may be needed. Further studies should also be done to confirm 
that T cells lack proliferative capacity, and whether they enter a state of dysfunction after 
differentiation or during the process of expansion. Molecular and cellular characterization 




HSC – hematopoietic stem cell 
CTL – cytotoxic T lymphocyte 
APC – antigen-presenting cell 
DC – dendritic cell 
TCR – T cell receptor 
pMHC – peptide major histocompatibility complex 
pHLA – peptide human leukocyte antigen 
TH – T helper 
CTLA-4 – cytotoxic T lymphocyte associated protein 4 
IL - interleukin 
aAPC – artificial antigen-presenting cell 
TAP1/2 – transporter associated antigen presentation 1/2 
ICAM-1 – intracellular adhesion molecule 1 
LFA – leukocyte function antigen 
PBMC – peripheral blood mononuclear cells 
MART-1 – melanoma antigen recognized by T cells-1 
gp – glycoprotein 
CMV – cytomegalovirus 
K32/4-1BB/CD3/28 – K562 erythomyeloid cell line expressing Fcγ receptor, human 4-
1BB, coated with anti-CD3 and anti-CD28 antibodies 
MP – matrix protein 
REP – Rapid Expansion Protocol 
SP – single positive 
DP – double positive 
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OVA257p-MHC – ovalbumin epitope (SIINFEKL) pMHC 
LCMV.GP34p-MHC – lymphocytic choriomeningitis virus glycoprotein epitope 
(AVYNFATC) pMHC 
PBS – phosphate buffered saline 
BSA – bovine serum albumin 
EDTA – ethylenediaminetetraacetic acid  
FBS – fetal bovine serum 
FITC – fluorescein isothiocyanate 
PE – phycoerythrin 
PECy7 – phycoerythrin cyanine 7 
APC-labeled – allophycocyanin-labeled 
APC-conjugated – allophycocyanin-conjugated 
RFU – random fluorescence units 
MDSC –myeloid-derived suppressor cell 
TREG – regulatory T cell 
RT-PCR – real-time polymerase chain reaction 
IFNγ – interferon gamma 
PRF1 – perforin 1 
Gzmm – granzyme M 
EGR – early growth response factor  
DNMT1 – DNA methyl transferase 1 
HAT – histone acetyl transferase 
HDAC – histone deacetylase inhibitor 
diAcH3 – diacetylated histone H3  
VPA – valproic acid 
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TNFα – tumor necrosis factor alpha 
hTERT – human telomerase reverse transcriptase 
SCID – severe combined immunodeficiency  
SIINFEKL – (serine – isoleucine – isoleucine – asparagine – phenylalanine – glutamic 
acid – lysine – leucine) 
AVYNFATC – (alanine – valine – tyrosine – asparagine – phenylalanine – alanine – 
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Chapter 5: The Effects of MHC Density and Presentation on Immature 
Thymocyte Signaling and Differentiation 
5.1 INTRODUCTION 
In the periphery, engagement of the T cell receptor (TCR) with cognate peptide 
major histocompatibility complex (pMHC)/human leukocyte antigen (pHLA) Class I or 





 T cells, respectively. TCR-pMHC engagement is critical for thymocyte 
development in vivo, as it directs of the production of a self-restricted and self-tolerant T 
cells. In the previous chapters, a novel system to differentiate human CD34
+
 cord blood 
hematopoietic stem cells (HSCs) into antigen-specific CD8
+
 T cells was detailed, and 
methods to expand progenitor-derived antigen-specific CD8
+
 T cells were explored. 
While considerable success to induce antigen-specific CD8
+
 T cell differentiation was 
demonstrated in the previous chapters, those systems employed soluble tetramers which 
do not accurately mimic the cell-based presentation of pMHCs in vivo.  
In the thymus and periphery, TCR-pMHC engagement occurs via pMHCs 
displayed on the surface of antigen-presenting cells (APCs). The orientation and density 
of APC-presented pMHCs is crucial for inducing T cell polarization, adhesion, TCR 
clustering, and lipid raft formation, all of which influence TCR signaling, T cell 
differentiation, and effector function. Many studies focus on the effects of pMHC surface 
presentation and density in the context of mature T cell activation and effector functions. 
In this chapter, the effects of plate- and bead-immobilized pMHC ligand density and 
solid-phase presentation on thymocyte signaling and differentiation are evaluated. The 
following section provides a review of current literature detailing the effects of TCR 
signaling on thymocyte fate and T cell function, factors governing TCR signaling 
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strength, and the various methods of acellular pMHC presentation that have been 
developed to date.  
5.1.1 Thymocyte Selection and CD4 Versus CD8 Lineage Commitment 
Approximately 98% of double positive (DP) cells will undergo apoptosis during a 
series of developmental checkpoints known as positive and negative selection which 
occur in the thymic cortex and medulla, respectively.
1
 During positive selection, DP 
thymocytes undergo “death by neglect” if their TCRs fail to engage pMHCs presented by 
cortical thymic epithelial cells (cTECs).
1
 DP cells that bind to self-antigen presenting 





positive (SP) T cells, respectively. SP thymocytes migrate to the medullary compartment, 
where they are eliminated by negative selection if they express TCRs that bind with high 
avidity to self-antigens.
1
 Thymocytes that pass both checkpoints become MHC-restricted 







5.1.1.1 Anatomical Differences of Positive and Negative Selection 
Positive and negative selection is temporally and spatially segregated within the 
cortical and medullary compartments of the thymus.
2
 The cortical and medullary thymic 
niches contain different types of APCs that use unique, cell-type specific antigen 
sampling and processing. Cortical TECs use a unique proteasome, β5t, to generate MHC 
Class I epitopes that are essential for positive selection.
3-5
 β5t deficiency does not alter 
negative selection, suggesting that β5t facilitates the presentation of unique self-epitopes 
to DP thymocytes within the cortex.
4,5
 In an analogous fashion, cTECs utilize cathepsin L 
and thymus-specific serine protease (TSSP) to display MHC Class II epitopes which are 






The medullary compartment of the thymus is crucial for producing self-tolerant T 
cells. Much of the medulla’s tolerogenic role is attributed to the expression of AIRE, a 
transcriptional regulator that promotes the promiscuous gene expression of tissue-
restricted antigens (TRAs), by medullary thymic epithelial cells (mTECs).
7,8
 The medulla 
also contains various DC subsets that facilitate negative selection and tolerance. In 
particular, resident conventional DCs (cDCs), which preferentially seed the medulla, 




The repertoire of mature, naïve, SP T cells generated after positive and negative 
selection is diverse, MHC-restricted, and self-tolerant. Mature T cells exit the thymus and 
upon encountering foreign antigen in the periphery, undergo dramatic clonal expansion 
and acquire effector or memory functions. CD8
+
 SP T cells, or cytotoxic T cells, 
recognize MHC Class I molecules and are capable of “killing” pathogen-infected cells or 
tumor cells. CD4
+
 SP T cells, or T helper (TH) cells, mediate B cell responses and 
facilitate cytotoxic T cell activation. 
5.1.1.2 The Influence of Signal Strength on Positive and Negative Selection 
Thymocyte survival and lineage commitment is highly dependent on the 
interaction between the developing cell’s TCR and pMHC molecules presented by 
thymic epithelia. These interactions span a wide range of affinities due to the diversity of 
TCRs and self-peptides displayed by each MHC. Much progress has been made to 
understand how the strength of TCR signaling determines qualitatively different cell 
fates.
9-13
 In the classic model of thymocyte selection, weak avidity interactions prevent 




Experiments using TCR transgenic mice have shown that strong affinity agonist 
pMHCs induce negative selection, while low affinity antagonists or weak agonists act as 
positively-selecting ligands. A narrow affinity window for positive versus negative 
selection has been determined and slight alterations in affinity have been shown to 
influence the fate of immature thymocytes.
16
 The recent development of Nur77-GFP 
knock-in reporter mice has facilitated the analysis of signal strength during selection on a 
cell-to-cell basis. Nur77 is an immediate response gene of TCR engagement and is 
directly proportional to signal strength due to activating stimuli. Work by Moran and 
colleagues have shown that Nur77 is more highly expressed in cells undergoing negative 
selection compared to cells undergoing positive selection.
2,17
 The Nur77-GFP model has 




 T regulatory (TREG) cells perceive stronger TCR 
signals than conventional CD4
+
 TH cells during development and selection.
17
  
Differences in signal strength perceived via the TCR during positive and negative 
selection are thought to induce differential intracellular kinase pathways that direct 
thymocyte fate. For example, during positive selection, weak TCR signals result in low, 
sustained Erk activation, while strong signals that induce negative selection result in 
transient Erk activation accompanied by JNK and p38 activation.
18-20
 The localization of 
Erk during positive and negative selection also occurs in different intracellular 
compartments. During positive selection, Erk remains in the Golgi membrane, while it 
resides in the plasma membrane during negative selection.
21
 Knock-down studies have 
demonstrated differential roles of various kinase and adapter proteins on selection. 
Deletion of Erk1 and Erk2 results in positive selection defects, but has no effect on 
negative selection.
22,23
 Additionally, knock-down of Grb2, an adaptor protein that 
mediates kinase activity downstream of TCR engagement, disrupts positive and negative 




 While much is still not fully understood about the role of signal 
transduction during selection, experiments performed to date highlight the quantitative 
and qualitative influence of signaling strength on thymocyte fate.  
5.1.1.3 The Influence of Signal Strength on the CD4 Versus CD8 Lineage Decision 
DP thymocytes expressing both CD4 and CD8 co-receptors are bipotential 
precursors that differentiate into either CD4
+
 TH cells or CD8
+ 
cytotoxic T lymphocytes 
(CTLs). The decision of lineage fate has been studied for decades, and three “classical” 
models have been proposed to explain the CD4 versus CD8 lineage choice. One classical 
model of T lineage commitment, the stochastic selection model, postulates that 
termination of co-receptor gene expression is a random event during positive selection. 
According to this theory, only thymocytes with matching TCRs and co-receptors survive 
positive selection and proceed with differentiation.
25-28
  
The instructive strength-of-signal model proposes that the fate of DP thymocytes 
is determined by the differences in the strength of signaling transduced by engagement of 
the TCR and co-receptor.
29-31
 In this model, quantitative differences in the signals 





commitment. Because CD4 binds to more intracellular Lck than CD8, it is postulated that 
TCR/CD4 co-engagement results in stronger signals than TCR/CD8 engagement.
31-33
 The 
differences in signal strength result in termination of either CD4 or CD8 expression. The 
duration-of-signal instructional model is a modified version of the strength-of-signal 
model, and considers TCR signal duration in the CD4 versus CD8 lineage choice.
34
 In 





) state disrupts MHC Class I signaling, but not Class II signaling. Therefore, 









 Both the stochastic and instruction models have been controversial, as 
experimental observations have been shown to contradict each theory.
35,36
  
To date, the best model to explain CD4 versus CD8 lineage commitment is the 
kinetic signaling model. This model postulates that the CD4 versus CD8 decision is 
determined by TCR signal duration and that cytokine receptors serve as sensors to detect 
the duration of TCR signaling.
37-39
 In this model, DP thymocytes undergo positive 





A decrease in surface CD8 expression abrogates CD8-dependent signaling from MHC 
Class I molecules. For DP cells to become CD8
+
 T cells, they must undergo IL-7 
dependent co-receptor reversal, whereby CD4 gene expression is terminated and CD8 
transcription is reinstated.
37
 Studies suggest that cytokine receptor signal transduction 
functions as a sensor for TCR signaling duration.
30,39-42
 Sustained TCR signaling by Class 
II molecules impairs IL-7R signaling, driving differentiation of ISPs into the CD4 
lineage.
37,39,42
 If TCR signaling through MHC Class I molecules is disrupted by CD8 






5.1.2 T Cell Receptor Engagement and Signaling 
The TCR is a heterodimer, composed of an α- and β- chain, that responds to short 
peptide sequences displayed in the context of Class I and Class II molecules.
43,44
 Each 
TCR chain contains a variable and constant immunoglobulin (Ig)-like domain, 
transmembrane segment, and short cytoplasmic tail.
43-45
 During development, the 
variable domains are generated via random, somatic recombination of the variable (V), 
diversity (D), and joining (J) gene segments (D not present on α-chain).43,44 This 
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recombination results in the development of T cells with a wide range of specificities and 
the ability to recognize a diverse range of pMHCs. The αβTCR has no intrinsic signaling 
capacity, but is associated with three CD3 signaling dimers (δε, γε, and ζζ) that contain 
immunoreceptor tyrosine-based activation motifs (ITAMs).
46,47
 Upon TCR-pMHC 
engagement, CD3 ITAMs are phosphorylated and recruit other molecules to initiate the 
downstream signaling cascade which directs T cell development and function.
43,44,46,47
 
The CD4 and CD8 co-receptors are indirectly associated with the TCR-CD3ε 
complex and facilitate the antigen recognition process by binding to the invariant portions 
of the pMHC during TCR-pMHC engagement.
48,49
 The intracellular portions of CD4 and 
CD8 interact with Lck, thus facilitating signal transduction during early TCR triggering, 
and are therefore essential for normal T cell activation and function.
32,33,50
 Experiments 
have shown that the absence or blockade of CD4 or CD8 co-receptors decreases TCR 
sensitivity by more than 10 to 100-fold. In addition to CD4/CD8 co-receptors, co-
stimulatory signals provided by CD28 ligation enhance TCR sensitivity to antigen 
receptor engagement.
51-53
 CD28 co-stimulation can increase IL-2 production by 50-fold, 
and as a result, promotes proliferation in suboptimal mitogenic conditions.
51,52
 The 
extracellular domain of CD28 binds to B7 proteins on APCs, and studies indicate that 
CD28/B7 ligation induces phosphorylation of tyrosine, serine, and threonine residues of 




The dynamic nature of the cytoskeleton is an essential component of TCR 
signaling and activation, as it provides T cells with the ability to migrate and remodel in 
response to APC contact. Intracellular cytoskeletal changes allow organelle redistribution 
and polarization during TCR-pMHC engagement and immunological synapse (IS) 
formation.
54-58
 The accumulation of lipid rafts at the IS plays a crucial role in TCR 
 150 
signaling and T cell activation. These microdomains, formed mainly by sphingomyelin 
and glycosphingolipids, amplify downstream TCR signaling by facilitating the clustering 




5.1.3 MHC Class I and MHC Class II Molecules 
Though MHC Class I and Class II molecules exhibit some structural similarities, 
they differ in the types of peptides they present and their distributions among cell 
types.
43,59
 Class I molecules are present on all nucleated cells, although their degree of 
expression varies between cell types and is highest on hematopoietic cells. The peptides 
that bind to Class I clefts are usually 8-10 amino acids in length and lie elongated within 
the peptide-binding groove.
43,59
 Class I molecules present natural self-antigens or 
epitopes from pathogens such as viruses or intracellular bacteria, and are recognized by 
CD8
+
 CTLs which secrete cytotoxic molecules such as perforins and granzymes to 
eliminate infected or cancerous cells.
43,59
   
MHC Class II molecules present peptides derived from endocytic or exogenous 
proteins and are normally found on hematopoietic cells, such as B lymphocytes, dendritic 
cells (DCs), and macrophages, that activate effector CD4
+
 TH or TREG cells ,which secrete 
cytokines to modulate the immune response.
43,59
 The peptide-binding groove of Class II 
molecules is open at both ends and can accommodate longer epitopes, ranging from 11 to 
30 amino acids in length.
43,59
  
5.1.4 Factors Influencing Cumulative TCR Signaling Strength 
During TCR-pMHC engagement, signals transmitted from the extracellular 
portion of the TCR result in intracellular changes that influence the fate and/or function 
of T lymphocytes. The binding of TCR to pMHC is highly specific and sensitive, and 
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subtle quantitative differences in TCR signaling strength can induce different levels of 
intracellular phosphorylation, resulting in diverse downstream signaling events. The 
advent of TCR cloning and the development of mice expressing TCRs of known 
specificity have enhanced the understanding of antigen avidity on TCR signaling. 
Additionally, the development of multimeric pMHC complexes has provided ligands for 
biochemical binding/kinetic assays, as well as facilitated the detection of rare, antigen-
specific populations.
60
 It is known that the affinity, duration, and density of TCR-pMHC 
interactions contribute to the cumulative strength of TCR signaling in vivo.  
5.1.4.1 Potency of TCR-pMHC Interactions  
In the context of TCR-pMHC engagement, potency refers to the ability of a 
pMHC ligand to stimulate effector functions such as cytokine production, proliferation, 
and cytotoxic activity. High potency ligands stimulate numerous effector functions, 
whereas low potency ligands only stimulate a subset of functions. The potency of TCR-
pMHC engagement is dependent on the affinity and half-life (k1/2) of the interaction.
61
 
The relationship between TCR affinity and potency was first noted by Syuklev et al. 
when they found that the affinities of six pMHC ligands correlated with the degree of 
target cell lysis.
62
 Later studies have shown that lower affinity pMHC ligands induce less 
cytotoxic granule polarization in tumor-specific T cells.
63
  
In early studies to determine the influence of binding kinetics on potency, Kersch 
and colleagues generated soluble forms of five known low- or high-potency ligands with 
similar equilibrium binding affinities (KD). Their studies indicate that low-potency 
ligands have faster off-rates than high-potency ligands.
61
 However, later experiments 
demonstrate that immunization with a pMHC that interacts with the TCR longer than the 
cognate pMHC decreases intracellular signaling, T cell function, and memory 
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5.1.4.2 Density of pMHC 
The density of pMHC plays a key role in the modulating the T cell-APC 
interaction and inducing effector function. The effect of cognate pMHC density on 
mature T lymphocyte activation has been well-studied and characterized.
65-68
 It is known 
that T cells cluster around DCs loaded with higher amounts of antigen than DCs 
presenting lower amounts of peptide.
69
 DCs presenting more antigen form stable 
interactions with naïve CD8
+
 T cells, and thus induce proliferation, more quickly than 
DCs loaded with lower levels of antigen.
69
  
Detailed studies indicate that as few as 1-50 pMHC molecules are sufficient to 
induce a CTL response and trigger target cell lysis; however, it has been demonstrated 
that a single agonist pMHC on the surface of an APC or bilayer can only induce transient, 






 In cells with functional co-
receptors, sustained calcium mobilization requires the presence of 10 pMHCs on an APC; 
20 pMHC complexes are required for sustained calcium response when co-receptors are 
not present.
70
 In more recent studies, Manz and colleagues designed a partitioned bilayer 
system, whereby the number of agonist peptides per TCR cluster could be modulated, 
without altering the total number of pMHCs engaged by the cell.
71
 Their results indicate 
that the minimal number of pMHCs needed to trigger calcium signaling is four.
71
  
While density plays an important role in T cell activation, it also influences the 
development of anergy and tolerance. To determine whether naïve T cells maintain 
tolerance by tuning their TCR signaling to match persistent stimuli, Singh et al., 
transferred naïve TCR transgenic T cells into mice presenting different levels of cognate 
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antigen. When transplanted into the recipient containing higher levels of antigen 
presentation, the adaptively tolerized T cells showed lower levels of TCR signaling, 
cytokine production, and proliferation compared to T cells residing in the recipient 
containing lower levels of antigen.
72
 
5.1.4.3 pMHC Oligomerization 
Encounter of T cells with antigenic stimuli presented by other cells occurs 
simultaneously with other non-antigen signals such as co-receptor binding, co-
stimulation, and interactions with adhesion molecules. Inducing TCR signaling in the 
absence of APCs can be done non-specifically using phytohemagglutinin (PHA), 
ionomycin, or agonist TCR/CD3 antibodies; however, stimulating antigen-specific T cell 
populations requires that the multivalent presentation of agonist pMHC molecules.
73-76
  
Initial experiments performed by Abastado et al. have demonstrated that soluble, 
cognate pMHC Class I monomers are unable to stimulate T cell lines, despite being 
bound to the cell.
77
 However, pMHC dimers sufficiently triggered the cells to secrete IL-
2.
74,77
  Data presented by Boniface and colleagues has shown that monomeric MCC/IE
k
 
fails to activate CD4
+
 T cells, even at concentrations 20,000 times higher than the 




 Similar experiments using murine 2C CD8
+
 T 
lymphocytes demonstrate that like CD4
+
 T cells, CD8
+
 T cells can be stimulated by 
soluble Class I dimers or higher-order oligomers, but not monomers. Increasing 
concentrations of soluble MHC monomers can actually compete off the activation 
observed with oligomeric pMHCs.
75
 
The aforementioned studies support the model that dimerization or 
oligomerization of the TCR-CD3 complex is required for T cell activation. According to 
Kuhns et al., TCR dimerization via pMHC oligomer engagement polarizes T cells to the 
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point of APC contact, which in turn collects pMHCs in high local density.
78
 Higher 
pMHC densities might enable more efficient formation of TCR clusters, bringing CD3 
ITAMs into close proximity where they are phosphorylated by Src kinases, resulting in 
sustained signaling.  
5.1.4.4 Mechanical Force 
The debate over whether dimerization or mechanical force is more important for 
initiation of TCR signaling is ongoing. The leading theory supporting the requirement of 
mechanical force in the earliest steps of TCR signaling is based on a conformational 
change of the TCR-CD3ε complex upon pMHC engagement. In the “classic-style water 
cooler” model, TCR engagement causes the TCR to pivot on top of and push down the 
CD3δε and γε heterodimers, while pulling up on the CD3ζζ located on the opposite side 
of the TCR.
78,79
 CD4 and CD8 might contribute to the force by holding the pMHC in an 
orientation with respect to the TCR and/or cellular membrane.
78,79
 The mechanical force 
of this action may expose tyrosines of the CD3ε and CD3ζζ ITAMS, making them 
accessible to phosphorylation by kinases.
78,79
  
Experiments performed by Kuhns et al. show that destabilizing the TCR-CD3 
complex delays the onset and magnitude of intracellular calcium mobilization upon 
contact of the TCR with agonist pMHC; however, impairment of TCR dimerization only 
slightly reduces calcium mobilization.
79
 The results from numerous experiments that 
attempt to discriminate between the effects of mechanical force and/or dimerization on 
early TCR signaling make it hard to clearly determine which mechanism predominates. It 
is likely that a sum of the two processes plays a role in modulating and sustaining TCR 
signaling.  
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5.1.5 Solid-Phase pMHCs Induce TCR Signaling and T Cell Activation 
Much focus has been given to the development of cost-effective and efficient 
methods to stimulate and expand antigen-specific T cells for adoptive transfer. 
Traditionally, autologous DCs, which express high levels of Class I and Class II 
molecules, have been used to activate and expand T cells in vitro. However, the use of 
autologous DCs is time-consuming, expensive, and inconsistent due to patient variability. 
Problems with yield and collection, primary cell expansion, and the inability to 
implement Good Manufacturing Practice have been driving forces for the development of 
new methods to stimulate antigen-specific T cells in vitro. Several acellular methods 
employing immobilized pMHC Class I or Class II molecules have been developed and 
represent “off the shelf”, low-cost alternatives to patient-derived DCs.  
5.1.5.1 Plate-Bound pMHCs to Expand Antigen-Specific CD8+ T Cells 
Peptide-specific CD8
+
 T cells have been successfully expanded using plate-bound 
pMHC Class I molecules. In these studies, Schmidt and colleagues immobilized 
biotinylated cytomegalovirus (CMV) epitope-loaded Class I molecules to plates using a 
streptavidin linker. PBMCs were seeded on the coated plates and co-stimulated with anti-
CD28, IL-2, and IL-7.
80
 Tetramer-staining indicated that stimulation with plate-bound 
CMVp-MHCs resulted in an 80-fold increase in the frequency of CMV-specific CD8
+
 T 
cells compared to the un-stimulated cell population.
80
 Approximately 80% of the 
stimulated cells secreted IFNγ during re-stimulation. CMV-specific CD8+ T cells 
proliferated up to 240-fold after 2 additional stimulations, indicating the promise of using 




5.1.5.2 HLA-Ig Dimer-Functionalized Microbeads 





 T cells to clinically relevant numbers. In an early study, 
Oelke et al. designed microbeads capable of providing two signals, antigen engagement 
(signal 1) and co-stimulation (signal 2), needed for T cell expansion.
81,82
 Their aAPC 
microbeads were functionalized with immobilized HLA.A2-Ig dimers and anti-CD28 
antibodies.
81,82
 Their studies show that HLA.A2-Ig microbeads, containing HLAs loaded 
with high-affinity CMVpp65 peptide or low-affinity MART-1 peptide, could induce 
robust expansion of the respective antigen-specific CTLs.
81,82
 Cells stimulated with these 
beads expanded 10
6




The capacity of aAPCs to generate antigen-specific CTLs was compared to that of 
autologous peptide-loaded DCs.
81,82
 After three rounds of stimulation, MART-1 aAPCs 
resulted in a higher frequency of tumor-specific CTLs (54.7%) compared to the DC-
stimulated population (20.4%).
81,82
 75% of the CD8
+
 T cells activated with aAPCs were 
capable of IFNγ secretion and specific lysis of melanoma target cells, indicating 
maintenance of CTL functionality after several rounds of stimulation.
81,82
   
5.1.5.3 HLA Tetramer-Functionalized Microbeads 
Maus and colleagues have demonstrated the ability of HLA tetramer- and anti-




 In their 
study, Maus et al. tested the efficiency of four types of HLA tetramer-functionalized 
microbeads to stimulate T cells: a) indirect conjugation of tetramers via anti-Class II 
monoclonal antibodies (mAbs), b) indirect conjugation of tetramers via anti-streptavidin 
mAbs, c) direct conjugation of tetramers, or d) direct conjugation of monomers.
83
 They 
found that beads with Influenza-epitope loaded HLA.DR tetramers, indirectly 
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immobilized via antibody linkers, induced more IL-2 mRNA expression in Influenza-
HA-specific CD4
+
 T cells compared to microbeads in which tetramers or monomers were 
covalently immobilized.
83
 The differences in activation are likely due to the enhanced 







The dependence of thymocyte fate on TCR signaling strength poses an interesting 
question as to whether the strength of signaling can be controlled in vitro to direct the 
development of T cells. It was hypothesized that by engineering substrates with various 
densities of pMHC ligand, the strength of TCR-pMHC signaling can be controlled, 
thereby providing an optimal surface for the generation of mature antigen-specific CD8
+
 
SP T cells. In this chapter, the effects of pMHC density and solid phase presentation on 
TCR signaling and thymocyte differentiation are presented.  
Plates and microbeads were fabricated with varying densities of pMHC 
molecules. The ability of these immobilized pMHC surfaces to stimulate TCR signaling 
in thymocytes and to induce antigen-specific differentiation was compared to that of 
soluble tetramers. It was hypothesized that plate- or bead-immobilized pMHC molecules 
would trigger signaling more efficiently than soluble tetramers, in a density-dependent 
manner. However, because thymocyte survival is induced by a narrow range of TCR 
signaling strength, it was uncertain whether higher levels of TCR signaling would 
directly correlate with more efficient antigen-specific CD8
+
 T cell differentiation. 
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5.3 MATERIALS AND METHODS 
5.3.1 Microplate Ligand Density Determination 
Corning® Not Treated Tissue Culture clear, flat-bottom 96-well plates were treated with 
200 µg/mL streptavidin (Promega) diluted in phosphate buffered saline (PBS) for 30 
minutes at 37°C in 5% CO2 at 100 µL/well working volume. Solution was removed and 
wells were washed 2 times with 200 µL/well of PBS. Wells were then blocked with 
Hank’s Balanced Salt Solution (HBSS)/2% bovine serum albumin (BSA) for 45 minutes 
at 20°C. Blocking solution was removed and wells were washed 2 times with 200 
µL/well of PBS. Wells were then incubated with the following concentrations of 
fluorescein-labeled biotinylated BSA (bBSA-FITC, diluted in PBS): 50, 25, 12.5, 6.25, 
and 3.13 µg/mL at 100 µL/well working volume. Plates were covered with aluminum foil 
and incubated at 37°C for 2 hours or at 4°C for 24 hours. Wells were washed 5 times with 
100 µL of PBS, and supernatant from washes was saved. The amount of unbound bBSA-
FITC was determined by the fluorescence of supernatant, which was quantified using a 









5.3.2 Microbead Ligand Density Determination 
6 x 10
7
 Dynabeads® M-280 Streptavidin (1.0 mg of beads) (LifeTechnologies, 11205D) 
were aliquoted into low protein-binding microcentrifuge tubes and washed 3 times with 
1.0 mL of PBS using a Dynabeads magnet (discontinued, LifeTechnolgies DynaMag™-2 
is a new version, 12321D) according to manufacturer’s protocols. Beads were then 
incubated with the following concentrations of bBSA-FITC: 100, 50, 25, 12.5, 6.25, and 
3.13 µg/mL at 100 µL/tube working volume (diluted in PBS). Microcentrifuge tubes 
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were covered with aluminum foil and rotated for at 20°C for 30 minutes. After rotation, 
beads were washed 3 times with 1.0 mL of PBS using the Dynabeads magnet according 
to manufacturer’s protocols. Supernatant was saved. The amount of unbound bBSA-FITC 
was determined by the fluorescence of the supernatant, which was quantified using a 











5.3.3  MHC Microplate Functionalization 
Corning® Not Treated Tissue Culture clear, flat-bottom 96-well plates were treated with 
200 µg/mL streptavidin (Promega) for 30 minutes at 37°C in 5% CO2 at 100 µL/well 
working volume. Solution was removed and wells were washed 2 times with 200 µL/well 
of PBS. Wells were then blocked with HBSS/2% BSA for 45 minutes at 20°C (room 
temperature). Blocking solution was removed and wells were washed 2 times with 200 
µL/well of PBS. Wells were then incubated with the following concentrations of 
biotinylated pMHC monomers (Baylor College of Medicine Tetramer Production 
Facility) containing either ovalbumin (OVA) peptide 257-264 (SIINFEKL) or 
lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP)34-41 (AVYNFATC) 
diluted in PBS: 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 µg/mL at 100 µL/well for 2 hours 
at 37°C. Before plating cells, wells were washed 3 times with 200 µL PBS. 
5.3.4 MHC Microbead Functionalization 
6 x 10
7
 Dynabeads® M-280 Streptavidin (1.0 mg of beads) were aliquoted into low 
protein-binding microcentrifuge tubes and washed 3 times with 1.0 mL of PBS using a 
Dynabeads magnet according to manufacturer’s protocols. Beads were then incubated 
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with the following concentrations of biotinylated pMHC monomers containing either 
OVA peptide 257-264 (SIINFEKL) or LCMV.GP34-41 (AVYNFATC): 100, 50, 25, 
12.5, 6.25, 3.13, and 1.56 µg/mL at 100 µL/tube working volume (diluted in PBS). Beads 
were gently rotated at 20°C for 30 minutes. After rotation, beads were washed 3 times 
with 1.0 mL of PBS using a Dynabeads magnet according to manufacturer’s protocols. 
Beads were resuspended in 600 µL of PBS (to yield a stock concentration of 108 
beads/mL) and stored at 4°C for up to 2 weeks. 
5.3.5 Thymocyte Isolation 
Thymi from C57BL/6 mice or OT-1 transgenic mice (C57BL/6-
Tg(TCRaTCRb)1100Mjb/J) (The Jackson Laboratory) were isolated. Thymi were 
crushed on top of BD Falcon Blue Nylon Mesh 40 µm Cell Strainers (BD Biosciences, 
352340) to release thymocytes into a single cell suspension. Red blood cells were lysed 
using 1X RBC Lysis Buffer (eBioscience, 00-4333-57) at a concentration of 2 
mL/thymus for 15 minutes at 20°C (room temperature). Cells were counted and washed 
with FACS buffer and centrifuged at 300 x g for 5 minutes at 4°C.  
5.3.6 Double Positive Thymocyte Sorting 
Cells for sorting were resuspended at a concentration of 10
7
 cells/mL in PBS containing 
0.1% BSA and 2 mM EDTA. Thymocytes were treated with FcR Block (eBioscience, 16-
0161) at a 1:100 dilution for 15 minutes on ice, then labeled with FITC-conjugated anti-
CD8a (clone 53-6.7, eBioscience, 11-0081) and PECy7-conjugated anti-CD4 (clone 
RM5-4, eBioscience, 25-0042) at a 1:100 dilution for 30 minutes on ice. Cells were 
washed with 10-fold excess of PBS containing 0.1% BSA and 2 mM EDTA and 
centrifuged at 300 x g for 5 minutes at 4°C. Pellets were resuspended at 107 cells/mL in 
PBS containing 0.1% BSA and 2 mM EDTA and transferred to sterile polystyrene 12 x 
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 DP thymocytes were sorted using BD FACSAria™II (BD 
Biosciences) and FACSDiva Software (BD Biosciences).  
5.3.7 Flow Cytometry 
All staining was done in polystyrene 12 x 75 mm test tubes in PBS containing 0.1% BSA 
and 2 mM EDTA. All tetramers and antibodies were diluted 1:100 and all staining was 
performed on ice. To determine antigen-specificity, cells labeled with APC-conjugated 
MHC tetramers for 30 minutes on ice prior to antibody labeling. For all samples, cells 
were treated with FcR block (eBioscience, 16-0161) for 15 minutes, followed by staining 
with antibodies. The following reagents were used: APC-conjugated OVAp257-MHC 
tetramers (SIINFEKL) (Baylor College of Medicine Tetramer Production Facility), APC-
conjugated LCMV.GP34-41 MHC tetramer (AVYNFATC) (Baylor College of Medicine 
Tetramer Production Facility), FITC-conjugated anti-CD8a (clone 53-6.7, eBioscience, 
11-0081), PECy7-conjugated anti-CD4 (clone RM5-4, eBioscience, 25-0042), and PE-
conjugated anti-CD69 (clone H1.2F3, BD Biosciences, 553237). Analysis was done 
using BD Accuri™ C6 (BD Biosciences) and FlowJo Version 7.6.5 (Treestar Inc.). 
5.3.8 OT-1 Thymocyte Activation using OVA257p-MHC-Functionalized 
Microplates 
OT-1 thymocytes were seeded in pMHC-functionalized Corning® Not Treated Tissue 
Culture clear, flat-bottom 96-well plates in RPMI 1640 supplemented with 10% FBS, 
penicillin (100 U/mL), and streptomycin (100 µg/mL) at a concentration of 105 OT-1 
thymocytes at a 200 µL working volume. After 2 hours, cells were collected and 
processed for flow cytometry.  
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5.3.9 OT-1 Thymocyte Activation using OVA257p-MHC-Functionalized 
Microbeads 
OT-1 thymocytes were seeded in Corning® Not Treated Tissue Culture clear, flat-bottom 
96-well plates at a concentration of 10
5
 cells/well with microbeads functionalized with 
varying densities of OVA257p-MHC in RPMI 1640 supplemented with 10% FBS, 
penicillin (100 U/mL), and streptomycin (100 µg/mL) at a 200 µL working volume. For 
some conditions, bead to cell ratios of 20:1, 10:1, 1:1, and 0.5:1 were used. After 2 hours, 
cells were collected and processed for flow cytometry. 
5.3.10 OT-1 Thymocyte Activation using Soluble OVA257p-MHC Class I 
Tetramers 
OT-1 thymocytes were seeded in Corning® Not Treated Tissue Culture clear, flat-bottom 
96-well plates in RPMI 1640 supplemented with 10% FBS, penicillin (100 U/mL), and 
streptomycin (100 µg/mL) at a concentration of 105 cells/well with soluble OVA257p-
MHC tetramers (Baylor College of Medicine Tetramer Production Facility) at a 200 µL 
working volume. After 2 hours, cells were collected and processed for flow cytometry.  






 DP thymocytes were seeded in Corning® Not Treated 
Tissue Culture clear, flat-bottom 96-well plates functionalized with varying densities of 
LCMV.GP34p-MHC monomers at a concentration of 10
5
 cells/well in RPMI 1640 
supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 µg/mL), anti-
CD28 (1.0 µg/mL, clone 37.51, eBioscience, 16-0281), anti-CD3 (1.0 µg/mL, clone 
17A2, eBioscience, 16-0032), IL-2 (10 ng/mL), and IL-7 (10 ng/mL) at a 200 µL 
working volume. Cells were cultured for a total of 7 days. Media and supplemental 
factors were replenished every 3 days. Cells were collected at Day 7 and analyzed for 
antigen-specificity and T cell markers. 
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5.3.12 Antigen-Specific Differentiation using LCMV.GP34p- and OVA257p-MHC-
Functionalized Microbeads 
Sorted C57BL/6 DP thymocytes were in seeded Corning® Not Treated Tissue Culture 
clear, flat-bottom 96-well plates with OVA257p-MHC- or LCMV.GP34p-MHC-
functionalized beads (bead to cell ratio of 10:1) at a concentration of 10
5
 cells/well in 
RPMI 1640 supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 
µg/mL), anti-CD28 (1.0 µg/mL, clone 37.51, eBioscience, 16-0281), anti-CD3 (1.0 
µg/mL, clone 17A2, eBioscience, 16-0032), IL-2 (10 ng/mL), and IL-7 (10 ng/mL) at a 
200 µL working volume. Cells were cultured for a total of 7 days. Media and soluble 
supplemental factors were replenished every 3 days. Cells were collected at day 7 and 
analyzed for antigen-specificity and T cell markers. 
5.3.13 Statistics 
Statistical significance was determined by one-way or two-way ANOVA. Post-hoc multi-
comparison analysis was performed using Dunnett’s multiple comparison test or Tukey’s 





5.4.1 Density on Ligand-Functionalized Microplates 
FITC-labeled biotinylated BSA (bBSA-FITC, approximately 66 kDa) was used as 
a model probe to estimate the ligand density of pMHC (approximately 47 kDa) 
monomers immobilized on plates. Streptavidin was immobilized on non-tissue culture or 
tissue culture-treated microplates. Following this, varying concentrations of bBSA-FITC 
were incubated with the plates at 4°C for 24 hours or at 37°C for 2 hours. Similar ligand 
densities of bBSA-FITC were immobilized on the plates regardless of plate type, 
incubation time, or temperature (Figure 5.1). 
 
Figure 5.1: Ligand density of bBSA-FITC on polystyrene non-tissue culture treated or 
tissue culture treated 96-well plates fabricated at 4°C for 24 hours or at 37°C 
for 2 hours (n = 5, ns = not significant, P < 0.05).  
5.4.2 Density of Ligand-Functionalized Microbeads 
As with the microplate functionalization, bBSA-FITC was used as a model probe 
to estimate the ligand density of pMHC monomers on stretpavidin Dynabeads®. Varying 
concentrations of bBSA-FITC were incubated with the beads at 20°C for 30 minutes. As 
expected, increasing densities of bBSA-FITC were immobilized as the incubation 
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concentration was increased. However, ligand density (molecules/cm
2
) was 
approximately 10-fold lower on the microbeads compared to the microplate (Figure 5.2). 
 
Figure 5.2: Ligand density of bBSA-FITC on magnetic microbeads. Unless indicated, all 
groups are statistically significant when compared to each other (n = 5, P < 
0.01). 
To compare the effects of surface presentation on TCR signaling and 
differentiation, and to account for the differences in molecules/cm
2
 on plates and beads, 
equal numbers of molecules pMHC per cell (determined from ligand density 
quantification) were used for stimulation and differentiation experiments. Density 
(molecules/cm
2
) was varied within each surface (i.e. plates, beads, or tetramers), while 
simultaneously providing equal numbers of pMHC molecules per cell between groups. 
5.4.3 Quantitative Control of TCR Signaling Using pMHC-Functionalized Plates, 
Microbeads, and Soluble Tetramers 
The quantitative effect of soluble or immobilized pMHC molecules on TCR 
signaling was determined using OT-1 thymocytes. Expression of CD69, an early T cell 
activation marker, was used to quantify TCR triggering due to agonist OVA257p-MHC 
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tetramers or OVA257p-MHC-functionalized plates and beads. OT-1 thymocytes were 
cultured for 2 hours with equivalent numbers of OVA257p-MHC molecules per cell, 
presented in soluble tetramer, plate-bound or bead-bound form. The data indicates that 
the percentage of DP cells expressing CD69 increased as a function of ligand density, 
regardless or presentation method (Figure 5.3A).  
 
Figure 5.3: Percentage of OT-1 DP thymocytes expressing CD69 after 2 hours of culture 
with OVA257p-MHC-functionalized plates, microbeads, or soluble 
tetramers. Effect of A) ligand density (n = 5, *P < 0.001, 
#
P < 0.05 when 





P < 0.01) on CD69 expression. 
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Although equal numbers of pMHC molecules were used to induce signaling, 
pMHC-functionalized plates and beads stimulated a significantly higher percentage of DP 
thymocytes compared to the soluble pMHC tetramers (Figure 5.3B). Unlike soluble 
tetramers, pMHC-functionalized plates and beads induced a significant percentage of DP 
cells to express CD69 even at the lower densities (0.1 to 0.8 x 10
6
 molecules per cell). At 
the low densities of 0.1 to 0.4 x 10
6
 molecules per cell, microbeads activated significantly 
more DP cells than plates. Interestingly, the percentage of CD69
+
 cells induced by the 
pMHC-functionalized beads did not decrease as suddenly it did with the plates, which 
yielded 2-fold lower numbers of CD69
+
 cells than the beads at the lowest density tested.  
The median fluorescence intensity (MFI) of CD69 expression appeared to follow 
a density-dependent trend when pMHCs were presented on microbeads and plates, but 
not soluble tetramers (Figure 5.4A). Soluble tetramers induced significantly lower levels 
of CD69 in DP cells compared to the plates and beads, at all the ligand densities (Figure 
5.4B). Microbeads were capable of inducing higher levels of CD69 expression compared 
to the plates throughout the range of densities tested. DP thymocytes expressed lower 
levels of CD69 as plate-immobilized pMHC density decreased. Interestingly, this trend 
did not occur to the same extent using microbeads, as CD69 expression level remained 
the same when triggered with bead-immobilized pMHC molecules ranging from 0.1 to 
0.8 x 10
6
 molecules per cell (Figure 5.4A). 
 169 
 
Figure 5.4: Median fluorescence intensity of CD69 in OT-1 DP thymocytes after 2 hours 
of culture with OVA257p-MHC-functionalized plates, microbeads, or 
soluble tetramers. Effect of A) ligand density (n = 5,*P < 0.001, 
#
P < 0.05 
when compared to 0 LCMV) and B) immobilization mode (n = 5, *P < 
0.001, 
#
P < 0.001, 
ψ
P < 0.01, 
±
P < 0.05) on CD69 expression. 
The effect of varying bead to cell ratios on thymocyte TCR signaling was 
determined using microbeads immobilized with varying ligand densities of OVA257p-
MHC molecules. OT-1 thymocytes were seeded with various OVA257p-MHC-
functionalized beads, at bead to cell ratios of 20:1, 10:1, 1:1, and 0.5:1. The results 
indicate that higher ligand densities (6.4 and 3.2 x 10
5
 molecules per bead) and higher 
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bead to cell ratios (20:1 and 10:1) triggered more DP cells to express CD69 compared to 
beads at lower bead to cell ratios (Figure 5.5A and 5.5B). At densities lower than 3.2 x 
10
5
 molecules per bead, increasing the bead to cell ratios did not induce more cells to 
express CD69.  
 
Figure 5.5: Percentage of DP thymocytes expressing CD69 after 2 hours of culture with 
OVA257p-MHC-functionalized microbeads. Effect of varying A) bead to 
cell ratios (n = 3, 
#
P < 0.005, 
ψ
P < 0.05) and B) ligand densities (n = 3,*P < 
0.0001, 
±
P < 0.0005 
#
P < 0.005, 
ψ
P < 0.05 when compared to 0 OVA 
control) on CD69 expression. 
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5.4.4 Effect of Ligand Density on Antigen-Specific Differentiation Using pMHC-
Functionalized Plates, Microbeads and Soluble Tetramers 
The effect of ligand density on antigen-specific differentiation was quantitatively 
evaluated using OVA257p-MHC- or LCMV.GP34p-MHC-functionalized plates, 
microbeads, and soluble tetramers. As with the previously described signaling assays, 
equal numbers of pMHC molecules per cell were used to induce differentiation. 
LCMV.GP34p-MHC functionalized plates and microbeads were found to be capable of 
inducing CD8
+
 LCMV.GP34-specific differentiation. 
5.4.4.1 Plate-Immobilized LCMV.GP34p-MHCs Induced LCMV.GP34-Specific CD8+ 
T Cell Differentiation 
Sorted C57BL/6 DP thymocytes were differentiated using streptavidin 
microplates functionalized with varying densities of biotinylated LCMV.GP34p-MHCs. 
After 7 days of culture on plates, the cells were collected and analyzed for T cell markers 
and antigen-specificity. Approximately 50% to 60% of the DP thymocytes differentiated 
into CD8
+
 SP T cells (Figure 5.6A). Negligible amounts of CD4
+
 SP cells were found in 
all conditions. At the higher ligand densities (6.4, 3.2, and 1.6 x 10
6
 molecules 
LCMV.GP34p-MHC per cell), antigen-specific differentiation was observed. From all of 
the conditions examined, 3.2 x 10
6
 molecules pMHC per cell resulted in the highest 
percentage of LCMV.GP34-specific cells (approximately 20%) (Figure 5.6B). Similar 
levels of antigen-specificity were observed using soluble tetramers at 1000-fold higher 
molecules per cell, suggesting that plate-immobilized pMHC molecules induce 
differentiation more efficiently than soluble pMHC tetramers (Figure 5.6B). The data 
indicates an interesting trend between plate-bound pMHC densities, as higher ligand 
densities resulted in more antigen-specific differentiation.   
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Figure 5.6: A) Percentage of CD8
+
 SP cells (n = 3, **P < 0.01, *P < 0.05 when compared 
to 0 LCMV) and B) LCMV.GP34-specific CD8
+
 T cells (n = 3, **P < 
0.005, *P < 0.05 when compared to 0 LCMV) after 7 days of culture with 
varying densities of plate-bound or soluble LCMV.GP34p-MHC molecules. 
5.4.4.2 Microbead-Immobilized LCMV.GP34p-MHCs Induced LCMV.GP34-Specific 
CD8
+
 T Cell Differentiation 
The ability of pMHC microbeads to induce antigen-specific T cell differentiation 
was determined using streptavidin microbeads fabricated with varying densities of 
biotinylated LCMV.GP34p-MHCs. In all conditions, regardless of the presence or 
absence of beads, approximately 50-70% of the C57BL/6 DP thymocytes differentiated 
into CD8
+
 SP cells; however, a significantly lower percentage of CD8
+
 T cells were 
found in the conditions without beads or containing OVA257p-MHC-functionalized 
beads (Figure 5.7A). Negligible amounts of CD4
+




Figure 5.7: A) Percentage of CD8
+
 SP T cells (n = 5, ****P < 0.0001, ***P < 0.0005 
when compared to 0 LCMV) and B) LCMV.GP34p-MHC-specific CD8
+
 T 
cells (n = 5, ****P < 0.0001, * P < 0.05 when compared to 0 LCMV) after 
7 days of culture with varying densities of microbead-bound LCMV.GP34p-
MHC molecules. 
A density-dependent increase in antigen-specific CD8
+
 T cell differentiation was 
observed. Approximately 30% of the CD8
+
 SP T cells bound to APC-conjugated 
LCMV.GP34p-MHC Class I tetramers after being trained with beads presenting the 
highest density (6.4 x 10
6
 molecules per cell) of LCMV.GP34p-MHC molecules. 
Significant LCMV.GP34 antigen-specific differentiation was induced by microbeads 
presenting 3.2 x 10
6
 molecules of LCMV.GP34p-MHC per cell; however, no significant 
difference in antigen-specificity was generated using microbeads containing 0.1 to 1.6 x 
10
6
 molecules of LCMV.GP34p-MHC per cell (Figure 5.7B).  
Interestingly, the highest amount of LCMV.GP34-specific differentiation 
occurred when DP thymocytes were cultured with microbeads functionalized with 
OVA257p-MHC Class I molecules (Figure 5.7B). This observation was consistent with 
the findings presented in Chapter 4. In the previous chapter, it was shown that DP 
thymocytes differentiated into LCMV.GP34-specific T cells more efficiently when 
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trained with OVA257p-MHC tetramers compared to LCMV.GP34p-MHC tetramers. It 
was hypothesized that the repertoire bias of C57BL/6 mice resulted in deletion of a 
population of cells in the presence of OVA257p-MHC Class I molecules, thus skewing 
the surviving cell population specificity. If this hypothesis was correct, bead-presented 
OVA257p-MHC Class I molecules should induce less OVA257-specific CD8
+
 T cell 
differentiation as a function of increasing density.  
5.4.4.3 The Effect of Bead-Immobilized OVA257p-MHCs on OVA257-Specific CD8+ T 
Cell Differentiation 
To determine the effect of bead-immobilized OVA257p-MHC molecules on 
antigen-specific differentiation, streptavidin microbeads were functionalized with varying 
densities of biotinylated OVA257p-MHCs. C57BL/6 DP thymocytes were sorted and 
differentiated with the beads for 7 days. After 7 days of culture, the cells were collected 
and stained for T cell markers and antigen-specificity. CD8 staining shows that 
approximately 40-60% of the DP thymocytes differentiated in CD8
+
 SP T cells, 
regardless of the presence or absence of pMHC-functionalized microbeads.  Cells 
differentiated with the highest density of OVA257p-MHC molecules resulted in 
significantly less CD8
+
 T cells when compared to the 0 molecules of pMHC control 
(Figure 5.8A). This finding was consistent with data presented in Figure 5.7A, where 
microbeads presenting 6.4 x 10
6
 molecules OVA257p-MHC molecules per cell also 
resulted in significantly lower CD8
+
 T cells than the 0 molecules of pMHC control.  
Staining with fluorescent OVA257p-MHC tetramers shows that OVA257-
specificity decreased with increasing OVA257p-MHC density (Figure 5.8B). When 6.4 x 
10
6
 molecules of OVA257p-MHC molecules per cell were used to induce differentiation, 
only about 2.0% of the CD8
+
 T cells were OVA257-specific. This was significantly 
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lower than background level of OVA257 antigen-specificity generated when using beads 
presenting 0 pMHCs or no beads (Figure 5.8B). 
 
Figure 5.8: A) Percentage of CD8
+
 SP T cells (n = 5, ***P < 0.0005 when compared to 0 
OVA) and B) OVA257p-MHC-specific CD8
+
 T cells (n = 5, ***P < 0.001, 
* P < 0.05 when compared to 0 OVA) after 7 days of culture with varying 




The data presented in this chapter indicates that plate- and bead- immobilized 
pMHC molecules can stimulate thymocytes more efficiently than soluble pMHC 
tetramers. This suggests that immobilized pMHCs may trigger stronger signaling in 
thymocytes compared to soluble ligands. The results are consistent with findings from 
several from other groups, which suggest that immobilized pMHC molecules induce 
more efficient immunological synapse formation.  
Chevrin and colleagues recently demonstrated that CD8 negative T cell 
hybridomas expressing low-affinity TCRs responded to pMHC Class I complexes 
immobilized as monomers or tetramers on plastic wells, despite being unresponsive to 
those pMHCs in soluble monomeric or oligomeric form.
84
 Another study performed by 
Segura et al. indicates that pMHC complexes on the surface of APCs are relatively 
immobile and cluster around ICAM molecules, and that disrupting the immobility of 
these complexes impaired antigen-sensitivity and recognition by CTLs.
85
 In the plate and 
bead-based stimulation systems presented, cognate pMHCs, immobilized via densely 
populated streptavidin linkers, may be present at a local concentration high enough to 
trigger signaling. The restricted movement of pMHC clusters might facilitate pMHC 
rebinding to the TCR, allowing engagement of many TCRs in a short frame of time, a 
mechanism termed signal spreading.
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 According to the results presented here, CD69 
expression was induced even at the lowest plate- and bead-immobilized density tested 
(0.1 x 10
6
 molecules per cell), suggesting that this density was above the critical 
threshold needed to recapitulate the functions of IS.  
When presented at equivalent molecules per cell, bead-immobilized pMHCs were 
better stimulators of thymocytes than plate-immobilized pMHCs. It is hypothesized that 
the method of pMHC presentation via microbeads facilitates more TCR-pMHC contacts 
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per cell. When seeded in a pMHC-coated well, each thymocyte contacts one limited, two-
dimensional area of the well once it has settled to the bottom. In comparison, microbeads 
facilitate multiple three-dimensional thymocyte contacts, as several beads can settle next 
to, or on top of a cell, enabling the formation of multiple IS’es. Microbeads might also 
induce signaling more efficiently if they had a higher degree of pMHC oligomerization 
compared to the plates. It is possible that the plate-adsorbed streptavidin was not fully 
saturated with biotinylated pMHCs, resulting in disperse distribution of pMHCs that were 
presented to the thymocyte as lower valency oligomers. Further studies to optimize the 
streptavidin to pMHC ratio should be performed, but are out of the scope of this work. 
LCMV.GP34p-MHC functionalized plates were capable of inducing the 
generation of LCMV.GP34-specific CD8
+
 T cells when used at the higher densities 
tested. Interestingly, plates presenting 3.2 x 10
6
 molecules per cell induced similar levels 
of antigen-specific differentiation as soluble tetramers presenting 1000-fold more 
molecules per cell. It was hypothesized that the plate-immobilized pMHC density 
triggered sufficient signaling in DP thymocytes to induce survival of weakly binding 
thymocytes. LCMV.GP34-specific T cells were also generated using LCMV.GP34p-
MHC-functionalized microbeads. The generation of antigen-specificity appeared to be 
directly dependent on ligand density, as microbeads presenting more molecules per cell 
induced more antigen-specific differentiation. The finding that increasing densities of 
bead-functionalized OVA257p-MHC complexes induced lower amounts of OVA257-
specific differentiation may be attributed to the TCR repertoire bias of C57BL/6 mice as 
described in Chapter 4.  
LCMV.GP34p-MHC-functionalized plates and microbeads were capable of 
inducing antigen-specific CD8
+
 SP differentiation from T cell progenitors at amounts 
much lower than what has been previously demonstrated using soluble tetramers. This 
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interesting finding suggests that pMHC-functionalized plates or microbeads could be 
used to generate antigen-specific T cells in a more cost-effective manner than soluble 
ligands or conventionally-used APCs. Microbeads hold particular promise because they 
can easily be transferred to large bioreactor cultures which are commonly used for scale-
up expansion procedures. 
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5.6 CONCLUSION  
In this chapter, the effect of pMHC density and presentation on thymocyte TCR 
signaling and differentiation was evaluated. It was demonstrated that cognate plate-
bound, bead-bound, and soluble pMHC Class I tetramers induced increasing amounts of 
signaling as a function of ligand density. Interestingly, pMHC-functionalized microbeads 
stimulated thymocytes most efficiently, possibly due to the unique spatial presentation of 
pMHCs when immobilized on beads. LCMV.GP34p-MHC-functionalized plates and 
microbeads were capable of inducing antigen-specific CD8
+
 SP differentiation from T 
cell progenitors at lower amounts than what has been previously demonstrated with 
soluble tetramers, suggesting the potential use of this system for cost-effective and high-




TCR – T cell receptor 
pMHC – peptide major histocompatibility complex 
pHLA – peptide human leukocyte antigen 
HSC – hematopoietic stem cell 
APC – antigen-presenting cell 
DP – double positive 
cTEC – cortical thymic epithelial cell 
SP – single positive 
TSSP – thymus-specific serine protease 
DC – dendritic cell 
TRA – tissue-restricted antigen 
mTEC – medullary thymic epithelial cell 
cDC – conventional dendritic cell 
CTL – cytotoxic T lymphocyte 
TREG – regulatory T cell 
ISP – intermediate single positive 
Ig – immunoglobulin 
VDJ – variable, diversity, joining 
ITAM – immunoreceptor tyrosine-based activation motif 
IS – immunological synapse 
TH – helper T cell 
K1/2 – half-life 
KD – equilibrium binding affinity 
PHA – phytohemagglutinnin 
 181 
aAPC – artificial antigen-presenting cell 
CMV – cytomegalovirus 
mAb – monoclonal antibody 
PBS – phosphate buffered saline 
HBSS – Hank’s Balanced Salt Solution 
BSA – bovine serum albumin 
LCMV.GP34p-MHC – lymphocytic choriomeningitis virus glycoprotein epitope 
(AVYNFATC) pMHC 
OVA257p-MHC – ovalbumin epitope (SIINFEKL) pMHC 
MFI – median fluorescence intensity 
SIINFEKL – (serine – isoleucine – isoleucine – asparagine – phenylalanine – glutamic 
acid – lysine – leucine) 
AVYNFATC – (alanine – valine – tyrosine – asparagine – phenylalanine – alanine – 
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Chapter 6: Conclusions and Future Directions 
6.1 GENERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS FROM CORD 
BLOOD CD34
+
 HEMATOPOIETIC PROGENITORS 
6.1.1 Conclusions 
In Chapter 3 of this dissertation, a novel differentiation system for generating 
antigen-specific CD8
+
 T cells from human cord blood hematopoietic stem cells (HSCs) 
was successfully demonstrated. This system employed exogenous Notch ligand, Delta 
like ligand 1 (DLL1), soluble peptide human leukocyte antigen (pHLA) Class I tetramers, 
and secreted stromal cell factors to induce T lineage commitment and antigen-specific T 
cell differentiation. Culture of human HSCs with Notch ligands resulted in early T cell 












Addition of cytomegalovirus (CMV) or influenza (GIL) pHLA Class I tetramers 
induced the differentiation of CMV- and GIL-specific CD8
+
 single positive (SP) T cells, 
respectively.
1
 Co-culture of CMV tetramer-differentiated effectors with CMV epitope-
loaded target cells resulted in more CD107a upregulation compared to co-culture with 
control target cells.
1
 Similar results were seen with GIL tetramer-differentiated cells. 
Granzyme B activity was assayed to determine cytotoxic killing ability of tetramer-
differentiated cells.
1
 CMV tetramer-differentiated T cells were of capable of inducing 
granzyme B activity against CMV epitope-loaded target cells, although with high 
background activity against control epitope-loaded target cells.
1
 
6.1.2 Future Directions 
The high background cytoxicity of the stem cell-derived antigen-specific CD8
+
 T 
cells suggested that the population needed to be sorted prior to assaying functionality. 
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This was done using fluorescence activated cell sorting (FACS) and was successfully 
demonstrated in Chapter 4. It is also possible that the stem cell-derived antigen-specific T 
cells exhibit cross- or self-reactivity. For clinical use, these cells can be tested for cross- 
or self-reactivity by co-culture with autologous peripheral blood mononuclear cells 
(PBMCs). Despite these concerns, the described system presents a novel method to 
generate antigen-specific T cells without the need for peripheral T cell isolation or the use 
of genetic modification. This differentiation system has several advantages over the 
conventional methods used to generate adoptive transfer T cells.  
First, cord blood-derived HSCs can be easily retrieved from banks and essentially 
used as an “on-demand” source for adoptive transfer T cells.
2
 The advent of induced 
pluripotent stem cells (iPSC) have made patient-specific stem cell-derived therapies 
increasingly possible.
3
 iPSCs are somatic cells that have been reprogrammed to a 
pluripotent state by the transduction with genes known to induce pluripotency in 
embryonic stem cells (ESCs).
3
 These cells have the ability to differentiate into all 3 germ 
layers, without any chromosomal abnormalities.
3
 The use of iPSCs is particularly 
attractive for clinical purposes because they would allow a patient to donate his or her 
own somatic cells, without the use of embryos. iPSCs could be used to generate 
therapeutic cells with patient-specific HLA molecules, eliminating the need to HLA-type 
and minimizing the chances of developing graft-versus-host-disease (GVHD) associated 
with allogeneic transfer. 
The success of several groups at differentiating ESCs or iPSCs into therapeutic, 
antigen-specific T cells is promising. The OP9-DL1 co-culture system has been used to 
direct murine ESCs into functional T cells, which are able to reconstitute the T cell 
compartment of immunodeficient mice and mount responses against viral infection.
4
 
Additionally, Lei et al. have shown that murine iPSCs can be differentiated into 
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progenitor T cells using OP9-DL1 co-culture.
5
 They have also shown that murine iPSCs, 
transduced with T cell receptors (TCRs) recognizing an MHC Class I-restricted 
ovalbumin (OVA) epitope, can develop into CD8
+
 cytotoxic T lymphocytes (CTL) when 





derived cells are functional and respond to peptide stimulation by secreting interleukin 
(IL)-2 and interferon gamma (IFNγ).5 In a more recent study, Themeli et al. generated 
human iPSCs expressing a chimeric antigen receptor (CAR) targeted to CD19.
6
 These 
CAR-transduced iPSCs differentiated into T cells in vitro, and could induce tumor 
regression when transplanted in a mouse xenograft model.
6
 These data suggest the 
potential of the differentiation system, described in Chapter 3, to generate ESC- or iPSC-
derived antigen-specific CTLs for therapeutic purposes.  
Future studies should move towards replacing the OP9-DL1 conditioned media 
used for differentiation, with defined, serum-free media that can be reproduced and 
manufactured consistently. Towards this end, early studies have provided insight into 
factors that may be needed to induce in vitro T cell differentiation. When Delaney et al. 
used serum-free media supplemented with IL-3, IL-6, thrombopoietin (TPO), FMS-
related tyrosine kinase 3 ligand (Flt3L), and stem cell factor (SCF) to expand HSCs, they 
induced early T cell development in addition to HSC expansion.
7,8
 Addition of IL-7 to 
this cocktail may enhance in vitro T cell differentiation.
9-11
 Further studies will need to be 
done to determine if other factors are necessary for in vitro differentiation.  
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6.2 ENRICHMENT AND EXPANSION OF PROGENITOR-DERIVED ANTIGEN-
SPECIFIC CD8
+
 T CELLS 
6.2.1 Conclusions 
The ability to enrich and expand antigen-specific CTLs is crucial for the 
generation of sufficient numbers of T cells needed for infusion during adoptive transfer. 
In Chapter 4, lymphocytic choriomeningitis virus (LCMV).GP34-specific CD8
+
 T cells, 
derived from murine progenitors using LCMV.GP34p-MHC Class I tetramers, were 
sorted by FACS and cultured for 7 days in expansion media. After 7 days, these cells 
were alive and exhibited specific cytotoxicity, without the high background observed 
previously. However, the cells did not robustly expand during the 7-day period despite 
the use of proliferative molecules and cytokines (1.0 µg/mL anti-CD3, 1.0 µg/mL anti-
CD28, and 10 ng/mL IL-2), suggesting that the differentiated cells entered a state of T 
cell dysfunction and indicating that the differentiation or expansion media may need to be 
optimized. 
Interestingly, it was also found that when OVA257p-MHC Class I tetramers were 
used for differentiation, a higher percentage of LCMV.GP34-specific T cells were 
generated compared to OVA257-specific T cells. This may due to the inherent repertoire 
bias of C57BL/6 mice for OVA257-H-2K
b
 molecules. Since approximately 7% of the DP 
thymocyte population was found to recognize the OVA257p-MHC tetramer, it was 
hypothesized that high-avidity cells were deleted when cultured with the OVA257p-
MHC tetramers, thus skewing the population. Cells with weak to high avidities for 
LCMV.GP34-H-2K
b
 molecules may have been positively selected with the OVA257p-
MHC tetramer. When LCMV.GP34p-MHC tetramers were used for differentiation, 
higher percentages of LCMV.GP34-specific CD8
+
 T cells were generated compared to 
OVA257-specific CD8
+
 T cells, suggesting that the LCMV.GP34p-MHC tetramer 
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enriched for cells with weak to medium avidity for LCMV.GP34-H-2K
b
 molecules. The 
lack of OVA257-specific T cells after culture with LCMV.GP34p-MHC tetramers may 
have resulted from death-by-neglect. The studies also show that after culture in expansion 
media, the OVA257-specific CD8
+
 T cells appear to be cross-reactive and bind to 
LCMV.GP34p-MHC tetramers.  
6.2.2 Future Directions 
An in-depth study to determine how varying avidity tetramers induce qualitatively 
and quantitatively different effects on antigen-specific T cell development could be done 
using a cohort of OVA-specific tetramers generated from point mutations of the native 
SIINFEKL epitope. Many of these variants (A2, G4, K4, Q4, R4, T4) are commercially 
available. Given the speculated bias of C57BL/6 mice for the SIINFEKL pMHC, the use 
of these variants would hypothetically induce the generation of antigen-specific T cells 
with varying avidities to the cognate SIINFEKL epitope. These anti-OVA T cells, 
exhibiting varying avidities for the SIINFEKL tetramers, could be sorted and evaluated 
for in vitro and in vivo functionality. The B16-OVA melanoma model could be used to 
evaluate tumor reduction, survival, and signs of autoimmunity as a function of TCR 
avidity.  
Several possible states of T cell dysfunction were examined in Chapter 4. Due to 
the maintained functionality of LCMV.GP34-specific CD8
+
 T cells after 7 days of culture 
in expansion media, it was hypothesized that the T cells became tolerized, exhausted, or 
senescent due to the differentiation or expansion culture conditions. To accurately 
determine the fate of these cells, in-depth cellular and molecular analysis of the 
differentiated thymocyte population and the antigen-specific T cell population should be 
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done. It is likely that chronic stimulation by antigen and/or co-stimulatory molecules lead 
to dysfunction. 
Lower concentrations of anti-CD3 and anti-CD28 may need to be used during the 
differentiation period. While CD28 signaling is required to prevent anergy of mature 
CTLs, its requirement during development is questionable. Previous studies done by Lin 
et al. have shown that the presence of anti-CD28 increases the production of antigen-
specific T cells, while findings from others suggest that CD28 inhibits SP development in 
vivo.
12-15
 In addition, after sorting the antigen-specific T cell population, it is not 
necessary to include tetramers in the expansion media. Elimination of antigen may 
prevent dysfunction resulting from chronic stimulation. Future studies should examine 
varying concentrations and combinations of tetramers and/or co-stimulatory molecules in 
order to optimize the conditions required to produce T cells that retain the capacity to 
expand. Additionally, antibody blockade of inhibitory molecules on T cells, or culture of 
the developing cells with IL-15 or histone deacetylase (HDAC) inhibitors, may be needed 





6.3 EFFECTS OF MHC LIGAND DENSITY AND PRESENTATION ON TCR 
SIGNALING AND THYMOCYTE DIFFERENTIATION 
6.3.1 Conclusions 
In Chapter 5, the effects of pMHC ligand density and solid phase surface 
presentation on thymocyte TCR signaling and antigen-specific differentiation were 
examined. In these studies, OVA257p-MHC plates and beads were more efficient at 
inducing expression of early activation marker, CD69, on OT-1 DP thymocytes 
compared to soluble tetramers, when given at equal numbers of molecules per cell. From 
this data, it was also determined that pMHC-functionalized microbeads stimulated 
thymocytes slightly better than pMHC-functionalized microplates. LCMV.GP34-
functionalized microplates were capable of inducing antigen-specific differentiation of 
DP thymocytes. Interestingly, similar levels of differentiation were seen using 1000-fold 
higher numbers of pMHC molecules per cell in soluble tetramer form, suggesting that 
plate-immobilized pMHC oligomers may be more efficient at inducing differentiation 
than soluble forms. When DP thymocytes were cultured with LCMV.GP34p-MHC-
functionalized microbeads, LCMV.GP34-specific CD8
+
 T cells were generated in a 
density-dependent manner. 
6.3.2 Future Directions 
Collectively, the data presented in this dissertation indicates that solid-phase 
presentation of pMHC molecules can induce TCR signaling in thymocytes more 
effectively than soluble pMHC tetramers. Antigen-specific CD8
+
 T cells can be generated 
using microplates or beads functionalized with much lower amounts of pMHC molecules 
compared to previous experiments utilizing soluble tetramers. This holds promise for the 
field of in vitro T cell differentiation, as such artificial antigen-presenting cells (aAPCs) 
could be fabricated in compliance with Good Manufacturing Practice and in a high-
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throughput manner. The ability to incorporate bead-based aAPCs into high volume 
systems, such as bioreactors, holds promise for the development of large-scale in vitro T 
cell differentiation systems.  
Future studies should be done to confirm that the antigen-specific CD8
+
 T cells 
generated from plate and microbead cultures are functional. Functionality could be 
evaluated by assaying for granzyme B, using assays similar to those described in previous 
chapters, as well as assaying for cytokine secretion and proliferation upon antigen 
stimulation. Further studies to determine if higher densities of microbead-immobilized 
pMHC molecules can induce more efficient differentiation and to confirm that the 
observed antigen-specific differentiation is reproducible using other epitopes, would be 
valuable. Additionally, it was noticed that microbeads aggregated after approximately 24 
hours in culture. This aggregation may reduce the amount of ligand surface area available 
for contact with cells. As a result, it may be necessary to incorporate slight agitation to 
the cultures to improve bead and cell contact. The detachment of microbeads from 
differentiating cells should also be optimized. Studies indicate that the majority of 
microbeads can be removed using magnetic separation following the manufacturer’s 
instructions. However, several rounds of this separation procedure may be needed to 
maximize cell retrieval, as some cells do end up inside bead aggregates. 
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6.4 CLOSING REMARKS 
In summary, this dissertation presents a unique and novel system from which 
functional, antigen-specific CD8
+
 T cells can be generated from human cord blood 
CD34
+ 
HSCs. To generate clinically relevant numbers T cells, the enrichment and 
expansion of progenitor-derived antigen-specific CD8
+
 SP T cells was attempted. 
Although more work is needed to optimize expansion conditions, the data indicates that 
cells remain viable and retain specific functionality after enrichment. In addition, the 
effects of pMHC ligand density and surface presentation on thymocyte signaling and 
differentiation were evaluated. The results from those experiments indicate that pMHC-
functionalized microbeads are capable of stimulating thymocytes and can efficiently 
induce epitope-specific differentiation, suggesting the potential for large-scale, high-





HSC – hematopoietic stem cell 
DLL1 – Delta like ligand 1 
pHLA – peptide human leukocyte antigen 
DP – double positive 
CMV – cytomegalovirus 
GIL – influenza 
SP – single positive 
FACS – fluorescence activated cell sorting 
PBMC – peripheral blood mononuclear cells 
iPSC – induced pluripotent stem cell 
ESC – embryonic stem cell 
GVHD – graft-versus-host-disease 
TCR – T cell receptor 
OVA – ovalbumin 
CTL – cytotoxic T lymphocyte 
RAG – recombination activating gene 
IL – interleukin 
IFNγ – interferon gamma 
CAR – chimeric antigen receptor 
TPO – thrombopoietin 
Flt3L – FMS-related tyrosine kinase 3 Ligand 
SCF – stem cell factor 
OVA257p-MHC – ovalbumin epitope (SIINFEKL) pMHC 
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LCMV.GP34p-MHC – lymphocytic choriomeningitis virus glycoprotein epitope 
(AVYNFATC) pMHC 
HDAC – histone deacetylase  
aAPC – artificial antigen-presenting cell 
SIINFEKL – (serine – isoleucine – isoleucine – asparagine – phenylalanine – glutamic 
acid – lysine – leucine) 
AVYNFATC – (alanine – valine – tyrosine – asparagine – phenylalanine – alanine – 
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